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The kidney is a bean-shaped organ that plays a vital role in maintaining body homeostasis. 
The kidney filters approximately 180 liters of primary urine a day, thereby excreting waste 
products such as urea, minerals and toxic substances. In addition, the kidney is important for 
the regulation of blood pressure and the release of hormones, such as renin, erythropoietin, 
prostaglandins and vitamin D. Each kidney consists of about 1 million nephrons, which are 
the functional units of the kidney. A nephron is composed of a glomerulus, where the filtration 
of the blood takes place, and a tubule, which is responsible for the reabsorption and 
secretion of ions and water. The glomerulus is a network of capillary loops that is enclosed 
by the Bowman’s capsule. Glomeruli receive their blood supply from an afferent arteriole. 
Unlike most other capillary beds, blood is drained away from the glomerulus into an efferent 
arteriole rather than a venule. This creates resistance to blood flow and produces high 
pressure on glomerular capillaries, aiding the process of glomerular ultrafiltration. Glomerular 
capillaries consist of three layers: glomerular endothelial cells, covered with a glycocalyx, at 
the inner side of the capillary wall, the glomerular basement membrane (GBM), and 
podocytes with interdigitating foot process covering the outer side of the capillaries (Figure 
1). Together these three layers form the glomerular filtration barrier (GFB), which is 
responsible for the size- and charge-selective filtration of the blood. Small and positively 
charged proteins can pass the GFB freely, whereas the passage of large and negatively 
charged proteins is restricted. Damage to any of the 3 layers of the GFB will facilitate 
passage of blood-derived proteins, thereby resulting in the development of proteinuria [1].  
 
 
Figure 1: Transmission electron microscopic picture of the glomerular filtration barrier. The 
glomerular filtration barrier is composed of fenestrated glomerular endothelial cells, the glomerular 
basement membrane (GBM) and podocytes with interdigitating foot processes. Courtesy of H. Dijkman 
and B. Willemsen.    
 
Proteinuria  
Proteinuria is characterized by the presence of an excess amount of proteins in the urine. 
Proteinuria is an early sign of many renal diseases and an independent risk factor for the 
progression to renal failure, all-cause mortality, and cardiovascular mortality [2, 3]. 
Proteinuria can be caused by damage to the GFB, increased quantity of proteins in the 
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serum (overflow proteinuria), or a reduced reabsorption of proteins in the tubuli [4]. Previous 
studies showed that damage to any layer of the GFB can eventually result in the 
development of proteinuria [1]. It is therefore important that all layers of the GFB remain 
intact to maintain a normal filtration barrier function.   
 
The role of the endothelial glycocalyx in proteinuric diseases 
Glomerular endothelial cells and podocytes are covered with a carbohydrate-rich layer, 
called the glycocalyx. The glycocalyx is connected to the endothelium and podocytes through 
cell membrane-bound proteoglycans, which, together with their glycosaminoglycan (GAG) 
chains, form the structural and functional backbone of the glycocalyx [5]. Soluble molecules 
like albumin, orosomucoid and lamican are incorporated in the glycocalyx and are connected 
either directly or via soluble proteoglycans and/or GAG chains [5, 6]. The presence of the 
endothelial glycocalyx is essential for controlling vascular permeability, signaling, vascular 
protection, mechanotransduction and attenuating blood cell-vessel wall interactions [5, 7-10]. 
Not much is known about the physiological role of the podocyte glycocalyx, but it has been 
suggested to play a role in maintaining foot process structure and keeping a certain distance 
between podocytes and parietal epithelial cells lining Bowman’s capsule [11].  
Several studies showed that the endothelial glycocalyx is degraded during renal failure. 
Patients with end-stage renal disease have a reduced glycocalyx thickness and elevated 
levels of circulating syndecan-1, which are both normalized after kidney transplantation [12]. 
Glycocalyx thickness was also reduced in patients with type 1 diabetes and correlated with 
the development of proteinuria, suggesting that the endothelial glycocalyx plays an important 
role in vascular permeability and the development of proteinuria [13]. This is further 
supported by several animal studies, where a reduced glycocalyx thickness was associated 
with the development of proteinuria [7, 14-16]. A recent study showed that infusion of mice 
with hyaluronidase, an enzyme that degrades hyaluronan, one of the constituents of the 
glycocalyx, reduced glycocalyx thickness and increased the passage of albumin across the 
endothelium [16]. Together, these studies suggest that an intact endothelial glycocalyx is 
essential to maintain a normal filtration barrier.          
 
Heparan sulfate proteoglycans    
Important constituents of the endothelial glycocalyx are heparan sulfate proteoglycans 
(HSPGs). HSPGs are negatively charged polysaccharides consisting of a core protein to 
which heparan sulfate (HS) side chains are covalently attached. HSPGs are located in 
extracellular matrices and at the cell surface of many cell types, including endothelial cells 
and podocytes. HSPGs play an important role in the interaction between cells and between 
cells and the extracellular matrix, and function as a receptor or co-receptor for the binding of 
Chapter 1   
10 
 
chemokines, cytokines, enzymes, growth factors or other bioactive molecules [17, 18]. The 
linear HS side chain consists of up to 150 repeating N-acetyl-glucosamine and glucuronic 
acid residues. HS can be modified extensively by several modification steps, including N-
deacetylation/N-sulfation of N-acetyl-glucosamine, C-5 epimerization of glucuronic acid to 
iduronic acid and O-sulfation at various positions (C-2, C-3, and C-6). In addition, the 
structure and length of the HS chain can be modified by the HS-modifying enzymes 6-O-
endosulfatase and heparanase [19-21]. By the combination of all aforementioned 
modifications, the structure of HS is extremely diverse, thereby enabling the specific binding 
of several soluble ligands, such as cytokines, chemokines and growth factors [18].  
Previous studies showed that the expression of HS in the GBM is reduced in many human 
and experimental glomerular diseases [22-28]. By using GAG-degrading enzymes or anti-HS 
antibodies to reduce HS expression in the GBM, it was shown that loss of HS in the GBM is 
associated with the development of proteinuria [29-31]. However, the primary role of HS in 
charge-selective filtration was questioned when animal models lacking HS in the GBM did 
not display overt proteinuria, despite the fact that they lacked the majority of anionic sites in 
the GBM [32-35]. However, in these aforementioned studies HS expression was mainly 
targeted in the GBM and not in the glomerular endothelium. Therefore, an important role for 
HS in the endothelial glycocalyx in charge selective filtration is still highly plausible.   
 
Heparanase 
Heparanase is the only known mammalian enzyme that can cleave HS, thereby yielding 
small HS fragments. Heparanase is synthesized as a 68 kDa pre-proheparanase and 
processed into a 65 kDa inactive proheparanase in the endoplasmatic reticulum by cleaving 
off the signal peptide. After transport to the Golgi apparatus, proheparanase is packaged into 
vesicles and secreted. Once secreted, heparanase is re-internalized through binding to cell-
associated HSPGs and other receptors such as low density lipoprotein receptor-related 
proteins and mannose-6-phosphate receptors [36]. After re-internalization, proheparanase is 
transported to the lysosomes, where it is processed and activated by cathepsin L (Figure 2) 
[37].  
Heparanase is active at a pH between 5.0 and 6.0, thereby limiting its activity to acidic 
microenvironments such as the glycocalyx, inflammatory sites, tumor cores, and the GBM 
facing sites of podocytes [24]. Heparanase is not enzymatically active at neutral pH, but 
through its binding to HS it can serve as a proadhesive molecule [38]. Heparanase plays an 
important role in several physiological processes, such as HS turnover, embryo 
development, hair growth and wound healing. In addition, heparanase is involved in various 
pathological processes, such as tumor growth, angiogenesis, metastasis, inflammation and 
glomerular diseases [39, 40].      
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Figure 2: Schematic representation of heparanase biosynthesis and trafficking. (1) Heparanase 
is synthesized as a pre-proheparanase in the nucleus. Pre-proheparanase is processed into a latent 
proheparanase in the endoplasmatic reticulum (ER) by cleaving off the signal peptide. (2) After 
transport to the Golgi apparatus, proheparanase is packaged into vesicles and secreted. (3) Once 
secreted, proheparanase binds to cell-associated HSPGs (in particular syndecan). (4) Binding of 
proheparanase to HSPGs is followed by endocytosis of the proheparanase-HSPG complex. (5) 
Endosomes are converted to lysosomes, where proheparanase is processed into an active 
heparanase heterodimer by cathepsin L after cleaving out an internal linker domain. HSPGs, heparan 
sulfate proteoglycans.  
 
Regulation of heparanase expression 
An increased heparanase expression plays an important role in several pathological 
processes. Heparanase mRNA expression is positively regulated by various transcription 
factors, including early growth response 1 (EGR1), Ets1 and Ets2, and Sp1 [40-42]. On the 
other hand, heparanase expression is negatively regulated by heparanase promoter 
methylation and by the tumor suppressor p53 [43, 44]. A previous study showed that 
heparanase expression is induced by estrogen in breast cancer, thereby contributing to 
breast tumor growth and neovascularization [45]. Several other studies showed that 
heparanase expression is also induced by high glucose, angiontensin II, aldosterone, 
reactive oxygen species (ROS), and proinflammatory cytokines such as tumor necrosis 
factor-α (TNF-α) and IL-1β [26, 46-51]. All aforementioned factors can be involved in the 
pathogenesis of glomerular diseases.   
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Heparanase expression in proteinuric diseases 
Previous studies showed that the expression of heparanase is increased in several human 
and experimental glomerular diseases, such as diabetic nephropathy, IgA nephropathy, 
minimal change disease, dense deposit disease, membranous glomerulopathy and 
adriamycin-induced nephropathy (AN) [23-26]. This increased glomerular heparanase 
expression inversely correlated with a reduced glomerular HS expression [24, 25, 52]. 
Several studies also showed an increased heparanase activity in the serum and urine of 
patients with type 1 and type 2 diabetes [53-55]. Inhibition of heparanase activity by an anti-
heparanase antibody or the heparanase inhibitor PI-88 reduced proteinuria in respectively 
rats with passive Heymann nephritis, which is a model for membraneous glomerulopathy, 
and rats with accelerated anti-GBM disease [27, 28, 56]. Moreover, a recent study showed 
that inhibition of heparanase activity by heparin reduced renal dysfunction after induction of 
severe systemic sepsis by cecal ligation and puncture in mice [57]. Together, these studies 
suggest that heparanase plays an important role in the development of proteinuria and renal 
damage.  
 
Established and hypothetical factors regulating heparanase expression and activity 
 
Cathepsin L 
Cathepsin L is a lysosomal cysteine protease that plays an important role in the degradation 
of proteins and the activation of enzymes. The expression of cathepsin L is increased in 
several glomerular diseases, including diabetic nephropathy, membraneous glomerulopathy, 
minimal change disease and focal segmental glomerulosclerosis (FSGS) [58]. Inhibition of 
cathepsin L activity results in a reduction of proteinuria in rats with accelerated anti-GBM 
disease, suggesting that cathepsin L plays an important role in the development of 
proteinuria [59]. More recent studies showed that induction of cathepsin L activity in 
podocytes results in a migratory event in podocyte foot processes, which subsequently 
results in the onset of proteinuria [60]. The CD2-associated protein (CD2AP), synaptopodin 
and dynamin are three known substrates of cathepsin L in the podocyte, and their presence 
is crucial for maintaining a normal architecture of the podocyte cytoskeleton [58, 61-63]. 
Degradation of either of these proteins resulted in the development of foot process 
effacement, proteinuria and renal failure [58, 62, 64-67]. In addition to the degradation of 
CD2AP, synaptopodin and dynamin, the presence of cathepsin L is essential for the 
activation of heparanase [37], indicating that the role of cathepsin L in the development of 
proteinuria may also be by the activation of heparanase.   
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Endothelin-1 
Endothelin-1 is a powerful vasoconstrictor that is released upon activation of endothelial 
cells. Endothelin-1 signals through two G-protein coupled receptors, the endothelin receptor 
type A and the endothelin receptor type B, which are both present in the kidney [68-70]. 
Endothelin-1 induces several intracellular signaling cascades, resulting in vascoconstriction, 
proliferation, inflammation, extracellular matrix production and fibrosis [71-74]. The 
expression of endothelin-1 is increased in several human and experimental glomerular 
diseases, including diabetic nephropathy, FSGS and glomerulonephritis [75-77]. Treatment 
with endothelin receptor antagonists reduced proteinuria and improved renal function in 
several human and experimental glomerular diseases [78-84], indicating that endothelin-1 
plays an important role in the development of proteinuria and renal damage in several 
glomerular diseases. Whether heparanase is contributing to the molecular mechanisms 
underlying the renoprotective effect of endothelin receptor antagonists, however, remains an 
open question.  
 
Endothelial nitric oxide synthase 
Endothelial nitric oxide synthase (eNOS) is an enzyme present in endothelial cells that is 
responsible for the generation of nitric oxide (NO). Previous studies showed that the 
presence of NO is important to maintain a healthy endothelium and that a reduced NO 
production contributes to endothelial dysfunction [85, 86]. The availability of eNOS is 
regulated by asymmetric dimethylarginine (ADMA), ROS, angiotensin II, protein kinase C, 
advanced glycation end products (AGEs), TNF-α, and vitamin D [87, 88]. Several studies 
showed that eNOS deficiency exacerbates renal injury in experimental FSGS, accelerated 
anti-GBM glomerulonephritis, and diabetic nephropathy [89-94]. Moreover, eNOS gene 
delivery reduced proteinuria and renal failure in a rat model for FSGS [95]. Whether 
heparanase is contributing to the molecular mechanisms underlying the renoprotective effect 
of eNOS, remains to be established.   
 
Vitamin D 
Vitamin D is a steroid hormone that plays an important role in the regulation of calcium and 
phosphate balance. Vitamin D3 is taken up from the diet and produced in the skin in 
response to ultraviolet light. Vitamin D3 is converted to 25-hydroxyvitamin D3 in the liver, and 
to the active form of vitamin D3, 1,25-dihydroxyvitamin D3, in the kidney. The availability of 
1α-hydroxylase, the enzyme responsible for the activation of vitamin D3 in the kidney, is 
reduced in patients with chronic kidney disease (CKD) as a result of the reduced renal mass 
[96]. As a consequence, many CKD patients become 1,25-dihydroxyvitamin D3-deficient [97]. 
Several clinical studies showed that 1,25-dihydroxyvitamin D3 supplementation reduced 
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proteinuria in CKD patients, in addition to standard anti-proteinuric therapy [98-104]. 
Moreover, proteinuria and podocyte loss were also reduced in several experimental models 
for FSGS [105-107]. Vitamin D may reduce proteinuria by reducing the expression of the 
transient receptor potential cation channel 6 (TRPC6), renin, or TNF-α [107-110]. Whether 
heparanase is also regulated by vitamin D remains to be elucidated.  
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Scope and outline of this thesis 
 
The major aim of this thesis is to evaluate the role of heparanase in the development of 
proteinuria. The first part of the research focuses on the identification of the exact role of 
heparanase in the development of proteinuria in experimental diabetic nephropathy and 
glomerulonephritis. In addition, possible mechanisms involved in the regulation of glomerular 
heparanase expression are evaluated in vivo and in vitro in the second part of this thesis.    
 
Heparanase expression in experimental diabetic nephropathy and glomerulonephritis 
In the first part of this thesis the role of heparanase in the development of proteinuria in 
experimental diabetic nephropathy and glomerulonephritis is examined. The role of 
heparanase in experimental diabetic nephropathy is evaluated by induction of diabetes with 
streptozotocin in wild type and heparanase-deficient mice (chapter 2). Albuminuria, 
heparanase and HS expression, and renal histology are analyzed. Furthermore, the 
molecular mechanism underlying the induction of heparanase expression in DN is evaluated. 
Finally, the effect of heparanase inhibition on the development of albuminuria and renal 
damage is evaluated in experimental DN.    
 
Cathepsin L is a lysosomal protease that can be involved in the development of proteinuria 
by the activation of heparanase or the degradation of the CD2-associated protein, 
synaptopodin and dynamin, three proteins that are important for normal podocyte 
architecture and function. In chapter 3 the exact role of cathepsin L in streptozotocin-
induced diabetes in wild type and cathepsin L-deficient mice is studied. Albuminuria, blood 
urea nitrogen levels and renal histology are measured. In addition, heparanase activity, HS 
expression and synaptopodin expression are determined. 
 
Since heparanase expression is increased in other glomerular diseases in addition to DN, in 
chapter 4 the role of heparanase is evaluated in two models of experimental 
glomerulonephritis, being anti-GBM and lipopolysaccharide (LPS)-induced 
glomerulonephritis, in wild type and heparanase-deficient mice. Albuminuria, blood urea 
nitrogen levels, renal histology, heparanase activity, glomerular HS expression and the influx 
of inflammatory cells are determined. In addition, the ability of tumor necrosis factor (TNF)-α 
and LPS to induce heparanase expression in cultured glomerular endothelial cells and 
podocytes is studied.     
 
The literature on the role of heparanase and the endothelial glycocalyx in the development of 
proteinuria is reviewed in chapter 5.   
Chapter 1   
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Regulation of heparanase expression 
In the second part of this thesis, mechanisms that could play a role in the regulation of 
heparanase expression are addressed. Treatment with endothelin receptor antagonists 
(ERAs) has a beneficial effect on proteinuria in several renal diseases. In chapter 6 the 
mechanism underlying the renoprotective effect of ERAs are evaluated. The effect of 
endothelin-1 on heparanase expression in cultured mouse glomerular endothelial cells and 
mouse podocytes is determined. Moreover, the effect of endothelin-1 on transendothelial 
albumin passage in vitro is studied. Additionally, podocyte-specific endothelin receptor 
knockout mice are used to evaluate the effect of endothelin-1 signaling in vivo on glomerular 
heparanase and HS expression and the thickness of the glomerular endothelial and 
podocyte glycocalyx.    
 
Endothelial nitric oxide synthase (eNOS) deficiency exacerbates proteinuria in several 
glomerular diseases, but the underlying mechanism is not completely understood. Previous 
studies showed that the glomerular endothelial glycocalyx is impaired in diabetic eNOS-
deficient mice and that heparanase is involved in the impairment of the glycocalyx [8, 94]. In 
chapter 7 the effect of eNOS deficiency on glomerular heparanase expression is studied. AN 
is induced in C57BL/6 wild type mice, an AN resistant strain, and C57BL/6 eNOS-deficient 
mice, and glomerular heparanase and HS expression are evaluated. In vitro, mouse 
glomerular endothelial cells are treated with an eNOS inhibitor and heparanase expression 
and transendothelial albumin passage are determined.     
 
Another novel therapeutic agent for the treatment of proteinuria is vitamin D. Vitamin D 
supplementation reduces proteinuria in many experimental and human glomerular diseases. 
In chapter 8 the effect of vitamin D on heparanase expression and promoter activity was 
studied. AN rats and 1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout mice, which are 
not able to produce the active form of vitamin D, are treated daily with active vitamin D and 
glomerular heparanase and HS expression are determined. In vitro, the effects of vitamin D 
on heparanase expression, HS expression and transendothelial albumin passage are 
evaluated in mouse glomerular endothelial cells and mouse podocytes. Finally, the effect of 
vitamin D on heparanase promoter activity and the direct binding of the vitamin D receptor to 
the heparanase promoter are evaluated.  
 
Interpretation 
In chapter 9 and chapter 10 the findings of the studies presented in this thesis are 
summarized and integrated, translational aspects are outlined and possible future directions 
of research are proposed.  
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Abstract 
 
Diabetic nephropathy (DN) is the major life-threatening complication of diabetes. Abnormal 
permselectivity of the glomerular basement membrane (GBM) plays an important role in DN 
pathogenesis. Heparanase is the predominant enzyme that degrades heparan sulfate (HS), 
the main polysaccharide of the GBM. Loss of GBM HS in diabetic kidney was associated 
with increased glomerular expression of heparanase. However, the causal involvement of 
heparanase in the pathogenesis of DN has not been demonstrated. We report for the first 
time the essential involvement of heparanase in DN. With the use of heparanase knockout 
mice, we found that deletion of the heparanase gene protects diabetic mice from DN. 
Furthermore, by investigating the molecular mechanism underlying induction of the enzyme 
in DN, we found that transcription factor early growth response 1 (Egr1) is responsible for 
activation of heparanase promoter under diabetic conditions. The specific heparanase 
inhibitor SST0001 markedly decreased the extent of albuminuria and renal damage in mouse 
models of DN. Our results collectively underscore the crucial role of heparanase in the 
pathogenesis of DN and its potential as a highly relevant target for therapeutic interventions 
in patients with DN. 
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Introduction 
 
The kidneys represent primary targets of diabetes, and diabetic nephropathy (DN) is the 
leading cause of end stage renal disease in the western world [1-3]. DN is characterized by 
glomerular hyperfiltration, increased renal albumin permeability, cellular and extracellular 
changes in the glomerular and tubulo-interstitial compartments, collectively resulting in 
progression of proteinuria and renal failure. The puzzle of mechanisms underlying DN 
pathogenesis involves complex interplay between haemodynamic and metabolic factors (i.e., 
systemic and intraglomerular pressure, activation of vasoactive hormone pathways, induction 
of inflammatory and prosclerotic cytokines) and is still far from being fully understood. 
Several studies suggested involvement of heparanase in DN [4, 5]. Heparanase is the only 
known mammalian endoglycosidase that cleaves heparan sulfate (HS) [6-8] the principle 
polysaccharide associated with the cell surface and extracellular matrix (ECM) of a wide 
range of tissues [9]. HS binds to and assembles structural basement membrane (BM) 
proteins, thus contributing to BM integrity and barrier function. In addition, HS moieties in the 
ECM sequester heparin-binding growth factors,  cytokines, and chemokines, thereby 
controlling their accessibility, function and mode of action [6, 9].  Enzymatic degradation of 
HS by heparanase leads to disassembly of ECM barriers and release of HS-bound bioactive 
molecules [10, 11], and is therefore involved in fundamental biological phenomena 
associated with tissue remodeling, including morphogenesis, inflammation, angiogenesis and 
cancer [6, 7, 12]. The findings linking  heparanase to DN and other proteinuric disorders 
include elevated levels of heparanase in the kidneys and urine of DN patients [13, 14], 
induction of glomerular heparanase expression in murine models of streptozotocin (STZ)-
induced diabetes [14] and passive Heymann nephritis [15], as well as in vitro studies 
demonstrating that hyperglycemic conditions enhance heparanase expression in rat and 
human glomerular epithelial cells [16]. Induction of glomerular heparanase in the course of 
diabetes may interfere with kidney function primarily through degradation of HS in the 
glomerular basement membrane (GBM). Indeed, GBM, along with fenestrated glomerular 
endothelium and podocyte foot processes/slit diaphragms, serves as the key functional 
component of the kidney filtration barrier, while HS represents a chief polysaccharide 
constituent of the GBM [17, 18], playing a key space-filling and molecular-sieving role in the 
GBM. Degradation/loss of HS in the GBM was tightly linked to the pathophysiology of DN 
(reviewed in [19]), yet, several recent reports challenged the importance of HS degradation in 
DN development [20, 21] and causative involvement of heparanase in DN has not been 
demonstrated. 
Our research was undertaken to elucidate the biological significance and regulation of 
heparanase in DN pathogenesis. Applying heparanase null (Hpse-KO) mouse model [22] we 
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demonstrated that unlike their wt littermates, Hpse-KO mice fail to develop albuminuria and 
renal damage in response to STZ-induced diabetes. Investigating the precise molecular 
mechanism underlying heparanase induction under hyperglycemic conditions, we revealed 
that Early Growth Response 1 (Egr1) transcription factor critically regulates heparanase 
overexpression. To block excessive heparanase, brought about in hyperglycemic mice by 
Egr1, we used a specific heparanase inhibitor SST0001 (non-anticoagulant N-acetylated, 
glycol split heparin = 100NA,RO-H) [23, 24]. Administration of SST0001 resulted in a marked 
decrease in the extent of albuminuria and renal damage in diabetic mice. Taken together, our 
results validate the role of heparanase in the pathogenesis of DN, reveal the molecular 
mechanism underlying induction of the enzyme in diabetic kidney and attest the enzyme as a 
promising therapeutic target in DN patients.   
 
 
Materials and methods 
 
Animals 
BALB/c, DBA-2, C57Bl/6J (Harlan Laboratories; Jerusalem, Israel) and heparanase-null 
Hpse-KO mice [22] were kept under pathogen-free conditions; all experiments were 
performed in accordance with the Hebrew University IACUC. 
 
STZ-induced diabetes  
Mice were injected intraperitoneally with 40 mg/kg body weight STZ in 100 mM citrate buffer 
(pH 4.6) for five consecutive days (following an overnight fast). Mice received 0.4 IU of 
insulin every other day when their blood glucose levels rose above 350 mg/dl. Blood glucose 
levels were measured using Ascensia ELITE Blood Glucose Meter (Bayer, Germany). 
Subcutaneous injections of compound SST0001 (300 µg in 100 µl saline, twice a day) were 
given to mice in the experimental group. Mice in the control group were injected with saline 
alone. For urine collection mice were placed in metabolic cages for 24 hours. Urinary 
albumin was measured using ELISA kit (Bethyl laboratories Inc, Montgomery, TX). 
Creatinine was measured using VITROS system 5.1, FS chemistry (Johnson & Johnson). 
Animals were sacrificed on indicated time points, half of each kidney was snap-frozen for 
RNA preparation/protein extraction and another half processed for histology and 
immunostaining.  
 
Renal histopathology 
Kidney tissue was immersion-fixed in 4% paraformaldehyde in PBS, routinely processed, 
and 2-4 µm sections were stained with Masson’s trichrome and periodic acid-Schiff (PAS). A 
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semiquantitative score was used to evaluate the extent of glomerular mesangial expansion 
essentially as described in [25]. Briefly, mesangial matrix expansion for each glomerulus was 
graded from 1 to 4 as follows: 1 represents no lesion, 2 sclerosis of >25% of the glomerulus, 
while 3 and 4 represent sclerosis of > 50% and >75% of the glomerulus, respectively. A 
whole kidney sclerosis index was obtained by averaging scores from all glomeruli on one 
section. Four mice per experimental condition were analyzed and >50 glomeruli were 
assessed per mouse. Immunohistochemistry of the paraffin-embedded and cryostat kidney 
sections was performed as previously described [26, 27]. 
 
Antibodies 
The following antibodies were used: anti-F4/80 (Serotec); anti-TGFβ (s.c.146); anti-Egr1 (s.c-
588, Santa Cruz Biotechnology, Santa Cruz, CA); anti-HS HS4C3 [27]; anti-heparanase 
#733 [28] and #01385-126 (kindly provided by Dr. P. Kussie; ImClone Systems Inc., New 
York, NY) [29]. 
 
Cell culture 
Human embryonic kidney cells 293 (HEK-293) were cultured at 37°C in a 5% CO2 humidified 
incubator in complete DMEM medium with 10% FCS. HK-160 primary human epithelial 
kidney cells (kindly provided by Dr. A. Katz, Bikur Holim Hospital, Jerusalem, Israel) were 
cultured at 37°C in a 8% CO2 humidified incubator in complete RPMI medium with 20% FCS. 
In some experiments, cells at 60-80% confluence were maintained for 24 hours in serum-free 
medium and then incubated in absence or presence of increasing concentrations of glucose, 
as indicated. 
 
Reverse transcription and real time PCR 
RNA isolation, reverse transcription and real-time quantitative PCR were performed as 
previously described [26]. Mouse RNA polymerase IIA and L-19, and human Gus-β primers 
were used as internal standards. Primer sequences are shown in Table 1.  
 
Immunoblotting 
Equal protein aliquots (20 µg) were subjected to SDS-PAGE (10% acrylamide) under 
reducing conditions. Proteins were transferred to a polyvinylidene difluoride membrane 
(Millipore Corporation) and probed with the anti-Egr1 rabbit polyclonal antibody s.c-588 
(Santa Cruse) (1:200), followed by horseradish peroxidase-conjugated secondary antibody 
(KPL) and a chemiluminescent substrate (iNtron Biotechnology), as described [26]. 
Membrane was stripped and incubated with anti-β-actin (1:1000) or anti-lamin (1:1000) 
antibodies to ensure equal protein load.  
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Table 1: Primers used in real-time PCR.   
Target gene Primer sequence  
mEgr1 (F) 5’-CCTTTTCTGACATCGCTCTGAA-3’ 
 (R) 5’-CGAGTCGTTTGGCTGGGATA-3’ 
mHPSE (F) 5’-GGAGCAAACTCCGAGTGTATC-3’ 
 (R) 5’-CAGAATTTGACCGTTCAGTTGG-3’ 
mHPSE (F) 5’-CAAGAAGGAATCAACCTTTGAAG-3’ 
 (R) 5’-GTAGTCCAGGAGCAACTGAG-3’ 
mPolRIIA (F) 5’-GTCCTCTACTCATGCTGTCTTGG-3’ 
 (R) 5’-AAATGCCTGTATCCCAATCAAG-3’ 
mL-19 (F) 5’-GAATGGCTCAACAGGTAAACA-3’ 
 (R) 5’-GGGTTCCAGAGTCAAGTTCAG-3’ 
hEgr (F) 5’-GAGCAGCCCTACGAGC-3’ 
 (R) 5’-AGCGGCCAGTATAGGT-3’ 
hHPSE (F) 5’-GTTCTAATGCTCAGTTGCTCCT-3’ 
 (R) 5’-ACTGCGACCCATTGATGAAA-3’ 
hGUS-β (F) 5’-CACAAGAGTGGTGCTGAGGA-3’ 
 (R) 5’-GTATTGGATGGTCCCTGGTG-3’ 
 
Heparanase activity assay 
For measurements of heparanase enzymatic activity, tissue lysates were incubated (16-36 
hours, 37°C, pH 6.2) on dishes coated with sulfate-labeled ECM, and analyzed as described 
[8]. Nearly intact heparan sulfate proteoglycans are eluted just after the void volume (peak I, 
Kav < 0.2, fractions 1-10) and HS degradation fragments are eluted later with 0.5< Kav <0.8 
(peak II, fractions 15-35) (8). These fragments were shown to be degradation products of HS 
as they were 5-6 fold smaller than intact HS side chains, resistant to further digestion with 
papain and chondroitinase ABC, and susceptible to deamination by nitrous acid.  
 
Chromatin immunoprecipitation (ChIP) 
Cross-linking of proteins to DNA, chromatin isolation and sonication was performed as 
described [30]. ChIP was performed with 5 µg of anti-Egr1 (s.c H-250) or anti-LAMP1 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) preincubated with magnetic bead-
conjugated rabbit IgG (Dynal Biotech ASA, Norway) at 4oC, overnight with rotation. Elution of 
immune complexes, reverse cross-linking and DNA extraction were carried out as previously 
described [30]. PCR analysis was performed using 5 µl of immunoprecipitated chromatin or 
input chromatin, using Titanium Taq PCR kit (Clontech, Mountain View, CA). Amplifications 
(38 cycles) were performed using specific primer set that covers functional Egr1 binding site 
in the heparanase promoter [31]. The following primers were used: Hpse promoter forward 
5’-TTCGTAAGTGAACGTCACCG-3’, reverse 5’-CTTCTGCATCCCTCCCACT-3’;  
L-19 forward 5’-ATGCCAACTCTCGTCAACAG-3’, reverse 5’-GCGCTTTCGTGCTTCCTT-3’. 
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Statistical analysis 
Values are expressed as mean ± SEM. Statistical analysis was performed using t-test or 
Mann-Whitney test. A p value of < 0.05 was considered significant. 
 
 
Results 
 
Heparanase KO mice fail to develop DN in response to streptozotocin induced 
diabetes 
Although several findings link heparanase to DN (reviewed in [5]), direct mechanistic 
demonstration of the role of the enzyme in the pathogenesis of this disease was not 
available. Here, to provide decisive evidence that heparanase is causally involved in the 
pathogenesis of DN, we utilized the model of STZ-induced DN [32] in heparanase null (Hpse-
KO) mice and their wt littermates. The Hpse-KO mice are fertile, viable and show normal 
gross appearance [22], including kidney size and renal histology. Blood glucose, serum 
creatinine, urea nitrogen (not shown) and urinary albumin excretion (Figure 1C) measured in 
healthy Hpse-KO mice were not different from those in wt littermates. Hpse-KO and wt mice 
were made hyperglycemic applying multiple low dose STZ administration (40 mg/kg/day for 5 
days), to mitigate the nonspecific renal toxicity of STZ [32]. By week 2 of the experiment, 
100% of the wt and KO mice developed diabetes as revealed by increased blood glucose 
levels (>300 mg/dL). Blood glucose levels were maintained at <350 mg/dL by treatment with 
insulin (0.4U/mouse), administered every other day. Mice were kept diabetic for 16 weeks 
and their urine samples were collected for analysis of albumin excretion. It should be noted 
that the body weight and blood glucose concentrations measured throughout the experiment 
(Table 2), as well as the amount of insulin required to maintain glycemic control, did not differ 
between Hpse-KO and wt mice.  
 
Table 2: Average blood glucose levels and body weight of Hpse-KO and wt mice on 
week 16 of the experiment.  
 Hpse-KO mice wt mice 
 Non-diabetic Diabetic Non-diabetic Diabetic 
Glucose (mg/dl) 96.09 ± 3.51 305.89 ± 19.09 93.57 ± 3.51 312.93 ± 17.24 
Mouse weight (g) 28 ± 1.1 29.8 ± 1.5 28 ± 1.74 28.4 ± 1.8 
 
Following 16 weeks of the experiment, mice were sacrificed, their kidneys excised and 
heparanase expression in the renal cortex was assessed by quantitative real-time PCR 
(qRT-PCR). A marked increase in heparanase mRNA was readily detected in the renal 
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cortex of diabetic wt mice, as compared to non-diabetic wt mice (p = 0.0493, Figure 1A). As 
expected, no heparanase mRNA was detected in the kidneys of either diabetic or non-
diabetic Hpse-KO mice (Figure 1A). In agreement with the increased expression of 
heparanase, immunofluorescence staining with anti-HS antibody HS4C3 [27] revealed 
statistically significant decrease in HS content along the GBM in the kidneys of diabetic vs. 
non diabetic wt mice, whereas no change in HS content was detected in the kidneys of 
diabetic Hpse-KO mice, as compared to their non-diabetic littermates (Figure 1B). 
Examination of albumin excretion in urine samples revealed a 5-fold increase in urine 
albumin excretion (quantified as µg albumin/mg creatinine) in diabetic wt mice vs. their non-
diabetic controls, while no increase in urine albumin excretion was noted in diabetic Hpse-KO 
mice compared to non-diabetic Hpse-KO mice (Figure 1C).  The occurrence of albuminuria 
was paralleled by glomerular morphological changes characteristic of DN (i.e., mesangial 
matrix expansion) in diabetic wt kidney tissue, exemplified by >2 fold increase in glomerular 
expansion score, as compared to normal glomerular architecture preserved in kidney tissue 
derived from diabetic Hpse-KO mice (Figure 2A-B).  Along with mesangial matrix expansion 
in glomeruli, tubulointerstitial injury is considered as a major feature of DN and an important 
predictor of renal dysfunction [33].  During progression of DN, the renal tubule is exposed to 
glomerular effluent, which includes, in addition to glycation end products and glucose, large 
quantities of protein. Excessive protein load to the proximal tubule ultimately leads to 
peritubular inflammation and fibrosis [33]. In agreement with this notion, massive interstitial 
fibrosis (as indicated by increased collagen deposition) was detected in the kidney of diabetic 
wt but not in diabetic Hpse-KO mice, by Masson’s trichrome staining (Figure 2C). 
Transforming growth factor-β (TGF-β) is implicated in cellular processes characteristic of DN, 
including glomerular hypertrophy with mesangial matrix expansion, renal tubular injury and 
interstitial fibrosis [34-36]. Immunohistochemical evaluation of TGF-β in kidney tissue 
specimens revealed a marked increase in TGF-β in diabetic wt mice vs. their non-diabetic 
controls (Figure 2D, left panels). No increase in TGF-β levels was noted in diabetic vs. non-
diabetic Hpse-KO mice (Figure 2D, right panels). In agreement, 2-fold increase in TGF-β 
mRNA expression was detected by qRT-PCR in the kidney of diabetic vs. non-diabetic wt 
mice, while no induction of TGF-β mRNA was noted in kidneys of diabetic Hpse-KO mice as 
compared to their non-diabetic littermates (not shown).  Macrophage accumulation is another 
characteristic feature of diabetic kidney disease, associated with both experimental and 
human DN [37-39]. Moreover, the intensity of the interstitial macrophage infiltrate is 
proportional to the rate of subsequent decline in renal function [39]. This notion led us to 
examine the degree of macrophage infiltration in wt and Hpse-KO diabetic kidney. Applying 
immunostaining with antibody directed against F4/80 (mouse macrophage specific marker 
[40]), we detected increased macrophage infiltration in the diabetic kidney of wt vs. Hpse-KO 
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mice (Figure 2E). Quantification of F4/80-positive macrophages per microscopic field, based 
on six sections from 3 independent mice of each group, revealed a 6-fold increase in 
macrophage accumulation in the cortex of diabetic vs. non-diabetic kidney in wt mice (95.3 
±15.8 vs. 15.9 ±10.5 macrophages/field, p=0.001), while no statistically significant difference 
in macrophage infiltration was noted in the kidneys of diabetic vs. non-diabetic Hpse-KO 
mice (63.9 ±27.7 vs. 40.9 ±10.3 macrophages/field, p>0.2). 
 
 
Figure 1: Changes in heparanase expression, HS content and urinary albumin excretion in wt 
and Hpse-KO mice in response to STZ induced diabetes. Kidney tissue samples were harvested 
from diabetic wt and Hpse-KO mice at 16 weeks after induction of diabetes and from their age-
matched non-diabetic littermates. (A) Heparanase expression in non-diabetic and diabetic kidney 
lysates was assessed by qRT-PCR (n=5 per experimental condition). (B) Semi-quantitative analysis of 
the glomerular HS recognized by antibody HS4C3. Staining intensity of HS was scored by three 
independent observers on a scale between 0 and 10 in arbitrary units (a.u.) expressed as means ± 
SEM (2 non-diabetic and 4 diabetic mice per genotype). (C) Urinary albumin excretion. 24 hour urine 
samples were collected from diabetic wt and Hpse-KO mice 16 weeks after induction of diabetes and 
from age-matched non-diabetic littermates. The experiment was repeated 3 times, n ≥ 5 per 
experimental condition. Albuminuria is expressed as µg albumin/mg creatinine. Urinary albumin (Alb) 
and creatinine (Cr) were determined as described in ‘Methods’. *p< 0.05. 
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Figure 2: Histopathological changes in the kidneys of wt and Hpse-KO mice in response to STZ 
induced diabetes. Kidney sections obtained from diabetic wt and Hpse-KO mice at 16 weeks after 
induction of diabetes and from age-matched non-diabetic littermates were processed for staining with 
periodic acid-Schiff (A), Masson-Trichrome (C) and for immunohistochemistry with antibodies directed 
against TGF-β1(D) and F4/80 (E). Representative microphotographs are shown, n ≥ 4 mice per 
experimental condition. (A,B) Glomerular mesangial expansion. (A) Representative glomerular 
histopathology. Note mesangial matrix expansion (black arrow), focal hypercellurarity (black 
arrowhead) and absence of visible clear vascular space in diabetic wt kidney (top, left), as compared 
to diabetic Hpse-KO kidney (top, right) displaying normal-looking glomerular structure, clear Bowman’s 
capsule (red arrow), clear vascular space (red arrowhead) and normal tuft architecture, resembling 
that of non-diabetic kidney (bottom). Original magnification X400. (B) Glomerular mesangial expansion 
scores in diabetic (black bars) wt and Hpse-KO mice and the age-matched non-diabetic littermates 
(grey bars). The scores were determined using light microscopy at x400, as described in ‘Methods’. 
**p< 0.001.  (C) Representative Masson's trichrome-stained kidney sections. Note higher degree of 
tubulointerstitial fibrosis (blue staining) in diabetic kidneys derived from wt vs. Hpa-KO mice. (D,E) 
Immunohistochemistry with antibodies directed against TGF-β1 (D) and F4/80 (E), reveals induction of 
TGF-β1 (D) and  increased accumulation of macrophages (E) in diabetic wt kidney (top, left), as 
compared to both diabetic Hpse-KO (top, right) and wt non-diabetic (bottom, left) kidney.  
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Induction of heparanase in diabetic kidney is mediated by Egr-1 transcription factor 
Causal involvement of heparanase in DN, along with the increased levels of heparanase 
observed in diabetic kidney tissue specimens [14] and in the urine and plasma of diabetic 
patients [13] prompted us to investigate how this enzyme is regulated under diabetic 
conditions. Highly relevant to DN setting, heparanase expression is induced in renal 
epithelial cells by high glucose [16]. However, the precise mechanism responsible for 
induction of heparanase by high glucose has not been fully elucidated. Among several 
factors controlling heparanase expression, the Early Growth Response 1 (Egr1) transcription 
factor is implicated in inducible transcription of the heparanase gene in immune cells and 
many (but not all) cancer cell types [31, 41, 42]. In light of the previously reported inducibility 
of Egr1 by glucose [43], it is logical to assume that when glomerular cells are exposed to 
high glucose levels (i.e., in the kidneys of diabetic patients), glucose-induced Egr1 may affect 
heparanase gene promoter activity, leading to over-expression of heparanase. To test this 
hypothesis, we first investigated the effect of glucose on Egr1 levels in kidney-derived cells. 
Human embryonic kidney (HEK-293) cells were exposed to increasing concentrations of 
glucose. Western blot analysis and qRT- PCR revealed a dose dependent increase in Egr1 
expression following exposure to glucose (Figure 3A). Similar results were obtained with HK-
160 human kidney epithelial cells (not shown). In agreement, a significant increase in Egr1 
mRNA and protein levels was revealed in mouse kidneys of diabetic C57BL/6 mice 10 weeks 
after induction of diabetes by STZ, as compared to healthy mice (Figure 3C and not shown), 
corroborating the relevance of the in vitro findings. This increase in Egr1 levels was 
invariably associated with induction of heparanase expression both in vitro (Figure 3B) and in 
the kidney tissue of diabetic mice, as demonstrated by real-time PCR, 
immunohistochemistry, immunoblotting and enzymatic activity assay (Figure 3D). 
These observations are in further support of our assumption that similar to immune and 
some cancer cells, in kidney tissue Egr1 acts as an activator of heparanase transcription. To 
further validate this hypothesis we applied the ChIP approach to study the effect of elevated 
levels of glucose on occupancy of the heparanase promoter by Egr1 in HEK-293 cells. For 
this purpose, HEK 293 cells were incubated in the presence of increasing concentrations of 
glucose (0; 1; and 4.5 g/l). Following chemical cross-linking, chromatin was isolated, 
sonicated to ~500-bp fragments and immunoprecipitated with anti-Egr1 antibody. DNA 
obtained from the immunoprecipitated chromatin was amplified using heparanase promoter-
specific primers, as well as a set of primers specific to the unrelated L-19 gene sequence, to 
normalize for equal chromatin amounts. As shown in figure 3E (top panels), markedly 
increased occupancy of the heparanase gene promoter by Egr1 was detected in cells that 
were incubated with high glucose. No enrichment was observed when antibody directed  
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Figure 3: Egr1 mediates glucose-induced over-expression of heparanase in the kidney. (A,B) 
Effects of glucose on Egr1 and heparanase expression in vitro. HEK 293 cells were incubated (1.5 
hours) in triplicates in the absence or presence of increasing concentrations of glucose (1, 2.5 and 4.5 
g/l). (A) Egr1 expression was assessed by immunoblotting of nuclear extracts (bottom) and qRT-PCR 
(top). (B) Heparanase mRNA expression was assessed by qRT-PCR. (C, D) Egr1 induction in the 
kidneys of diabetic mice correlates with over-expression of heparanase. (C) Kidney tissue was 
harvested from non-diabetic and diabetic mice 10 weeks after induction of diabetes by STZ and Egr1 
mRNA expression was determined by qRT-PCR. Error bars represent ±SE (n= 4 mice for each group). 
(D) Heparanase expression in non-diabetic and diabetic kidney lysates was assessed by qRT-PCR 
(left), immunostaining (left, inset), enzymatic activity assay (right) and immunoblotting (right, inset). (E) 
Increased recruitment of Egr1 to the heparanase promoter in the presence of high glucose. Following 
cross-linking of proteins to DNA, chromatin was isolated from HEK 293 cells incubated (1.5 hours) in 
the presence of increasing concentrations of glucose (0, 1, and 4.5 g/l), sonicated into fragments of 
average length ≤500 bp and immunoprecipitated with antibodies against Egr1 (top panels), or an 
unrelated protein LAMP1 (middle panels). The final DNA extractions were amplified using primer set 
that covers functional Egr1 binding site in the heparanase promoter (left panels), or primer set specific 
to unrelated L-19 gene sequence, used as control (right panel). Samples were equilibrated for DNA 
loading amounts using primers specific to the heparanase promoter and DNA that was PCR amplified 
from chromatin preparations before immunoprecipitation (lower panels). The results are representative 
of three independent experiments. *p<0.05, **p<0.01, ***p<0.001.   
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against an irrelevant protein (LAMP1) was used for the ChIP analysis (Figure 3E, middle 
panels). 
Finally, to validate the ability of Egr1 to induce heparanase expression in our system, HEK-
293 cells were co-transfected with plasmids encoding for luciferase (LUC) driven by  
heparanase promoter [44] together with either Egr1 expressing vector (pEgr1) or empty 
pcDNA3 vector and incubated in the absence or presence of 4.5 g/l glucose.  Luciferase 
activity was measured in cell lysates 24 hours post transfection and normalized with β-
galactosidase. A 3-fold increase in heparanase promoter activity was detected in cells 
(incubated in medium without glucose) that were co-transfected with the Egr1 expressing 
vector, as compared to cells co-transfected with empty vector (p<0.05; Figure 4). Notably, 
both co-transfection with pEgr1 or incubation with high glucose levels activated heparanase 
promoter to a similar extent (Figure 4), in further support of the role of Egr1 in glucose-
induced heparanase expression. Collectively these results demonstrate that in the presence 
of elevated glucose levels Egr1 directly binds to the heparanase promoter and stimulates its 
transcriptional activity. 
 
 
Figure 4: Egr1 expression and high glucose levels activate heparanase promoter in HEK 293 
cells. HEK 293 cells were co-transfected with plasmid encoding for luciferase (LUC) driven by the 
heparanase promoter (Hpa-LUC) reporter gene construct and with either Egr1 expressing vector 
(pEgr1) (filled bar), or empty plasmid (pcDNA3) (empty bars), and incubated (24 hours) in the absence 
or presence of glucose (4.5 g/l). LUC activity in cell lysates was measured 24 hours later and 
normalized with β-Gal. Error bars represent ±SE.*p<0.05. 
 
Specific heparanase inhibitor decreases albuminuria in mouse models of DN  
The above-described results led us to hypothesize that inhibition of excessive heparanase  
(induced in diabetic kidney via Egr1 dependent mechanism) may prevent the progression of 
DN in a manner similar to that observed in Hpse-KO mice (Figure 1-2). To validate this 
hypothesis, we investigated the effect of the specific heparanase inhibitor SST0001 on the 
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development of proteinuria in diabetic mice. Compound SST0001 is 100% N-acetylated, 25% 
glycol-split heparin that effectively inhibits heparanase enzymatic activity in vitro and, unlike 
unmodified heparin, is devoid of anticoagulant and pro-angiogenic activities [23, 24, 45]. The 
effectiveness of SST0001 in suppressing the biological activity of heparanase in vivo was 
demonstrated in models of heparanase-driven processes other than DN, such as 
inflammation, tumor growth and metastatic spread [24, 26, 46]. To test the effect of 
heparanase inhibition on DN, we utilized BALB/c mouse strain, known to be particularly 
prone to DN [25]. Diabetes was induced by multiple low dose STZ administration (40 
mg/kg/day for 5 days). Five days after the last STZ administration, diabetic mice (blood 
glucose levels >300 mg/dL) were divided into 2 groups (n=7) and treated with either 
SST0001 (administered i.p. twice a day, 300 µg per injection) or vehicle (saline) alone. Blood 
glucose levels in experimental mice were maintained at ~300 mg/dL by treatment with 0.4U 
insulin, administered every other day. As expected, 12 weeks after induction of diabetes, a 
marked increase in 24 h albumin excretion was detected in the urine of vehicle treated 
diabetic BALB/c mice (Figure 5, black bars). Importantly, SST0001 treatment resulted in a 
statistically significant (p < 0.0351) two-fold decrease in 24 h albumin excretion (Figure 5, 
gray bars). The difference between 24 h albumin excretion in SST0001-treated vs. vehicle-
treated mice was maintained on week 16 of the experiment as well, although it did not reach 
statistical significance (not shown). In addition, assessment of renal function in vehicle 
treated diabetic mice on experimental week 16 revealed a significant increase in serum 
creatinine (p=0.016) and blood urea nitrogen BUN (p=0.0171) (Figure 5B, black bars), as 
compared to healthy non-diabetic mice, while in SST0001 treated diabetic mice the 
corresponding values did not increased significantly compared to those observed in non-
diabetic mice (Figure 5B, gray bars). In a similar manner, treatment with SST0001 resulted in 
a ≥ 2 fold decrease in 24 h urinary albumin excretion in two additional in vivo experimental 
systems: STZ-induced type 1 DN in DBA-2 mice (data not shown), which, along with BALB/c 
strain, is considered  as one of the most useful platforms for DN modeling [25], and in type 2 
DN in obese db/db mice (p=0.010)  (data not shown), regarded as one of the best genetic 
models of diabetic renal disease [47], further validating heparanase inhibition as a possible 
therapeutic approach in DN. 
 
 
Discussion 
 
Diabetes mellitus and its complications represent one of the most important health problems 
worldwide, which is likely to worsen to critical levels in the next decades [3]. Therefore, DN 
(one of the most relevant complications secondary to diabetes) is becoming one of the  
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Figure 5: Effect of SST0001 on albuminuria and renal damage in diabetic BALB/c mice. Mice 
were made hyperglycemic applying multiple low dose STZ as described in ‘Methods’ and either 
remained untreated (black bars) or treated with compound SST0001 (300 µg/mouse injected twice a 
day i.p.) for 12 weeks (grey bar).(A) 24-hour albumin excretion on week 1 and 12 after the onset of 
diabetes was monitored by ELISA. Seven mice per experimental condition were used. Treatment of 
diabetic mice with SST0001 resulted in more than 2 fold decrease in urine albumin (*p=0.035). (B) 
Vehicle treated diabetic mice exhibited a significant increase in serum creatinine (left, **p=0.0157) and 
BUN (right, **P=0.0171), as compared to healthy mice (n= 5 mice per group). The corresponding 
values in SST0001 treated diabetic mice did not increased significantly compared to basal levels.  
 
primary medical concerns [1-3]. Thus, more data about the identity of downstream effectors 
responsible for DN pathogenesis are needed to properly address the disease treatment.  
Considerable progress has been made in deciphering the role of multiple signaling pathways 
leading to kidney damage in diabetic patients. Much less is known about the exact role of 
ECM-degrading enzymes in DN pathophysiology. Here we demonstrate for the first time the 
essential involvement of heparanase in experimental DN and describe a molecular 
mechanism underlying heparanase induction under hyperglycemic conditions.  
Despite the lack of experimental data directly confirming causative role of heparanase in the 
pathogenesis of DN, several reports pointed on a possible link between heparanase and DN 
[4, 5]. On the other hand, relationship between heparanase and DN progression was 
disputed in recent publications, opposing the involvement of the enzyme in diabetic kidney 
disease [20, 21]. In light of this controversy, recent generation of heparanase-null (Hpse-KO) 
mice [22] offered a unique opportunity to assess the relevance of heparanase to the 
development of DN. Importantly, all Hpse-KO mice utilized in our experiments failed to 
develop proteinuria in response to STZ-induced diabetes, and their urinary albumin excretion 
rate remained at the same level as before the onset of diabetes. In contrast, >5-fold increase 
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in urinary excretion rate of albumin was detected in wt mice following STZ-induced diabetes. 
In addition, heparanase deficiency resulted in amelioration of mesangial matrix expansion, 
macrophage infiltration, tubulointerstitial fibrosis and TGF-β over-expression in the diabetic 
kidneys of Hpse-KO vs. wt mice. In further support of a causal involvement of heparanase in 
DN are our findings showing lower degree of albuminuria in type 1 and type 2 diabetic mice 
treated with the heparanase inhibitor SST0001 vs. mice treated with vehicle alone. 
Amelioration of albuminuria by SST0001 represents a proof of concept for heparanase 
inhibition as a relevant therapeutic approach in DN and warrants further studies aimed at 
identifying the most effective dose and schedule administration schemes for SST0001 
treatment, toward future translation to clinical setting.  
In addition, elucidation of the precise molecular mechanism(s) underlying heparanase 
induction and pathogenic action in diabetic kidney is critically important toward effective 
implementation of anti-heparanase treatment modalities in the future.  Here we report that 
the transcription factor Egr1 mediates over-expression of heparanase in diabetic kidney. In 
agreement with the previously reported glucose responsiveness of Egr1 in other cell types 
[48], we have demonstrated dose-dependent induction of Egr1 expression in cultured kidney 
cells in vitro, and in diabetic kidney in vivo.  Interestingly, Egr1 can both induce and repress 
the expression of heparanase, depending on the tissue/cell type; it was shown to activate 
heparanase expression in T lymphocytes and carcinomas of the breast, prostate and colon, 
but to inhibit heparanase transcription in melanoma and pancreatic carcinoma cells [31, 49]. 
Transactivation studies using Egr1 expression vector, co-transfected with a heparanase 
promoter - reporter construct, showed that in kidney cells Egr1 acts to stimulate heparanase 
transcription. At the same experimental setting, ChIP analysis revealed increased occupancy 
of the heparanase promoter by Egr1 in the presence of elevated glucose levels, further 
confirming the role of  Egr1 in glucose-dependent  induction of heparanase in the kidney. 
A limitation of the present study is that our findings do not provide enough information 
regarding the exact mode of heparanase action in DN pathogenesis. In the past it was 
generally accepted that induction of glomerular heparanase in the course of diabetes may 
contribute to DN progression primarily through degradation of HS in the GBM. Findings 
supporting importance of HS integrity in permselectivity of the glomerular filtration (reviewed 
in [19]), include: i) occurrence of massive proteinuria following administration of monoclonal 
anti-HS antibody to rats, ii) increased GBM permeability as a result of HS removal, and iii) 
decreased GBM HS content in human/experimental diabetes, which inversely correlated with 
the degree of proteinuria. Nevertheless, the impact of GBM-residing HS and its enzymatic 
degradation on DN development was questioned by several recent studies, showing no 
change in glomerular HS content/structure in early human and experimental DN [20, 21]. 
These reports challenged the notion that heparanase-mediated loss of HS in the GBM is the 
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primary mechanism implicating the enzyme in DN. In parallel, it was suggested that 
additional mechanisms (i.e., changes in glomerular cell-GBM interactions due to loss of HS, 
or release of HS-bound growth factors, cytokines and bioactive HS fragments in the 
glomeruli) may drive heparanase-mediated renal failure [4, 5]. In addition, our unpublished 
results indicate that a previously unappreciated mechanism (i.e., heparanase-driven 
activation of macrophages leading to unresolved inflammation [26]) may be critically 
important in DN, as well as in additional kidney pathologies previously linked to heparanase 
[4, 5]. The important role of chronic inflammation and macrophages in DN [37-39, 50],  taken 
together with the reduced number of macrophages infiltrating Hpse-KO diabetic kidneys 
(Figure 2E) and the recently revealed ability of heparanase to facilitate macrophage 
activation by lipopolysaccharide [26] and by components of the diabetic milieu (i.e., glucose, 
our unpublished data), strongly suggest that under diabetic conditions, heparanase, induced 
in the kidney epithelium via Egr1 dependent mechanism, sustains continuous activation of 
kidney-damaging macrophages, thus fostering DN development and progression. Studies 
are underway to accurately evaluate the pathophysiological significance of each of the 
above-mentioned heparanase-dependent mechanisms in DN progression and thus better 
define future combination treatment options, as well as target patient populations in whom 
future anti-heparanase therapies could be particularly beneficial.   
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Abstract 
 
Proteinuria is one of the first clinical signs of diabetic nephropathy (DN) and an independent 
predictor for the progression to renal failure. Cathepsin L, a lysosomal cysteine protease, can 
be involved in the development of proteinuria by degradation of proteins that are important 
for normal podocyte architecture, such as the CD2-associated protein, synaptopodin and 
dynamin. Cathepsin L also activates heparanase, a heparan sulfate (HS) endoglycosidase 
previously shown to be crucial for the development of DN. In the current study, we evaluated 
the exact mode of action of cathepsin L in the development of proteinuria in streptozotocin-
induced diabetes. Cathepsin L-deficient mice, in contrast to their WT littermates, failed to 
develop albuminuria, mesangial matrix expansion, tubulointerstitial fibrosis, renal 
macrophage influx and showed a normal renal function. In WT mice the early development of 
albuminuria correlated with the activation of heparanase and loss of HS expression, whereas 
loss of synaptopodin expression and podocyte damage occurred at a later stage. Our results 
indicate that cathepsin L is causally involved in the pathogenesis of experimental DN. Most 
likely, cathepsin L-dependent heparanase activation is crucial for the development of 
albuminuria and renal damage.  
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Introduction 
 
Diabetic nephropathy (DN) is the leading cause of end-stage-renal-disease in the Western 
world [1, 2]. Proteinuria is one of the first clinical signs of DN and microalbuminuria is an 
independent risk factor for the progression of renal failure [3]. Proteinuria is caused by 
damage to the glomerular filtration barrier (GFB), which consists of glomerular endothelial 
cells covered by a glycocalyx, the glomerular basement membrane (GBM) and podocytes. 
Damage to any of these layers can eventually result in the development of proteinuria, and 
therefore all layers need to be intact to maintain a normal filtration barrier [4, 5].  
Cathepsin L is a lysosomal cysteine protease involved in the breakdown of proteins and the 
activation of enzymes. Cathepsin L-deficient mice are fertile, develop normal and have no 
visible or renal phenotype. However, some reports have described that cathepsin L-deficient 
mice display periodic hair loss, skin thickening, bone and heart defects, an enhanced 
susceptibility to bacterial infections, and reduced serum levels of glucose [6-9]. Cathepsin L 
expression is increased in many glomerular diseases, such as membranous 
glomerulonephritis (MGN), minimal change disease (MCD), focal segmental 
glomerulosclerosis (FSGS) and DN [10]. Previous studies associated the induction of 
cathepsin L expression in podocytes, either by lypopolysaccharide (LPS) or puromycin 
aminonucleoside (PAN), with the development of proteinuria [10, 11]. Importantly, treatment 
with cathepsin inhibitor cysteine-type cathepsins trans-epoxysuccinyl-L-leucylamido-(4-
guanidino)butane (E-64) reduced proteinuria in rats with accelerated anti-GBM disease [12]. 
Recent studies suggest that the onset of proteinuria reflects a migratory event in the foot 
processes of the podocyte that is associated with the activation of cathepsin L [11]. Three 
known substrates of cathepsin L in the podocyte are the CD2-associated protein (CD2AP), 
synaptopodin and dynamin [10, 13, 14]. CD2AP, synaptopodin and dynamin are proteins that 
are crucial for the normal architecture of the cytoskeleton of the podocyte, and cathepsin L-
mediated degradation of CD2AP, synaptopodin and dynamin has been associated with the 
reorganization of the actin cytoskeleton, foot process effacement, proteinuria and renal 
failure [10, 14-19].  
In addition to the breakdown of CD2AP, synaptopodin and dynamin, cathepsin L is also 
involved in the activation of heparanase. Heparanase is an endo-β(1,4)-D-glucuronidase that 
cleaves the negatively charged heparan sulfate (HS) side chains of HS proteoglycans 
(HSPGs), which are abundantly expressed in basement membranes and at the surface of 
various cell types. HSPGs are involved in cell-cell and cell-matrix interaction, and function as 
a (co)receptor for the binding of various bioactive molecules, such as chemokines, cytokines 
and growth factors [20, 21]. The expression of HS is decreased in many (experimental) 
glomerular diseases, and this decrease inversely correlates with the level of proteinuria [5, 
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22, 23]. Heparanase is synthesized as a pre-proheparanase of 68 kDa, which is processed 
into a proheparanase by removing the signal peptide in the endoplasmatic reticulum. 
Proheparanase is further processed in the lysosomes into an active heparanase heterodimer 
by cathepsin L-mediated cleaving of a 10 kDa linker domain [24]. We recently showed that 
heparanase is crucial for the development of proteinuria in DN [25]. In response to 
streptozotocin-induced diabetes, heparanase-deficient mice, in contrast to their wild type 
(WT) littermates, failed to develop proteinuria and renal failure. In addition, treatment with the 
heparanase inhibitor SST0001 reduced proteinuria and improved renal function [25]. 
Moreover, we showed that heparanase, induced by high glucose and activated by cathepsin 
L, contributes to the inflammatory cascade during the pathogenesis of DN, by sustaining 
macrophage activation [26].    
As stated, cathepsin L may be involved in the pathogenesis of proteinuria at several levels, 
including the degradation of CD2AP, synaptopodin and dynamin, and the activation of 
heparanase. In the current study, we evaluated the role of cathepsin L in the development of 
proteinuria by inducing diabetes in cathepsin L-deficient mice and their WT littermates. Our 
results indicate that cathepsin L is causally involved in the pathogenesis of proteinuria in DN. 
Most likely, cathepsin L-mediated activation of heparanase results in the loss of glomerular 
HS expression and the development of proteinuria.  
 
 
Materials and methods 
 
Animals  
C57BL/6n mice (Charles River Laboratories, Wilmington, MA, USA) and cathepsin L-
deficient mice in a C57BL/6n background [7] were kept under pathogen-free conditions and 
housed in a temperature-controlled room with a 12-hour light/dark cycle with ad libitum 
access to food and water. All experiments were approved by the Animal Ethical Committee 
of the Radboud University Nijmegen.  
 
Streptozotocin-induced diabetes 
6-8-week-old WT and cathepsin L-deficient mice were injected intraperitoneally with 50 
mg/kg streptozotocin (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) in 250 mM 
sodium citrate buffer (pH 4.5) or sodium citrate buffer alone for 5 consecutive days, after a 4 
hour fasting period. Blood glucose levels were measured twice a week using the Accu-Chek 
Aviva Blood Glucose Meter (Roche Diagnostics, Almere, The Netherlands). Mice were 
implanted half an insulin pellet (LinShin Canada, Toronto, Canada) when their blood glucose 
level raised above 25 mmol/l. Mice were sacrificed after 4, 8 and 16 weeks, and kidneys and 
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blood were collected. Collected kidneys were snap frozen in liquid nitrogen. Urine was 
collected after 18 hours in metabolic cages. Six mice were used per time-point. Urinary 
albumin was measured by radial immunodiffusion (Mancini) and blood urea nitrogen 
concentrations were determined routinely in our clinical diagnostic facility. Plasma creatinine 
concentrations were measured by HPLC as described previously [27]. 
 
RNA isolation and real-time PCR 
Total RNA was isolated from renal cortex using the RNeasy mini-kit (Qiagen, Venlo, The 
Netherlands). Reversed transcription of 1 µg RNA was performed using the RevertAid First 
Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). Quantitative real-time 
PCR was performed using SYBR Green SuperMix (Roche Diagnostics, Mannheim, 
Germany) with gene-specific primers (10µM; Isogen Life Sciene, De Meern, The 
Netherlands) (Table 1) on the CFX real-time PCR system (Bio-Rad Laboratories, Hercules, 
CA, USA). Gene expression levels were quantified by the delta-delta CT method using RNA 
polymerase II as the housekeeping gene.  
 
Table 1: Primers used in real-time PCR.   
Target gene Primer sequence  
RNA polymerase II (F) 5’-AGCCCACGATATACACCACAG-3' 
 (R) 5’-AGCTGGGACTGTAGGAAGGACTA-3’ 
Heparanase (F) 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’ 
 (R) 5’-GATCCAGAATTTGACCGTTCAGTTGG-3’ 
Cathepsin L (F) 5’-TCTGTTGCTATGGACGCAAG-3’ 
 (R) 5’-CCGGTCTTTGGCTATTTTGA-3’ 
TGF-β1 (F) 5’-GAGCGACGTCACTGGAGTTGTACG-3’ 
 (R) 5’-GATCCCGTTGATTTCCACGTGGAG-3’ 
CTGF (F) 5’-GTCCAGACCACAGAGTGGAG-3’ 
 (R) 5’-CTCCAGGTCAGCTTCGCAG-3’ 
TNF-α (F) 5’-CATCTTCTCAAAATTCGAGTGACAA-3’ 
 (R) 5’-TGGGAGTAGACAACGTACAACCC-3’ 
IFN-γ (F) 5’-GGTGACCTTGTGACAAGCTC-3’ 
 (R) 5’-TGCTGTGTGGTCTGTCTGTC-3’ 
TGF-β1, transforming growth factor-β1; CTGF, connective tissue growth factor; TNF-α, tumor necrosis 
factor-α; INF-γ, interferon-γ. F, forward; R, reverse. 
 
Immunofluorescence staining 
Immunofluorescence staining was performed on renal cryosections (2 µm) as described [28]. 
Primary antibodies included anti-CD68 (MCA1957, Serotec, Oxford, UK), anti-heparanase 
(HPA1, ProsPecTany, Rehovot, Israel), anti-synaptopodin (G1D4, Progen, Heidelberg, 
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Germany), anti-desmin (Y-20, Santa Cruz Biotechnology, Dellas, Texas, USA), anti-WT1 (C-
19, Santa Cruz), anti-VCAM-1 (Novus Biologicals, Abingdon, UK)  and the VSV-tagged anti-
HS antibody HS4C3 (recognizing N-, 2-O, 3-O and 6-O sulfation) [29]. Appropriate 
secondary antibodies included Alexa 488-conjugated antibodies (Invitrogen Life 
Technologies, Breda, The Netherlands) and the anti-VSV-Cy3 antibody (Sigma-Aldrich 
Chemie, Zwijndrecht, The Netherlands). For visualization of the capillary loops we used the 
hamster anti-agrin antibody (MI91) [30], which is recognized by anti-hamster Cy-3-labeled 
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). Glomerular 
heparanase, HS, synaptopodin, desmin and VCAM-1 were scored semiquantitatively for 
linearity and/or intensity on a scale between 0 and 5 (0= no staining, 2.5= 50% staining and 
5= 100% staining) for heparanase, desmin and VCAM-1, and a scale between 0 and 10 (0= 
no staining, 5= 50% staining, 10= 100% staining) for HS and synaptopodin, respectively. 
Tubulointerstitial influx of macrophages was scored semiquantitatively from 0 to 5 (0: no 
macrophage influx; 1: macrophage influx <5% in area; 2: macrophage influx 5-15% in area; 
3: macrophage influx 15-25% in area; 4: macrophage influx 25-50% in area; 5: macrophage 
influx >50% in area). Tubulointerstitial macrophage score was obtained by averaging scores 
from 10 randomly chosen microscopic fields per mouse. The number of podocytes per 
glomerulus was determined by counting the number WT-1 positive cells per 50 glomeruli and 
averaging the numbers. Scoring was performed by two independent investigators on blinded 
sections using a Leica CTR6000 microscope.  
 
Renal histology 
Renal tissue was fixed in 4% buffered formaldehyde and embedded in paraffin. Sections (5 
µm) were deparaffinized and stained with periodic acid-Schiff and Masson’s trichrome. 
Mesangial matrix expansion was scored semiquantitatively as described previously [25]. 
Briefly, mesangial matrix expansion in each glomerulus was scored from 1 to 4 (1: no 
mesangial expansion; 2: mesangial expansion in 25%-50% of the glomerulus; 3: mesangial 
expansion in 50%-75% of the glomerulus; 4: mesangial expansion in >75% of the 
glomerulus). Mesangial expansion score was obtained by averaging scores from 50 
glomeruli in one section. Tubulointerstitial fibrosis was scored semiquantitatively from 1 to 4 
(1: no fibrosis; 2: mild fibrosis (10-30% in area); 3: moderate fibrosis (30-50% in area); 4: 
severe fibrosis (>50% in area)) as described [31]. Tubulointerstitial fibrosis score was 
obtained by averaging scores from 10 microscopic fields per mouse section.         
 
Cathepsin L and heparanase activity assays 
Cathepsin L activity in renal cortex was determined using a commercially available assay 
(Abcam, Cambridge, UK) according to manufacturer’s instructions.  
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Heparanase activity in renal cortex was determined using a commercially available assay 
(AMS Biotechnology, Abingdon, UK) according to manufacturer’s instructions.  
 
Determination of glomular ultrastructure by Transmission Electron Microscopy 
Small pieces of cortex were fixed in 2.5% glutaraldehyde dissolved in 0.1 M sodium 
cacodylate buffer (pH 7.4). After an overnight incubation at 4ºC, samples were washed in 
cacodylate buffer. Samples were postfixed in Palade-buffered 2% OsO4 for 1 hour, 
dehydrated, and embedded in Epon 812, Luft’s procedure (Merck, Darmstadt, Germany). 
Ultrathin sections were stained with 4% uranyl acetate for 45 minutes and subsequently with 
lead citrate for 5 minutes at room temperature. Sections were analyzed with a Jeol JEM 1400 
electron microscope (JEOL, Tokyo, Japan).   
 
Determination of urinary IgG levels by ELISA 
Mouse IgG levels were measured using a commercially available assay (Roche Diagnostics, 
Mannheim, Germany) according to manufacturer’s instructions.  
 
Statistical analysis 
Values are expressed as mean ± SEM. Significance was determined by a one-way ANOVA 
and post hoc analysis with Tukey’s multiple comparison test. Comparison of expression 
between two different groups was evaluated using the Student’s t-test. Statistical analysis 
was performed using GraphPad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA). 
A p-value of ≤ 0.05 was considered statistically significant.   
 
 
Results 
 
Cathepsin L expression and activity are increased in response to STZ-induced 
diabetes 
Although recent studies suggest that cathepsin L is involved in the pathogenesis of 
proteinuria, the exact role of cathepsin L in the pathogenesis of DN is still unknown. To 
evaluate the role of cathepsin L in the pathogenesis of proteinuria in DN, we induced type 1 
diabetes in WT and cathepsin L-deficient mice following the low-dose streptozotocin 
induction protocol to avoid the non-specific renal toxicity effects of streptozotocin [32]. One 
week after induction of diabetes, all mice developed diabetes, as measured by their blood 
glucose levels (>16 mmol/l). Blood glucose levels remained high throughout the experiment 
(Table 2). Mice were sacrificed 4, 8 and 16 weeks after the induction of diabetes. Blood 
glucose levels (Table 2), body weight (Table 2) and the amount of insulin required to 
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maintain glycemic control did not differ between diabetic WT and diabetic cathepsin L-
deficient mice (data not shown). As described previously, non-diabetic cathepsin L-deficient 
mice have a better glucose control than non-diabetic WT mice [6]. Cortical cathepsin L 
mRNA expression in WT mice was significantly increased 16 weeks after the induction of 
diabetes (Figure 1A). Cortical cathepsin L activity was increased 4 and 8 weeks after the 
induction of diabetes, but comparable to control after 16 weeks (Figure 1B). As expected, 
cathepsin L was not expressed or active in the cathepsin L-deficient mice (Figure 1A-B).   
 
Table 2: Average blood glucose levels and body weight of WT and CTSL-KO mice at 
week 4, 8 and 16. 
 WT mice  CTSL-KO mice 
 Non-diabetic Diabetic Non-diabetic Diabetic 
4 weeks     
Blood glucose (mmol/l) 8.4 ± 1.9 21.2 ± 8.6 6.2 ± 0.4 21.7 ± 3.8 
Body weight (g) 24.2 ± 3.7 23.9 ± 3.4 23.9 ± 2.7 23.3 ± 1.0 
     
8 weeks     
Blood glucose (mmol/l) 7.9 ± 0.9 22.3 ± 3.0 6.8 ± 1.3 22.8 ± 2.0 
Body weight (g) 25.3 ± 3.8 23.2 ± 2.8 24.9 ± 1.4 24.5 ± 0.6 
     
16 weeks     
Blood glucose (mmol/l) 7.8 ± 0.7 21.3 ± 3.1 6.6 ± 1.3 21.3 ± 3.4 
Body weight (g) 30.2 ± 5.5 23.8 ± 3.2 26.3 ± 1.8 24.9 ± 1.8 
WT, wild type; CTSL-KO, cathepsin L-deficient. The mean ± SD of six mice per group are depicted.  
 
 
Figure 1: Streptozotocin-induced diabetes increased cortical cathepsin L expression and 
activity in WT mice. (A) Cathepsin L mRNA expression in WT mice was significantly increased 16 
weeks after the induction of diabetes. (B) Cathepsin L activity in WT mice was significantly increased 
4 and 8 weeks after induction of diabetes. Cathepsin L was not expressed or active in the cathepsin L-
deficient mice. 5-6 mice per group were used for analysis. Dotted lines indicate relative cathepsin L 
mRNA expression or activity of non-diabetic control mice. #P<0.05 versus non-diabetic control. 
*P<0.05 versus diabetic WT mice. WT; wild type. CTSL-KO; cathepsin L-deficient.     
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Cathepsin L-deficient mice fail to develop albuminuria and show better renal function 
after induction of experimental DN 
Diabetic WT mice developed a significant albuminuria (4-fold increase in albumin-creatinine 
ratio versus non-diabetic controls), starting at week 4 and continuing until week 16, whereas 
diabetic cathepsin L-deficient mice failed to develop significant albuminuria (Figure 2A). Next 
we evaluated whether albuminuria in diabetic WT mice was caused by glomerular damage. 
The development of albuminuria in diabetic WT mice was accompanied by an increased IgG 
excretion in the urine (Figure 2B), indicating that the development of albuminuria in the 
diabetic WT mice is caused by glomerular damage. Renal function, as measured by the 
blood urea nitrogen (BUN) concentration and plasma creatinine concentration, was impaired 
16 weeks after induction of diabetes in the WT mice, but remained normal in the cathepsin L-
deficient mice (Figure 2C-D).   
 
Cathepsin L-deficient mice fail to develop DN in response to STZ-induced diabetes 
Characteristics features of DN include mesangial matrix expansion, tubulointerstitial fibrosis 
and macrophage infiltration. WT mice developed mild mesangial matrix expansion 16 weeks 
after the induction of diabetes, whereas diabetic cathepsin L-deficient mice did not develop 
mesangial matrix expansion (Figure 3A). A mild, but progressive tubulointerstitial fibrosis, as 
indicated by an increased collagen deposition, was observed in WT mice 8 and 16 weeks 
after the induction of diabetes, which was significantly reduced in the diabetic cathepsin L-
deficient mice (Figure 3B). The mRNA expression of the cytokine transforming growth factor 
(TGF)-β1, which is involved in the induction of fibrotic processes [33, 34], was significantly 
increased in the diabetic WT mice after 8 and 16 weeks, whereas TGF-β1 expression 
remained normal in the cathepsin L-deficient mice, except for week 4 (Table 3). The 
expression of connective tissue growth factor (CTGF), another fibrogenic protein [35], was 
significantly higher in the diabetic WT mice versus diabetic cathepsin L-deficient mice (Table 
3).  
Macrophage accumulation in the diabetic kidney may predict a decline in renal function [36]. 
Tubulointerstitial macrophage infiltration was significantly increased in diabetic WT mice, 
starting at week 4 and continuing until week 16, which was not observed in diabetic 
cathepsin L-deficient mice (Figure 3C). Macrophages can be activated by cytokines such as 
tumor necrosis factor (TNF)-α and interferon (IFN)-γ. We observed an increased TNF-α and 
INF-γ mRNA expression in the diabetic WT mice, whereas TNF-α and IFN-γ mRNA 
expression were normal in the diabetic cathepsin L-deficient mice (Table 3).  
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Figure 2: Cathepsin L-deficient mice show better renal function during streptozotocin-induced 
diabetes. (A) The albumin/creatinine ratio was significantly increased in diabetic WT mice compared 
with non-diabetic WT mice 4, 8, and 16 weeks after induction of diabetes. Cathepsin L-deficient mice 
failed to develop albuminuria at these time points. (B) IgG excretion in the urine, as measured by an 
IgG ELISA, was significantly increased in diabetic WT mice compared with non-diabetic WT mice 4, 8, 
and 16 weeks after induction of diabetes. (C) Plasma blood urea nitrogen (BUN) levels and (D) 
plasma creatinine levels were significantly increased in diabetic WT mice compared with non-diabetic 
WT mice 16 weeks after induction of diabetes. Plasma BUN and plasma creatinine levels were normal 
in the diabetic cathepsin L-deficient mice. 5-6 mice per group were used for analysis. Dotted lines 
indicate the average albumin-creatinine ratio and BUN of non-diabetic control mice. #P<0.05 versus 
non-diabetic control. *P<0.05 and **P<0.01 versus diabetic WT mice. WT; wild type. CTSL-KO; 
cathepsin L-deficient.   
 
Table 3: Quantitative mRNA expression of TGF-β1, CTGF, TNF-α and IFN-γ in renal 
cortex of WT and cathepsin L-deficient mice during type 1 diabetesa.   
 4 weeks 8 weeks 16 weeks 
 WT CTSL-KO WT CTSL-KO WT CTSL-KO 
TGF-β1 0.93 ± 0.08 1.60 ± 0.20*# 1.75 ± 0.15* 1.12 ± 0.12# 1.79 ± 0.23** 1.20 ± 0.11# 
CTGF 2.58 ± 0.31** 1.47 ± 0.13*# 2.46 ± 0.56* 1.23 ± 0.11# 2.35 ± 0.46** 1.19 ± 0.14# 
TNF-α 2.09 ± 0.45** 1.32 ± 0.11# 2.37 ± 0.47* 1.35 ± 0.18# 1.93 ± 0.20** 1.12 ± 0.16# 
IFN-γ 1.74 ± 0.22* 1.18 ± 0.21 2.43 ± 0.53*  1.16 ± 0.19# 2.24 ± 0.23** 1.27 ± 0.18# 
TGF-β1, transforming growth factor-β1; CTGF, connective tissue growth factor; TNF-α, tumor necrosis 
factor-α; INF-γ, interferon-γ; WT, wild type; CTSL-KO, cathepsin L-deficient. The mean ± SEM of six 
mice per group are depicted. *P<0.05 and **P<0.01 versus control mice; #P<0.05 CTSL-KO versus 
WT mice. aThe relative expression compared with non-diabetic WT or non-diabetic CTSL-KO mice is 
depicted, with both non-diabetic WT and non-diabetic CTSL-KO mice set at 1.  
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Figure 3: Cathepsin L-deficient mice fail to develop mesangial matrix expansion, 
tubulointerstitial fibrosis and macrophage infiltration in experimental diabetes. Kidney sections 
of diabetic WT and cathepsin L-deficient mice were stained with (A) periodic acid-Schiff, (B) Masson-
Trichome and (C) CD68. Representative pictures of mice at t=16 weeks are shown. (A) Diabetic WT 
mice developed mild mesangial matrix expansion (black arrow) after 16 weeks, which was significantly 
reduced in the diabetic cathepsin L-deficient mice (scale bar: 20 µm). (B) Diabetic WT mice developed 
mild tubulointerstitial fibrosis (green staining) after 8 and 16 weeks, which was significantly reduced in 
the diabetic cathepsin L-deficient mice (scale bar: 40 µm). (C) Tubulointerstitial macrophage infiltration 
(green) was significantly increased in diabetic WT mice after 4, 8 and 16 weeks, but normal in diabetic 
cathepsin L-deficient mice (scale bar: 40 µm). 5-6 mice per group were used for analysis. See 
methods section for scoring parameters. Dotted lines indicate mesangial expansion score, 
tubulointerstitial fibrosis score or tubulointerstitial macrophage infiltration score of non-diabetic control 
mice. #P<0.05 versus non-diabetic control. *P<0.05 and **P<0.01 versus diabetic WT mice. WT; wild 
type. CTSL-KO; cathepsin L-deficient.  
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Cathepsin L deficiency preserves glomerular HS expression in experimental DN 
Next, we evaluated the effect of cathepsin L deficiency on glomerular heparanase and HS 
expression in experimental DN. Heparanase mRNA expression in kidney cortex was 
significantly increased 4, 8, and 16 weeks after the induction of diabetes in both WT and 
cathepsin L-deficient mice (Figure 4A). Notably, the higher heparanase mRNA expression in 
WT mice compared to cathepsin L-deficient mice may be explained by a higher presence of 
tubulointerstitial macrophages in WT mice. In WT mice, the increased heparanase mRNA 
expression correlated with an increased glomerular heparanase protein expression (Figure 
4B) and heparanase activity (Figure 4C). The anti-heparanase antibody we used specifically 
recognizes the active form of heparanase. Therefore, as expected, no heparanase protein 
expression or activity could be observed in the cathepsin L-deficient mice. Glomerular HS 
expression in diabetic WT mice was reduced, starting at week 4 and continuing until week 
16, whereas glomerular HS expression was preserved in the diabetic cathepsin L-deficient 
mice (Figure 4D).   
 
 
Figure 4: Cathepsin L deficiency preserves glomerular HS expression in experimental diabetes. 
By induction of diabetes in WT mice, (A) cortical heparanase mRNA expression, (B) glomerular 
heparanase protein expression, and (C) cortical heparanase activity were significantly increased, 
whereas (D) glomerular HS expression was significantly reduced. Heparanase mRNA expression was 
significantly increased in the diabetic cathepsin L-deficient mice, but no heparanase protein 
expression or activity was observed in the cathepsin L-deficient mice. Glomerular HS expression was 
preserved in the diabetic cathepsin L-deficient mice. (B,D) Representative images showing glomerular 
heparanase protein expression and glomerular HS expression of mice at t=16 weeks, respectively, as 
determined by immunofluorescence staining (scale bar: 20 µm). 5-6 mice per group were used for 
analysis. Dotted lines indicate heparanase/HS expression/activity of non-diabetic control mice. 
#P<0.05 versus non-diabetic control. *P<0.05 and **P<0.01 versus diabetic WT mice. WT; wild type. 
CTSL-KO; cathepsin L-deficient. AU; arbitrary units.     
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Cathepsin L deficiency reduces podocyte and endothelial damage in experimental DN 
As outlined, cathepsin L is also involved in the degradation of the podocyte protein 
synaptopodin, which may be another contributing factor in the development of DN and 
albuminuria. Synaptopodin protein expression in WT mice was significantly reduced 8 and 16 
weeks after induction of diabetes, whereas synaptopodin expression was preserved in the 
diabetic-cathepsin L-deficient mice (Figure 5A). Despite the reduced synaptopodin protein 
expression, we could not observe significant podocyte foot process effacement (Figure 6A) 
or podocyte loss (Figure 6B) in diabetic WT mice, although partial foot process effacement 
could be recognized in diabetic WT mice (Figure 6A). Furthermore, there appeared no clear 
loss of endothelial fenestrations 16 weeks after the induction of diabetes (Figure 6A).  
However, the expression of the podocyte damage marker desmin, a protein that is not 
directly targeted by cathepsin L, was significantly increased 16 weeks after induction of 
diabetes in WT mice, whereas desmin protein expression remained normal in the diabetic 
cathepsin L-deficient mice (Figure 5B).    
In the early stages of DN that is mimicked by the streptozotocin model, glomerular 
endothelial injury is the most prominent phenotype and develops prior to podocyte injury. To 
assess endothelial activation, we determined the glomerular expression of vascular cell 
adhesion molecule-1 (VCAM-1). VCAM-1 expression was significantly increased 4 weeks 
after induction of diabetes in WT mice, whereas VCAM-1 expression was normal in the 
diabetic cathepsin L-deficient mice (Figure 5C). No significant increase in VCAM-1 
expression was observed 8 and 16 weeks after the induction of diabetes in WT mice. 
However, VCAM-1 expression was significantly reduced in diabetic cathepsin L-deficient 
mice versus diabetic WT mice 16 weeks after the induction of diabetes (Figure 5C).      
 
 
Discussion  
 
In this study we showed that cathepsin L is crucial for the development of DN in experimental 
diabetes. Diabetic cathepsin L-deficient mice failed to develop albuminuria, had a normal 
renal function and less mesangial matrix expansion, tubulointerstitial fibrosis and 
macrophage accumulation. In WT mice, we showed that the development of albuminuria was 
associated with the induction of heparanase activity and loss of HS expression, whereas loss 
of synaptopodin expression and podocyte injury was observed at a later stage.  
The present study is the first study to show that cathepsin L is essential for the development 
of DN. A previous study showed that cathepsin L is essential for the development of type 1 
diabetes in autoimmune diabetes-prone NOD mice [37]. Cathepsin L-deficient mice showed 
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Figure 5: Cathepsin L deficiency prevents podocyte and glomerular endothelial injury in 
experimental diabetes. (A) synaptopodin protein expression was reduced  8 and 16 weeks after 
streptozotocin-induced diabetes in WT mice. Synaptopodin expression was normal in the diabetic 
cathepsin L-deficient mice. (B) Desmin protein expression was increased 16 weeks after induction of 
diabetes in WT mice. Desmin expression was normal in the diabetic cathepsin L-deficient mice. (C) 
VCAM-1 expression was increased 4 weeks after induction of diabetes in WT mice, but normal in the 
diabetic cathepsin L-deficient mice. Representative picture of mice at t=4 weeks for VCAM-1 and t=16 
weeks for synaptopodin and desmin are shown. 5-6 mice per group were used for analysis. Dotted 
lines indicate synaptopodin/desmin/VCAM-1 expression of non-diabetic control mice. Scale bar: 20 
µm. #P<0.05 versus non-diabetic control. *P<0.05 and **P<0.01 versus diabetic WT mice. WT; wild 
type. CTSL-KO; cathepsin L-deficient. VCAM-1; vascular cell adhesion molecule-1. AU; arbitrary units.     
  Cathepsin L induces diabetic nephropathy 
 
  59 
 
 
 
 
Figure 6: Glomerular ultrastructure and the number of podocytes per glomerulus is normal in 
both diabetic WT and diabetic cathepsin L-deficient mice. (A) Glomerular ultrastructure, as 
visualized by transmission electron microscopy, was normal in both diabetic WT and diabetic 
cathepsin L-deficient mice 16 weeks after induction of diabetes, although partial foot process 
effacement could be recognized in the diabetic WT mice (black arrow). Scale bar: 2 µm. (B) The 
number of podocytes per glomerulus, as visualized by immunofluorescence staining, was not affected 
by induction of diabetes in both WT and cathepsin L-deficient mice. Dotted lines indicate the number 
of podocytes of non-diabetic control mice. WT; wild type. CTSL-KO; cathepsin L-deficient. 
 
an increased proportion of regulatory T cells compared with their WT littermates, protecting 
them to develop type 1 diabetes. In the present study we were able to induce type 1 diabetes 
in the cathepsin L-deficient mice, as indicated by increased blood glucose levels. In contrast 
to the previous study, we induced type 1 diabetes by streptozotocin, a drug that enters beta 
cells in the pancreas via the glucose transporter (GLUT)-2 and damages the DNA [38-40]. A 
seeming limitation of the streptozotocin-induced model in our hands  may be the lack of 
development of overt DN accompanied with overt podocyte foot process effacement. 
However, our model may be very relevant for the development of microalbuminuria in 
humans, which is an early and specific predictor for the development of overt DN and 
macroalbuminuria [41-44]. Importantly, we show that diabetic cathepsin L-deficient mice 
failed to develop albuminuria, in contrast to their WT littermates.  
Previous studies showed that cathepsin L plays a role in the development of proteinuria, as 
treatment with the cysteine-cathepsin inhibitor E-64 reduced proteinuria in rats with 
accelerated anti-GBM disease [12]. Moreover, cathepsin L-deficient mice are protected from 
LPS-induced foot process effacement and proteinuria [10]. Two substrates of cathepsin L, 
synaptopodin and dynamin, are key stabilizers of the podocyte actin cytoskeleton [10, 13]. In 
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vivo synaptopodin gene delivery or podocyte-specific transgenic expression of a 
synaptopodin mutant lacking cathepsin L cleavage sites protects mice from LPS-induced 
proteinuria, suggesting that cleavage of synaptopodin by cathepsin L is required for the 
induction of foot process effacement [13, 45]. In addition, synaptopodin can control dynamin 
levels [13]. In the present study we observed no development of foot process effacement, 
although diabetic WT mice did develop albuminuria. Previous studies showed that proteinuria 
can occur without foot process effacement and that foot process effacement is not correlated 
with the level of proteinuria [46-49]. Moreover, we observed a reduced synaptopodin protein 
expression 8 weeks after induction of diabetes, and podocyte injury, as indicated by an 
increased desmin expression, and 16 weeks after induction of diabetes, whereas mice 
developed already a significant albuminuria 4 weeks after streptozotocin-induced diabetes. 
This suggest that synaptopodin is not involved in the initial development of proteinuria in 
experimental DN, which may be relevant for the microalbuminuric phase in the human 
setting. However, our findings do not exclude a role for synaptopodin at a later stage in the 
development of proteinuria and overt DN.      
In addition to albuminuria, we showed that cathepsin L is involved in the development of 
mesangial matrix expansion and tubulointerstitial fibrosis. This is most likely caused by loss 
of heparanase activity, as diabetic heparanase-deficient mice also failed to develop 
mesangial matrix expansion and tubulointerstitial fibrosis [25]. Moreover, a recent study 
showed that heparanase is a key player in renal fibrosis, as it regulates TGF-β expression 
and activity and subsequently epithelial-mesenchymal transition (EMT) [50, 51]. In addition, 
under diabetic conditions heparanase induces macrophage activation [26], which has been 
suggested to drive  renal fibrosis [52, 53].  
Induction of heparanase activity, loss of HS expression and macrophage accumulation 
correlated with the development of albuminuria. Previously, we showed that heparanase is 
essential for the development of experimental DN, as heparanase-deficient mice failed to 
develop albuminuria and DN after streptozotocin-induced diabetes [25]. Moreover, we 
showed that the heparanase-deficient mice had a preserved glomerular HS expression. In a 
follow-up study, we showed that under diabetic conditions heparanase, activated by 
cathepsin L of tubular origin, sustains continuous activation of macrophages, resulting in an 
increased production of TNF-α. No increase in macrophage activation or TNF-α production 
was observed in the heparanase-deficient mice [26]. Similar results we have now observed 
in the diabetic cathepsin L-deficient mice, which also showed no increase in macrophage 
infiltration and TNF-α expression, most likely caused by loss of heparanase activity. Whether 
proteinuria mediated by heparanase in DN  is caused by loss of HS expression in the GFB, 
the activation of macrophages or both should be addressed in future research.  
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Heparanase is expressed by several cells in the glomerulus, including endothelial cells and 
podocytes, but also by several cells of the immune system, such as macrophages, 
leukocytes and platelets. The activation of heparanase by cathepsin L can occur both 
intracellular and extracellular. After activation, heparanase is able to cleave HS on both 
endothelial cells and podocytes, resulting in a reduced HS expression on both cell types. We 
and others previously showed that loss of HS in the endothelial glycocalyx is essential for the 
development of proteinuria in experimental DN [54-56]. Other studies showed that loss of 
podocyte HS resulted in the development of foot process effacement, suggesting that 
podocyte damage may be secondary to loss of HS [57, 58]. However, the presence of 
synaptopodin is also essential to maintain a normal podocyte architecture [13], and future 
studies should address whether podocyte damage is caused by loss of HS, cathepsin L-
mediated degradation of synaptopodin, or a combination of both.  
The important role of cathepsin L in the development of proteinuria is most likely not limited 
to DN. Previous studies showed that the expression of cathepsin L is increased in several 
other glomerular diseases, such as MGN, MCD and FSGS [10]. Treatment with a cathepsin 
L inhibitor reduced proteinuria in a rat model for glomerulonephritis [12]. We recently showed 
that heparanase is essential for the development of experimental glomerulonephritis [59]. 
Moreover, we showed that the expression of heparanase is increased in adriamycin-induced 
nephropathy, an experimental model for FSGS [60, 61]. Together, these studies suggest that 
cathepsin L may play an important role in the development of proteinuria in other glomerular 
diseases by the activation of heparanase. But, as mentioned, cathepsin L-mediated 
degradation of synaptopodin and dynamin may also play an important role in the 
development of proteinuria.  
Not much is known about the role of other cathepsins in the development of DN. Only for the 
cysteine proteases cathepsin B and S there are studies indicating that they play a role in the 
development of DN. Cathepsin B plays a role in the degradation of fibronectin. In DN there is 
an inadequate cathepsin B activity, which results in an insufficient degradation of fibronection 
and a progressive accumulation of extracellular matrix [62]. Cathepsin S is involved in the 
induction of proteinuria and glomerular endothelial cell injury in type 2 diabetic mice, by 
activating the protease-activated receptor-2 (PAR2) [63].     
In conclusion, in this study we showed that cathepsin L is causally involved in the 
development of experimental DN. Most likely, cathepsin L-deficiency is essential for 
heparanase activity, leading to the development of albuminuria, mesangial matrix expansion, 
tubulointerstitial fibrosis and macrophage accumulation. The current study suggests that 
targeting cathepsin L or heparanase represents an attractive therapeutic target for the 
treatment of DN.      
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Abstract 
 
Heparanase, a heparan sulfate (HS)-specific endoglucuronidase, mediates the onset of 
proteinuria and renal damage during experimental diabetic nephropathy. Glomerular 
heparanase expression is increased in the majority of proteinuric diseases. Here, we 
evaluated the role of heparanase in two models of experimental glomerulonephritis, being 
anti-glomerular basement membrane and lipopolysaccharide (LPS)-induced 
glomerulonephritis, in wild type (WT) and heparanase-deficient mice. Induction of 
experimental glomerulonephritis led to an increased heparanase expression in WT mice, 
which was associated with a decreased glomerular expression of a highly sulfated HS 
domain and albuminuria. Albuminuria was reduced in the heparanase-deficient mice in both 
models of experimental glomerulonephritis, which was accompanied by a better renal 
function and less renal damage. Notably, glomerular HS expression was preserved in the 
heparanase-deficient mice. Glomerular leukocyte and macrophage influx was reduced in the 
heparanase-deficient mice, which was accompanied by a reduced expression of both Th1 
and Th2 cytokines. In vitro, tumor necrosis factor (TNF)-α and LPS directly induced 
heparanase expression and increased transendothelial albumin passage. Our study shows 
that heparanase contributes to proteinuria and renal damage in experimental 
glomerulonephritis by decreasing glomerular HS expression, enhancing renal leukocyte and 
macrophage influx, and affecting the local cytokine milieu.  
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Introduction 
 
Proteinuria is a hallmark of many glomerular diseases and an independent risk factor for the 
progression of renal failure [1]. Heparan sulfate (HS) is a highly negatively charged 
glycosaminoglycan (GAG) that is covalently attached to a core protein, so called HS 
proteoglycans (HSPGs). In seminal papers Kanwar and Farquhar demonstrated the 
presence of HS in the glomerular filtration barrier (GFB), which is composed of glomerular 
endothelial cells covered by a glycocalyx, the glomerular basement membrane (GBM) and 
podocytes [2-4]. Due to its negative charge, HS seems to play an important role in the 
charge-selective permeability of the GFB [5]. Removal of HS with bacterial heparinase leads 
to a dramatic increase in glomerular permeability for neutral and cationic macromolecules [6]. 
Genetic targeting of HS in the GFB compromised permselectivity and barrier function to a 
lesser extent [7-9], although the development of proteinuria has been associated with a 
reduced expression of HS in the GFB [3, 5, 10]. The HS chain is composed of up to 150 α(1-
4)-glucuronate-β(1,4)-N-acetyl-glucosamine disaccharide units that can be modified 
extensively. HS is characterized by an enormous structural diversity, which dictates the 
binding of several soluble ligands, such as cytokines, chemokines and growth factors [11, 
12]. In addition, specific endothelial HS domains mediate the trafficking of leukocytes [13].  
In many human and experimental glomerular diseases the reduced expression of HS in the 
GFB is associated with an increased expression of heparanase [3, 14]. Heparanase is an 
endo-β(1,4)-D-glucuronidase that can cleave HS side chains. Heparanase is synthesized as 
a pre-proheparanase of 68 kDa. To gain its biological activity, pre-proheparanase is 
processed in the endoplasmatic reticulum, where the signal peptide is removed, and further 
processed in lysosomes, where cathepsin L cleaves off a linker domain to form the active 
form of heparanase [14, 15]. Outside the kidney heparanase is involved in cancer 
progression, in particular metastasis and neovascularization [16-18]. Heparanase is also 
involved in the pathogenesis of several inflammatory disorders, such as inflammatory lung 
injury, rheumatoid arthritis and chronic colitis [19-22]. Recently, we demonstrated that 
heparanase is essential for the development of proteinuria in experimental diabetic 
nephropathy (DN) [23]. In streptozotocin-induced diabetes, heparanase-deficient mice failed 
to develop proteinuria and renal damage, in contrast to their wild type (WT) littermates. In 
addition, proteinuria was reduced and renal function improved by treatment with the 
heparanase inhibitor SST0001 [23]. In a follow-up study, we showed that heparanase 
contributes to the inflammatory cascade during the pathogenesis of diabetic nephropathy 
[24]. Although heparanase plays a crucial role in the development of diabetic nephropathy, 
the exact role of heparanase in inflammatory glomerular diseases, such as 
glomerulonephritis, is still unknown.  
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Glomerulonephritis is characterized by the influx of inflammatory cells, proteinuria, hematuria 
and a decline in renal function. Previous studies revealed that heparanase may be involved 
in the development of proteinuria in passive Heymann nephritis (PHN) and in a model of 
accelerated anti-GBM disease, as treatment of rats with a polyclonal antibody against 
heparanase or the heparanase inhibitor PI-88 reduced proteinuria in both experimental 
diseases [25-27]. In addition, it has been recently described that lipopolysaccharide (LPS)-
induced glomerulonephritis involves an increased heparanase expression and a damaged 
glomerular endothelium, which is in large part mediated by tumor necrosis factor (TNF)-α 
[28]. Interestingly, heparanase inhibition prevented glycocalyx loss and neutrophil adhesion 
during sepsis-induced acute lung injury, indicating that heparanase may also be involved in 
the influx of inflammatory cells [19]. In another recent study, severe systemic sepsis was 
induced by cecal ligation and puncture, and it was suggested that heparanase mediated 
early renal dysfunction. Unfortunately, in the latter study there was no direct proof for a 
reduced HS expression in the GFB mediated by heparanase, whereas the applied anti-HS 
antibody (3G10) suggests involvement of bacterial-derived heparinases instead of 
mammalian heparanase [29].  
In order to elucidate the role of heparanase in the development of glomerulonephritis, we 
evaluated the involvement of heparanase in two experimental glomerulonephritis models, 
anti-GBM and LPS-induced glomerulonephritis, in WT and heparanase-deficient mice. Our 
results indicate that heparanase drives anti-GBM and LPS-induced glomerulonephritis by 
enhancing the renal influx of inflammatory cells and by influencing the local cytokine 
production.  
 
 
Materials and methods 
 
Animals  
C57Bl/6 (Harlan Laboratories, Jerusalem, Israel) and heparanase knockout (KO) mice [30] in 
a C57Bl/6 background were kept under pathogen-free conditions, housed in a temperature-
controlled room with a 12-hour light/dark cycle, and had ad libitum access to food and water. 
All animal experiments were performed in accordance with, and approved by, the Hebrew 
University Institutional Animal Care and Use Committee.  
 
Induction of anti-GBM and LPS glomerulonephritis and determination of albuminuria 
and blood urea nitrogen 
Experimental anti-GBM glomerulonephritis was induced as previously described [31]. Wild 
type (WT) and heparanase-deficient mice, 14- to 15-weeks-old, were injected in the tail vein 
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with 7 mg rabbit anti-mouse GBM IgG serum. Mice were sacrificed after 2 hours, 1 day and 4 
days to collect kidneys and blood. LPS glomerulonephritis was induced in 14- to 15-weeks-
old WT and heparanase-deficient mice by an intraperitoneal injection with 80 µg LPS 
(O111:B4; Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands). Mice were sacrificed after 
2 days to collect kidneys and blood. Eight mice were used per time-point. Urine was 
collected through a bladder punction or after 24 hours in metabolic cages. Collected kidneys 
were snap frozen in liquid nitrogen. Urinary albumin was measured by radial immunodiffusion 
(Mancini) and blood urea nitrogen and urinary creatinine concentrations were determined 
routinely in our clinical diagnostic facility. 
 
Immunofluorescence staining 
Immunofluorescence staining was performed on 2 µM thick cryosections as described [31]. 
Directly labeled antibodies included rat anti-mouse GR-1 (RB6.8C5)-FITC (BD Biosciences, 
Alphen aan de Rijn, The Netherlands) and rat anti-mouse CD41-Alexa 488 (ITK Diagnostics, 
Uithoorn, The Netherlands). Unlabeled primary antibodies included CD68 (MCA1957) 
(Serotec, Oxford, UK), and the VSV-tagged anti-HS antibodies HS4C3, AO4B08, EW4G2, 
and EW3D10 [31, 32]. Appropriate secondary antibodies include Alexa 488 antibodies 
(Invitrogen Life Technologies, Breda, The Netherlands) or anti-VSV-Cy3 antibody (Sigma-
Aldrich). Capillary loops were visualized with the hamster anti-agrin antibody (MI91) [33], 
recognized by a Cy-3-labeled antibody (Jackson ImmunoResearch Laboratories, West 
Grove, PA). Sections were postfixed with 1% paraformaldehyde-PBS and embedded in 
Vectashield mounting medium H-1000 (Brunschwig Chemie, Amsterdam, The Netherlands). 
HS was scored semi-quantitatively for staining intensities on a scale between 0 and 10 (0= 
no staining, 5= 50% staining, 10= 100% staining) by two investigators. Glomerular influx of 
granulocytes and macrophages was determined by counting the number of cells per 50 
glomeruli. Glomerular influx of platelets in LPS glomerulonephritis was determined by 
counting the number of platelets per 50 glomeruli, whereas the number of glomeruli with 
platelet aggregates per 50 glomeruli was counted for anti-GBM glomerulonephritis. Scoring 
was performed using a Leica CTR6000 microscope by two independent investigators on 
blinded sections. 
 
Renal histology 
Renal cryosections (2 µM) were fixed in 96% ethanol and stained with periodic acid-Schiff 
(PAS). Sections were counterstained with hematoxylin and evaluated by an experienced 
nephropathologist. At least 50 glomeruli per mouse were analyzed for the presence of 
glomerular lesions and mesangial matrix expansion. The average of glomeruli with lesions or 
mesangial matrix expansion was calculated.   
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Heparanase activity assay 
The activity of heparanase in renal cortex was determined by a commercially available assay 
(AMS Biotechnology, Abingdon, UK). Briefly, tissue lysates (100 µl) were mixed 1:1 with 
reaction buffer and incubated on biotinylated HS-coated plates for 1.5 hours at 37°C. Plates 
were washed and incubated with Strep-HRP for 60 minutes at room temperature. Peroxidase 
substrate was added and the reaction was stopped by 0.2 N H2SO4. Absorbance was 
measured at 450 nm.  
 
Cell Culture 
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) and mouse 
podocytes (MPC-5) were cultured as previously described [34, 35]. Silencing of heparanase 
in mGEnC-1 was achieved after transfecting a heparanase shRNA construct (Qiagen, Venlo, 
The Netherlands) with Lipofectamine 2000 into undifferentiated mGEnC-1 and subsequent 
selection with G418 (Sigma-Aldrich). Where indicated, differentiated mGEnC-1 and 
podocytes were stimulated with 10 ng/ml TNF-α (Invitrogen Life Technologies) or 1 µg/ml 
LPS (Sigma-Aldrich) for 18 hours. All experiments were performed at least twice for 
confirmation.   
 
Transendothelial albumin passage 
mGEnC-1 seeded on polyester membranes in tissue culture inserts (0.4 µm pore size; 
Corning Incorporated, NY, USA) were after differentiation treated with TNF-α or LPS as 
outlined. After 18 hours, medium in the insert was replaced by serum free medium (SFM) 
containing 0.5 mg/ml FITC-labeled BSA (Sigma-Aldrich) and medium in the well was 
replaced by SFM. Aliquots were removed from the well after 1, 2 and 3 hours and replaced 
by SFM. Fluorescence was measured with excitation at 495 nm and emission at 520 nm and 
the amount of albumin passing the endothelial cell monolayer was determined by a set of 
standard dilutions.  
 
RNA isolation and real-time PCR 
Total RNA was isolated from mGEnC-1, MPC-5 podocytes and kidney cortex using the 
RNeasy mini kit (Qiagen). 1 µg RNA was reverse transcribed into cDNA using the RevertAid 
First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). One-tenth of cDNA 
was used as template in real-time PCR reaction using SYBR Green SuperMix (Roche 
Diagnostics, Mannheim, Germany) with gene-specific primers (Isogen Life Science, De 
Meern, The Netherlands; Table 1) on the CFX real-time PCR system (Bio-Rad Laboratories, 
Hercules, CA, USA). Gene expression levels were quantified using the delta-delta CT method 
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the housekeeping gene.  
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Table 1: Primers used in real-time PCR. 
Target gene Primer sequence  
HPSE (F) 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’ 
(R) 5’-GATCCAGAATTTGACCGTTCAGTT-3’ 
TNF-α (F) 5’-CATCTTCTCAAAATTCGAGTGACAA-3’ 
(R) 5’-TGGGAGTAGACAACGTACAACCC-3’  
IFN-γ (F) 5’-GGTGACCTTGTGACAAGCTC-3’ 
(R) 5’-TGCTGTGTGGTCTGTCTGTC-3’ 
IL-6 (F) 5’-TTCCTCTCTGCAAGAGACT-3’ 
(R) 5’-TGTATCTCTCTGAAGGACT-3’ 
IL-10 (F) 5’-GTGGAGCAGGTGAAGAGTGA-3’ 
(R) 5’-TGCAGTTGATGAAGATGTCAAA-3’ 
IL-12α (F) 5’-GGGAGAAGCAGACCCTTACAGA-3’ 
(R) 5’-GGGTGCTGAAGGCGTGAA-3’ 
IL-12β (F) 5’-GGAAGCACGGCAGCAGAATC-3’ 
(R) 5’-AACTTGAGGGAGAAGTAGGAATGG-3’ 
TNFRSF1a (F) 5’-CCATCATTTGTAGGGATCCC-3’ 
(R) 5’-TCTCAGAGCCTCGAGGATAT-3’ 
TNFRSF1b (F) 5’-GAAATCCCAGGATGCAGTAG-3’ 
(R) 5’-TCAGGCCACTTTGACTGCAA-3’ 
Sdc-1 (F) 5’-GACTCTGACAACTTCTCTGGCTCT-3’ 
(R) 5’-GCTGTGGTGACTCTGACTGTTG-3’ 
HPSE, heparanase; Sdc-1, syndecan-1; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; IL, 
interleukin; TNFRSF, TNF receptor; F, forward; R, reverse. 
 
Statistical analysis 
Values are expressed as mean ± SEM. Significance was evaluated by a one-way ANOVA 
and post hoc analysis with Tukey’s multiple comparison test. Comparison of expression 
between two different groups was evaluated using the Student’s t-test. The non-parametric 
Spearman’s rank test was used to calculate the correlation between HS expression and 
proteinuria. A 2-way repeated measures ANOVA with Bonferroni post-test was used to 
evaluate significance for the transendothelial albumin passage experiments. Statistical 
analysis was performed using GraphPad Prism 5.03 (GraphPad Software, Inc., San Diego, 
CA, USA). A P-value of ≤ 0.05 was considered statistically significant.   
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Results 
 
Heparanase expression and activity are increased by induction of experimental 
glomerulonephritis  
Heparanase mRNA expression in kidney cortex was significantly increased 2 hours, 1 day 
and 4 days after the induction of anti-GBM glomerulonephritis (Figure 1A) and 2 days after 
the induction of LPS glomerulonephritis (Figure 1B). In WT mice, the increased heparanase 
expression correlated with an increased heparanase activity after induction of both anti-GBM 
and LPS glomerulonephritis, although heparanase activity was not significantly increased 2 
hours after the induction of anti-GBM glomerulonephritis (Figure 1C and 1D; P = 0.09). 
Notably, we choose to evaluate day 2 for the LPS-induced model for glomerulonephritis, 
since we did not observe differences in the urinary albumin/creatinine ratio, nor in renal 
heparanase activity 1 day after administration of LPS in WT mice (Figure 2). 
 
 
Figure 1: Experimental glomerulonephritis increases renal heparanase expression and activity 
in WT mice. (A,B) Heparanase mRNA expression and (C,D) heparanase activity are increased by 
induction of (A,C) anti-GBM glomerulonephritis and (B,D) LPS glomerulonephritis. Heparanase was 
not expressed or active in the heparanase-deficient mice. *P<0.05 versus control. WT; wild type. 
HPSE-KO; heparanase-deficient.             
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Figure 2: Renal function and heparanase activity are normal 1 day after induction of LPS 
glomerulonephritis. (A) WT mice failed to develop albuminuria 1 day after the induction of LPS 
glomerulonephritis. (B) Heparanase activity is comparable to control 1 day after induction of LPS 
glomerulonephritis in WT mice. (C) Glomerular PMN influx, analyzed by immunofluorescence staining, 
was significantly increased 1 day after induction of LPS glomerulonephritis in WT mice, whereas (D) 
glomerular macrophage influx was comparable to control 1 day after the induction of LPS 
glomerulonephritis. *P<0.05 versus control.   
 
Heparanase-deficient mice show better renal function and less renal damage after 
induction of experimental glomerulonephritis  
A significant proteinuria was observed 1 and 4 days after the induction of anti-GBM 
glomerulonephritis (Figure 3A) and 2 days after the induction of LPS glomerulonephritis in 
WT mice (Figure 3B). Proteinuria was reduced in the heparanase-deficient mice in both 
models, although this was borderline significant 4 days after induction of anti-GBM 
glomerulonephritis (P = 0.06). Renal function, as measured by the blood urea nitrogen (BUN) 
concentration, was impaired 4 days after induction of anti-GBM glomerulonephritis in the WT 
mice, whereas it was normal in the heparanase-deficient mice (Figure 3C). By induction of 
LPS glomerulonephritis, renal function was significantly decreased in both WT and 
heparanase-deficient mice (Figure 3D). However, renal function was significantly better in the 
heparanase-deficient mice compared to WT mice. WT mice showed significantly more 
glomerular damage compared to the heparanase-deficient mice, for both the anti-GBM and 
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LPS model (Figure 4A-C). By induction of anti-GBM glomerulonephritis, WT mice showed 
significantly more glomerular lesions compared to the heparanase-deficient mice (Figure 4A-
B). Moreover, in the LPS model, mesangial matrix expansion, although limited, was only 
observed in the WT mice and not in the heparanase-deficient mice (Figure 4A,C).  
 
 
Figure 3: Heparanase-deficient mice show better renal function during anti-GBM and LPS-
induced glomerulonephritis. The albumin/creatinine ratio was significantly increased in WT mice 
compared with untreated control mice (A) 1 and 4 days after induction of anti-GBM glomerulonephritis 
and (B) 2 days after induction of LPS glomerulonephritis. Heparanase-deficient mice showed a lower 
albuminuria at these time points (P = 0.06 versus WT mice 4 days after induction of anti-GBM 
glomerulonephritis). (C) Plasma blood urea nitrogen (BUN) levels were significantly increased in WT 
mice compared with untreated control mice 4 days after induction of anti-GBM glomerulonephritis. 
Plasma BUN levels were normal in the heparanase-deficient mice. (D) Plasma BUN levels were 
significantly lower in the heparanase-deficient mice compared with WT mice 2 days after induction of 
LPS glomerulonephritis. †P<0.05 versus control. *P<0.05 versus anti-GBM/LPS-injected WT mice. 
WT; wild type. HPSE-KO; heparanase-deficient.                
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Figure 4: Heparanase-deficient mice show less glomerular injury during anti-GBM and LPS-
induced glomerulonephritis. (A) Representative pictures of renal histology and semi-quantitative 
analysis of the percentage of (B) glomeruli with lesions (arrow) and (C) glomeruli with mesangial 
matrix expansion (arrowhead), as determined by a PAS stain. WT mice showed significantly more 
glomerular injury compared with heparanase-deficient mice 2 days after induction of LPS 
glomerulonephritis and 4 days after induction of anti-GBM glomerulonephritis. (A) Magnification x 400. 
(B,C) *P<0.05 versus anti-GBM/LPS-injected WT mice. WT; wild type. HPSE-KO; heparanase-
deficient.                   
 
Heparanase deficiency preserves glomerular HS expression in experimental 
glomerulonephritis 
As heparanase plays an important role in HS turnover, we determined the glomerular 
expression of a highly sulfated HS domain recognized by the anti-HS antibody HS4C3. 
Glomerular HS expression in WT mice was reduced 1 and 4 days after the induction of anti-
GBM glomerulonephritis (Figure 5A-B) and 2 days after the induction of LPS 
glomerulonephritis (Figure 5A,C). Heparanase deficiency preserved HS expression in both 
models. HS expression inversely correlated with the level of proteinuria (Figure 5D; r = -0.79, 
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P < 0.0001), which is in line with previous results [10], but also in line with the data on 
heparanase expression and activity (Figure 1).  
 
 
Figure 5: Heparanase deficiency preserves glomerular HS expression in experimental 
glomerulonephritis. (A) Immunofluorescence staining and (B,C) semi-quantitative analysis of the 
glomerular expression of the highly sulfated HS domain recognized by the anti-HS antibody HS4C3 
showed a reduced glomerular expression (B) 1 and 4 days after the induction of anti-GBM 
glomerulonephritis and (C) 2 days after the induction of LPS glomerulonephritis. HS expression was 
significantly higher in the heparanase-deficient mice. (D) HS expression inversely correlated with the 
level of proteinuria (r=-0.79, P<0.0001). (A) Magnification x 400. (B,C) †P<0.05 versus control. 
*P<0.05 versus anti-GBM/LPS-injected WT mice. AU; arbitrary units. WT; wild type. HPSE-KO; 
heparanase-deficient.                         
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Heparanase deficiency leads to a reduced glomerular influx of leukocytes and 
macrophages in experimental glomerulonephritis 
Next, we evaluated the role of heparanase on renal inflammation by determining the 
glomerular influx of polymorphonuclear granulocytes (PMNs) and macrophages. Glomerular 
PMN influx is an important mediator of glomerular damage and proteinuria in the early 
heterologous phase of anti-GBM glomerulonephritis. Glomerular PMN influx was maximal 2 
hours after the induction of anti-GBM glomerulonephritis in both WT and heparanase-
deficient mice and decreased over time (Figure 6A). Notably, after 2 hours, glomerular PMN 
influx was significantly reduced in the heparanase-deficient mice compared to the WT mice.  
 
 
Figure 6: Heparanase deficiency reduces glomerular leukocyte and macrophage influx during 
experimental glomerulonephritis. (A) Glomerular PMN influx, analyzed by immunofluorescence 
staining, peaked 2 hours after induction of anti-GBM glomerulonephritis in both WT and heparanase-
deficient mice, but was significantly lower in the heparanase-deficient mice. (B) Glomerular PMN influx 
was increased by induction of LPS glomerulonephritis, but not significantly different between WT and 
heparanase-deficient mice. Glomerular macrophage influx was significantly increased after induction 
of both (C) anti-GBM glomerulonephritis and (D) LPS glomerulonephritis. Heparanase-deficient mice 
showed a significantly reduced glomerular macrophage influx 4 days after induction of anti-GBM 
glomerulonephritis and 2 days after induction of LPS glomerulonephritis. †P<0.05 versus control. 
*P<0.05 versus anti-GBM/LPS-injected WT mice. WT; wild type. HPSE-KO; heparanase-deficient.                     
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In line with this, the expression of several inflammatory HS domains on endothelium that 
were previously shown to be important for leukocyte trafficking was also reduced in the 
heparanase-deficient mice (Figure 7) [13, 31, 36]. Mice with LPS-induced glomerulonephritis 
did not show significant differences in glomerular PMN influx when comparing WT mice and 
heparanase-deficient mice (Figure 6B). Glomerular macrophage influx was increased after 
induction of both anti-GBM and LPS glomerulonephritis (Figure 6C-D). A significant lower 
number of macrophages was observed in glomeruli of heparanase-deficient mice 4 days 
after the induction of anti-GBM glomerulonephritis and 2 days after the induction of LPS 
glomerulonephritis (Figure 6C-D). Taken together, heparanase deficiency significantly 
reduced glomerular leukocyte influx in anti-GBM glomerulonephritis and glomerular 
macrophage influx in both models of experimental glomerulonephritis.  
 
 
Figure 7: Heparanase deficiency reduces the expression of inflammatory HS domains during 
anti-GBM-induced glomerulonephritis. (A) Immunofluorescence staining and (B) semi-quantitative 
analysis of the glomerular expression of inflammatory HS domains recognized by the anti-HS 
antibodies AO4B08, EW4G2 and EW3D10 showed a reduced expression of the inflammatory HS 
domains in the heparanase-deficient mice compared with WT mice 2 hours after induction of anti-GBM 
glomerulonephritis. (A) Magnification x 400. (B) †P<0.05 versus control. *P<0.05 and ***P<0.001 
versus anti-GBM/LPS-injected WT mice. AU; arbitrary units. WT; wild type. HPSE-KO; heparanase-
deficient.                           
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The presence of glomerular platelets is decreased in LPS-induced glomerulonephrits 
and increased in anti-GBM glomerulonephritis 
Heparanase during experimental glomerulonephritis may originate from glomerular cells, 
inflammatory cells and/or platelets. Therefore, we also evaluated the glomerular presence of 
platelets using the platelet-specific marker CD41. At day 2 after LPS administration the 
number of platelets was similar for WT and heparanase-deficient mice. Interestingly, in the 
LPS model the number of platelets was decreased compared to untreated controls in both 
WT and heparanase-deficient mice (Figure 8), which may suggest that in the LPS model 
platelet-derived heparanase is not contributing to pathology. In anti-GBM glomerulonephritis 
in both WT and heparanase-deficient mice, there was a significant increase in the number of 
glomeruli with aggregates of platelets already 2 hours after administration of anti-GBM 
serum, which further increased at day 1 and 4 (Figure 8). The number of glomeruli with 
platelet aggregates was significantly reduced in the heparanase-deficient mice 4 days after 
induction of anti-GBM glomerulonephritis (Figure 8).   
 
 
Figure 8: Glomerular platelet influx is increased in anti-GBM glomerulonephritis and reduced in 
LPS-induced glomerulonephritis. (A) Glomerular platelet influx, analyzed by counting the number of 
glomeruli with platelet aggregates per 50 glomeruli, was significantly increased 2 hours, 1 day and 4 
days after induction of anti-GBM glomerulonephritis. The presence of glomerular platelet aggregates 
was significantly reduced in the heparanase-deficient mice 4 days after induction of anti-GBM 
glomerulonephritis. (B) Glomerular platelet influx, analyzed by counting the number of platelets per 50 
glomeruli, was significantly reduced 2 days after induction of LPS glomerulonephritis in both WT and 
heparanase-deficient mice. †P<0.05 versus control. *P<0.05 versus anti-GBM-injected WT mice. WT; 
wild type. HPSE-KO; heparanase-deficient.                     
 
Heparanase deficiency leads to a reduced expression of Th1 and Th2 cytokines in 
anti-GBM and LPS glomerulonephritis 
As we observed a reduced glomerular influx of leukocytes and macrophages in heparanase-
deficient mice after induction of experimental glomerulonephritis in both the anti-GBM and 
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LPS model, we analyzed the expression of Th1 and Th2 (promoting) cytokines in the renal 
cortex of these mice (Table 2 and 3). The mRNA expression of Th1 (promoting) cytokines 
TNF-α, interferon-γ, interleukin (IL)-12α and IL-12β was lower in the heparanase-deficient 
mice compared to the WT mice in both anti-GBM and LPS-induced glomerulonephritis. In 
addition, mRNA expression of the Th2 cytokine IL-10 was also lower in the heparanase-
deficient mice in both models. The expression of IL-6, which is both a pro- and anti-
inflammatory cytokine, was higher in the heparanase-deficient mice compared to the WT 
mice in the very early phase after induction of anti-GBM glomerulonephritis, but was 
significantly lower in the heparanase-deficient mice compared to the WT mice after induction 
of LPS glomerulonephritis. Furthermore, the expression of TNF receptor 1a was lower in the 
heparanase-deficient mice compared to the WT mice, whereas the expression of TNF 
receptor 1b was comparable to the WT mice. We previously showed that syndecan-1 
deficiency aggravates anti-GBM glomerulonephritis, by skewing the Th1/Th2 response [31]. 
In line with previous results, in the current study syndecan-1 mRNA expression is increased 
after induction of anti-GBM and LPS glomerulonephritis in the WT mice, whereas syndecan-1 
mRNA expression was lower in the heparanase-deficient mice compared to WT mice in the 
very early phase of the anti-GBM model, and 10-fold lower in the LPS model (Table 2 and 3). 
Taken together, heparanase deficiency in experimental glomerulonephritis leads to a less 
pro-inflammatory cytokine milieu in the kidney.      
 
Table 2: Quantitative mRNA expression of syndecan-1 and Th1 and Th2 cytokines in 
renal cortex of WT and heparanase-deficient mice during LPS glomerulonephritisa.   
 2 days 
 WT HPSE-KO 
TNF-α 18.02 ± 5.69** 6.05 ± 1.13***,† 
IFN-γ 1.64 ± 0.38 1.02 ± 0.29 
IL-6 1341 ± 764** 282 ± 141* 
IL-10 37.92 ± 15.41* 22.80 ± 10.45 
IL-12α 4.78 ± 1.66*  0.90 ± 0.25† 
IL-12β 1.68 ± 0.79 1.55 ± 0.84 
TNFRSF1a 4.25 ± 0.63*** 2.29 ± 0.33**,† 
TNFRSF1b 9.77 ± 3.08* 14.32 ± 3.96** 
Sdc-1 19.51 ± 6.02** 2.10 + 0.42*,† 
TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; IL, interleukin; TNFRSF, TNF receptor; Sdc-1, 
syndecan-1; WT, wild type; HPSE-KO, heparanase-deficient. The mean ± SEM of eight mice per 
group are depicted. *P<0.05, **P<0.01, and ***P<0.001 versus control mice; †P<0.05 HPSE-KO 
versus WT mice. aThe relative expression compared with untreated WT or HPSE-KO mice is shown, 
with both untreated WT and untreated HPSE-KO mice set at 1.  
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TNF-α and LPS increase transendothelial albumin passage in vitro  
Next, we evaluated whether TNF-α and LPS regulate heparanase expression in glomerular 
endothelial cells and podocytes in vitro. Activation of mGEnC-1 with TNF-α or LPS resulted 
in a 2-fold and 1.5-fold increased heparanase mRNA expression, respectively (Figure 9A). 
Activation of mouse podocytes with TNF-α or LPS resulted in a 2.5-fold and 2-fold increased 
heparanase mRNA expression, respectively (Figure 9B). At the functional level, activation of 
mGEnC-1 with TNF-α or LPS resulted in a 1.5 and 1.3-fold increased transendothelial 
albumin passage, respectively (Figure 9C). Silencing of heparanase expression in mGEnC-1 
with shRNA (~60% knockdown) led to a significant reduction in transendothelial albumin 
passage after activation with TNF-α or LPS compared with mGEnC-1 transfected with a 
scrambled shRNA (Figure 9D). These data suggest that heparanase mediates 
transendothelial albumin passage under inflammatory conditions.  
 
 
Figure 9: TNF-α and LPS induce heparanase expression and increase transendothelial albumin 
passage in vitro. Activation of (A) mouse glomerular endothelial cells (mGEnC-1) and (B) mouse 
podocytes with TNF-α or LPS for 18 hours resulted in an increased heparanase mRNA expression. 
(C) Activation of mGEnC-1 with TNF-α or LPS for 18 hours increased the passage of albumin across 
the endothelial monolayer 1.5 and 1.3-fold compared to control, respectively. (D) Activation of 
heparanase-silenced mGEnC-1 with TNF-α or LPS for 18 hours showed a lower transendothelial 
albumin passage compared with scrambled mGEnC-1 activated with TNF-α or LPS, respectively. 
*P<0.05, **P<0.01 and ***P<0.001 versus control. ††P<0.01 versus TNF-α scrambled. ‡‡‡P<0.001 
versus LPS scrambled. Ctrl; control.   
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Discussion 
 
In this study, we showed that heparanase deficiency ameliorated proteinuria, reduced 
glomerular damage and reduced the pro-inflammatory cytokine milieu in the kidney during 
experimental glomerulonephritis. Induction of experimental glomerulonephritis led to an 
increased heparanase expression and activity in WT mice, which was associated with a 
decreased glomerular expression of a highly sulfated HS domain and a significant proteinuria 
1 and 4 days after induction of anti-GBM glomerulonephritis and 2 days after induction of 
LPS glomerulonephritis. This is supported by the in vitro data, where we showed that TNF-α 
and LPS directly induced heparanase expression in mouse glomerular endothelial cells and 
mouse podocytes. Moreover, TNF-α and LPS also increased transendothelial albumin 
passage in vitro, most likely through heparanase-mediated loss of HS expression on 
glomerular endothelial cells, since silencing of heparanase led to a reduced transendothelial 
albumin passage. Proteinuria was reduced in the heparanase-deficient mice, which was 
accompanied by a preserved HS expression in the capillary filter as measured by an anti-HS 
antibody recognizing a highly sulfated HS domain. On the other hand, the expression of 
previously identified inflammatory HS domains that mediate binding of leukocytes and 
chemokines was reduced in heparanase-deficient mice during disease [13, 31, 36]. Our 
results are in line with previous studies, where treatment of rats with an anti-heparanase 
antibody or the heparanase inhibitor PI-88 reduced proteinuria in Passive Heymann nephritis 
and accelerated anti-GBM disease [25-27]. In addition, Lygizos et al. showed that treatment 
with a heparanase inhibitor attenuated septic acute kidney injury [29]. 
We previously showed that heparanase deficiency prevented the development of proteinuria 
and renal damage in experimental DN [23]. However, in contrast to DN, heparanase 
deficiency did not completely prevent proteinuria during experimental glomerulonephritis in 
two different models. Whereas heparanase deficiency prevented the influx of macrophages 
during diabetic nephropathy [23, 24], in the current study neutrophils and macrophages, 
although reduced, were still present in the glomeruli of heparanase-deficient mice during 
experimental glomerulonephritis. Since neutrophils and macrophages are important 
mediators of proteinuria, glomerular damage, and the local cytokine milieu, this may explain 
the persisting proteinuria in the heparanase-deficient mice during experimental 
glomerulonephritis albeit lower compared to the WT mice.  
PMN influx peaked 2 hours after the induction of anti-GBM glomerulonephritis. PMNs are 
one of the key determinants of proteinuria and glomerular injury in the early phase of anti-
GBM glomerulonephritis. PMN influx was significantly lower in the heparanase-deficient 
mice, which could result in a reduced release of proteinases, which can destruct the capillary 
wall [37]. This reduced PMN influx may lead to a reduced proteinuria and to an improved 
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renal function after 1 and 4 days. Heparanase may affect the glomerular PMN influx in 
several ways. A first possibility is that heparanase may affect the availability of adhesion 
molecules. This was previously described for lung injury during sepsis [19]. During acute lung 
injury, activated heparanase cleaves HS from the pulmonary endothelial glycocalyx, thereby 
exposing endothelial surface adhesion molecules that allow neutrophil adhesion. A second 
possible mechanism is by shaping the glomerular endothelial expression of specific 
inflammatory, N- and 6-O-sulfated, HS domains that mediate leukocyte trafficking. We 
previously showed that the expression of these inflammatory HS domains is increased on 
activated glomerular endothelial cells and that they enhance leukocyte adhesion in vitro [13]. 
In addition, an increased expression of these inflammatory HS domains was observed 2 
hours after induction of anti-GBM glomerulonephritis, at the time leukocyte influx peaked [31, 
36]. It can be speculated that heparanase contributes to the shaping of an inflammatory 
glycocalyx, thereby promoting the presence of inflammatory HS domains mediating PMN 
binding. Indeed we observed a decreased expression of the inflammatory HS domains in the 
heparanase-deficient mice. A third possible mechanism may involve the HSPG syndecan-1. 
A recent study in a myeloma cell line showed that heparanase enhanced the expression and 
shedding of syndecan-1 [38-40]. We previously showed that syndecan-1 deficiency 
aggravates anti-GBM glomerulonephritis by increasing leukocyte influx, suggesting that 
syndecan-1 has anti-inflammatory properties [31]. Loss of heparanase may lead to less 
shedding of syndecan-1, which may lead to a reduced inflammatory response, thereby 
reducing the PMN influx.  
No significant differences in PMN influx were observed between WT and heparanase-
deficient mice after induction of LPS glomerulonephritis. The mechanisms of proteinuria and 
inflammation for anti-GBM and LPS-induced glomerulonephritis may be different. Whereas 
the development of our anti-GBM glomerulonephritis model is PMN-dependent, the 
development of LPS glomerulonephritis is also mediated by a direct effect of LPS on 
podocytes. Mice deficient of synaptopodin, an actin-associated protein highly expressed by 
podocytes, show aggravated proteinuria after LPS administration [41]. LPS induces the 
expression of cytoplasmic cathepsin L [42]. Synaptopodin is a known substrate of cathepsin 
L [43], and degradation of synaptopodin by cathepsin L resulted in the reorganization of the 
actin cytoskeleton, foot process effacement and proteinuria. In line with these results, we 
observed an increased cathepsin L mRNA expression and reduced synaptopodin protein 
expression (data not shown) after induction of LPS glomerulonephritis. Heparanase-
deficiency reduced cathepsin L mRNA expression and increased synaptopodin expression 
(data not shown).  
In addition to PMNs, macrophages may play a role in establishing the inflammatory milieu 
and the subsequent destruction of the glomerular capillary wall. We observed an increased 
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glomerular macrophage influx in both models of experimental glomerulonephritis, which was 
reduced in the heparanase-deficient mice. Macrophages can be activated by cytokines such 
as interferon-γ and TNF-α, bacterial LPS, extracellular matrix proteins and other chemical 
mediators. We observed an increased renal expression of the proinflammatory cytokine TNF-
α in both experimental models for glomerulonephritis, which was reduced in the heparanase-
deficient mice as well. The fact that TNF-α, like LPS, can activate macrophages could 
explain the increased macrophage influx. Recently, Lerner et al. showed that macrophages 
are more prone to activation by LPS after they have been pre-treated with heparanase [22]. 
In intestinal inflammation, macrophages stimulate epithelial cells, resulting in an increased 
heparanase expression, which is mainly caused by TNF-α. In addition, macrophages can 
secrete mature cathepsin L, and thereby process and activate heparanase [15]. In turn, this 
active heparanase could also induce macrophage activation. Similar results were observed 
in diabetic nephropathy, where high glucose induced heparanase expression [24]. 
Heparanase is processed by cathepsin L produced by tubular cells and this active 
heparanase sustains macrophage stimulation, resulting in an increased production of TNF-α. 
Interestingly, in that study no increase in TNF-α production and macrophage influx was 
observed in the heparanase-deficient mice. In addition, heparanase expression is normal 
after induction of LPS glomerulonephritis in TNF receptor 1-deficient mice, which also 
showed a normal renal function [28]. Although the exact mechanism of macrophage 
activation by heparanase is not fully understood, toll-like receptors (TLRs) may play an 
important role [44]. Extracellular HS both inhibits and activates TLR4 signaling and 
macrophage activation [45-48]. Activated heparanase can cleave HS on the macrophage cell 
surface and thereby facilitate ligand binding to TLR4 [22]. In addition, this cleaved HS can 
directly stimulate TLR4 [45, 46, 49, 50], thereby sustaining macrophage activation and 
promoting renal damage.  
In this study we showed an increased heparanase expression by induction of experimental 
glomerulonephritis in vivo and stimulation of mGEnC-1 or mouse podocytes with TNF-α or 
LPS in vitro. Previously, we showed that the early growth response 1 (EGR1) transcription 
factor can stimulate heparanase expression in kidney cells [23]. Both TNF-α and LPS can 
induce the expression of EGR1 [22, 51], suggesting that heparanase expression is induced 
via an EGR1-dependent mechanism.  
Our data are not conclusive with respect to the origin of heparanase in our in vivo models for 
experimental glomerulonephritis. We can conclude that in the LPS-induced model for 
glomerulonephritis heparanase is not derived from platelets, but heparanase may originate 
from the glomeruli and/or inflammatory cells, such as PMNs and macrophages. In the anti-
GBM induced model, heparanase may be derived from platelets as well. Notably, the anti-
GBM model is very specifically targeting the glomerulus due to the use of anti-GBM serum, 
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which specifically attracts inflammatory cells and platelets to the glomeruli. Therefore, it may 
be suggested that heparanase in anti-GBM glomerulonephritis is locally produced by 
attracted inflammatory cells and platelets, in addition to local production by glomerular cells 
like podocytes and glomerular endothelial cells. Nevertheless, the exact contribution of cells 
and tissue in local heparanase production should be addressed in future research by 
repeating the LPS-induced and anti-GBM-induced experiments in hematopoietic chimera, i.e. 
heparanase-deficient bone marrow in WT mice and vice versa. In addition, although 
challenging, experiments could be repeated in WT  mice with kidney transplants of 
heparanase-deficient mice and vice versa.  
In conclusion, heparanase deficiency significantly ameliorates proteinuria and renal damage 
during experimental glomerulonephritis by preserving glomerular HS expression, reducing 
the glomerular influx of leukocytes and macrophages and by affecting the local cytokine 
milieu. Further studies are required to further precise the underlying mechanisms, but overall, 
heparanase represents an attractive therapeutic target for the treatment of 
glomerulonephritis.  
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Abstract  
 
Proteinuria is a hallmark of many glomerular diseases and an independent risk factor for the 
progression of renal failure. Proteinuria results from damage to the glomerular filtration 
barrier (GFB), which plays a critical role in size- and charge-selective filtration. The GFB 
consists of three layers, which is the fenestrated endothelium that is covered by the 
glycocalyx, the podocytes, and the intervening glomerular basement membrane. Defects in 
one of the three layers in the GFB can lead to the development of proteinuria. Heparan 
sulfate (HS) is a negatively charged polysaccharide that is abundantly expressed in all layers 
of the GFB. HS expression in the GFB is reduced in the majority of patients with proteinuria, 
which is associated with an increased glomerular expression of the HS-degrading enzyme 
heparanase. The primary role of HS in the development of proteinuria has been challenged 
after the establishment of several genetically engineered mouse models with an altered HS 
expression that did not display development of overt proteinuria. However, in a recent study 
we showed that heparanase is essential for the development of proteinuria in diabetic 
nephropathy, which suggests that loss of HS contributes to the development of proteinuria. 
Recent studies also further highlight the importance of the glomerular endothelial glycocalyx 
in charge-selective filtration and the development of proteinuria. This review aims to 
summarize our current knowledge on the role of in particular HS and heparanase in the 
development of proteinuria. 
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Introduction  
The kidney plays an important role in filtering the blood and thereby eliminates waste 
products. This filtering process takes place in a large number of small functional units within 
the kidney, called glomeruli that consist of a tuft of microcapillaries. The glomerular capillary 
wall is semi-permeable, small and positively charged molecules pass the glomerular filtration 
barrier (GFB) freely, whereas the passage of large and negatively charged molecules is 
restricted. The GFB is composed of fenestrated glomerular endothelial cells covered by a 
glycocalyx, the glomerular basement membrane (GBM) and the podocytes with their 
interdigitated foot processes and slit diaphragms. Damage to the GFB results in proteinuria, 
which is characterized by proteins with the size of albumin (69 kDa) or larger in the urine. 
Proteinuria is an independent risk factor for the progression of renal failure [1]. It is therefore 
critical to understand the mechanisms leading to proteinuria and to identify therapeutic 
targets for patients with proteinuria. The importance of podocytes and the GBM has been 
extensively reviewed elsewhere [2-5]. Several proteins in the slit diaphragms of podocytes 
and in the GBM have been shown to be crucial for a normal GFB function. In this review we 
provide an update on heparanase and the endothelial glycocalyx, including the heparan 
sulfate proteoglycans, and their role in the pathogenesis of proteinuria 
 
Glomerular endothelial cells and the glycocalyx 
Glomerular endothelial cells are highly specialized cells covering the inner layer of 
glomerular capillaries. The glomerular endothelium contains numerous fenestrations, 
transcellular pores of 60-80 nm in diameter. The size of these fenestrations is large 
compared to albumin. Therefore, it was initially thought that the glomerular endothelium did 
not play a critical role in providing a barrier to proteins. The formation and maintenance of 
endothelial cell fenestrations depends on the vascular endothelial growth factor (VEGF) [6]. 
In the glomerulus VEGF is produced by podocytes. Loss of VEGF in podocytes results in 
renal disease characterized by proteinuria and endotheliosis. VEGF signals from the 
podocytes to the glomerular endothelial cells in a paracrine manner, and thereby regulates 
the structure and function of the adjacent endothelial cell [7]. Glomerular endothelial cells 
and their fenestrations are covered with a carbohydrate-rich cell-surface layer, the 
glycocalyx, that might provide a barrier to proteins [6]. The endothelial glycocalyx is a 
network of glycoproteins anchored to the endothelium through the cell membrane-bound 
proteoglycans [8]. The cell membrane-bound proteoglycans with their glycosaminoglycan 
(GAG) chains form the functional and structural backbone and can bind soluble molecules 
such as albumin, orosomucoid and lumican [9]. These soluble molecules are linked to each 
other either directly or via soluble proteoglycans or their GAG chains [8]. Heparan sulfate HS 
is the most common GAG in the endothelial glycocalyx, and accounts for ~50% of the total 
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amount. Chondroitin sulfate (CS) is typically present in a ratio of 1:4 with HS. However, this 
expression is variable, since the expression of GAGs in the glycocalyx depends on various 
stimuli, such as endothelial cell activation or stimulation [8]. The major non-sulfated GAG in 
the glycocalyx is hyaluronan (HA), which plays an important role in the structural 
maintenance of vascular integrity [10]. The endothelial glycocalyx plays an important role in 
many physiological processes, which includes vascular permeability, attenuation of blood cell 
– vessel wall interactions, mechanotransduction, signaling, and vascular protection [2, 8, 11-
14]. Damage to the glycocalyx may lead to disturbances in these aforementioned 
physiological processes. Therefore, the glycocalyx plays an important role in several 
vascular pathologies, including the development of proteinuria and inflammation [13, 15-19] 
(Figure 1).  
 
 
Figure 1: Role of the endothelial glycocalyx in proteinuria and inflammation. (A) Under 
physiological conditions, the glycocalyx forms a barrier for the passage of proteins and it prevents the 
adherence of inflammatory cells to the endothelium. (B) When the glycocalyx is damaged, proteins 
can pass the filtration barrier, resulting in proteinuria, and inflammatory cells can adhere to HSPGs 
and transmigrate through the endothelium, resulting in glomerular inflammation.  
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Heparan sulfate proteoglycans 
The major functional GAG in the glycocalyx is HS. HS proteoglycans (HSPGs) consist of a 
core protein, to which one or more HS polysaccharide side chains are covalently attached. 
These HS chains are highly negatively charged due to the presence of acidic sugar residues 
and/or sulfate groups. HS belongs to the family of negatively charged GAGs that also include 
heparin, chondroitin sulfate, dermatan sulfate, keratan sulfate and the non-sulfated 
hyaluronan. HSPGs are present in extracellular matrices (ECMs) and at the cell surface of all 
cell types, including endothelial cells and podocytes. Agrin, perlecan and collagen XVIII are 
the HSPGs present in the GBM and the mesangial matrix. Cell surface HSPGs include 
glypicans, syndecans, CD44 and betaglycan [15].  
HSPGs are involved in a large variety of physiological processes. They participate in cell-cell 
and cell-ECM interactions via their HS chains. Furthermore, HSPGs function as a receptor or 
co-receptor for the binding of several soluble ligands, including growth factors, cytokines and 
chemokines [15]. This indicates that HSPGs play a pivotal role in the control of multiple 
physiological and pathological processes. The interaction between HS and its ligands is very 
specific and is dictated by HS sequences of well-defined length and structure. Changes in 
HS structure will therefore influence the binding of ligands to HS and, subsequently, their 
physiological activities [15].  
HS biosynthesis is a multistep process that occurs in the Golgi apparatus, which is 
characterized by chain initiation, polymerization and modification. HS synthesis starts with 
the addition of a pentasaccharide linkage to specific serine residues within the core protein 
(xylose-xylose-galactose-galactose-glucuronic acid), which is catalyzed by several 
carbohydrate transferases [20]. The HS copolymerase complex EXT1/EXT2 subsequently 
adds alternating N-acetyl-glucosamine (GlcNAc) and glucuronic acid (GlcA) residues to the 
pentasaccharide linker. In addition to HS polymerization, several modification steps take 
place in the HS biosynthesis, such as N-deacetylation/N-sulfation (catalyzed by 4 N-
deacetylases/N-sulfotransferases), C-5 epimerization of glucuronic acid to iduronic acid 
(catalyzed by a single C5-epimerase), and O-sulfation at 2-O, 3-O and 6-O positions 
(respectively catalyzed by a single 2-O-sulfotransferase, 7 3-O sulfotransferases and 3 6-O 
sulfotransferases) (Figure 2). The structure of the HS chain can also be modified by HS-
modifying enzymes such as 6-O-endosulfatases and heparanase. 6-O-endosulfatase 
enzymes (sulf1 and sulf2) edit the final sulfation pattern and function of HS by specifically 
removing 6-O-sulfate groups [21]. Finally, HS can be degraded by heparanase, a β(1-4)-
endoglucuronidase that cleaves HS at specific sites via hydrolysis. The combination of 
possible modifications in a HS chain gives rise to an enormous structural diversity, which 
dictates the binding and modulation of a myriad of factors that include growth factors, 
chemokines, cytokines, enzymes, and other proteins [5, 15] (Figure 2).  
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Figure 2: HS biosynthesis, editing and degradation. Schematic overview of the biosynthesis of a 
HS chain: 1) The EXT1/EXT2 complex recognizes a pentasaccharide linker and generates the initial 
HS chain, 2) N-deacetylases/N-sulfotransferases (NDSTs) catalyze the N-deacetylation/N-sulfation of 
glucosamine residues, 3) C5-epimerase catalyzes the epimerization of GlcA to IdoA, 4) 2-O-
sulfotransferases (2-OSTs) catalyze the sulfation of GlcA and IdoA and 3-O-sulfotransferases (3-
OSTs) and 6-O-sulfotransferases (6-OSTs) catalyze the sulfation of glucosamine residues, and 5) 6-
O-endosulfatases (sulf 1 and 2) catalyze the removal of 6-O-sulfate groups and heparanase cleaves 
the HS chain at specific sites via hydrolysis. Abbreviations: Ser, serine; GlcA, glucuronic acid; IdoA, 
iduronic acid; GlcNAc, N-acetyl-glucosamine; GlcNS, N-sulfated-glucosamine.     
 
No primary role of HS in charge-selective filtration 
For several decades it was assumed that the presence of negatively charged HS in the GBM 
is essential for the charge-selective permeability of the GFB. Seminal studies demonstrated 
the presence of GAGs, including HS, in the GBM. Furthermore, it has been shown that in situ 
removal of GAGs in the GBM by perfusion of bacterial GAG-degrading enzymes led to the 
passage of ferritin and bovine serum albumin [22, 23]. Moreover, injection of anti-HS(PG) 
antibodies in rats led to albuminuria [24]. Finally, in many (experimental) glomerular 
diseases, such as diabetic nephropathy, systemic lupus erythematosus, minimal change 
disease and membranous glomerulopathy, a decreased expression of HS in the GBM was 
observed, which in general was inversely correlated with the level of urinary protein excretion 
[5, 25]. However, the primary role of HS in charge-selective filtration has been challenged 
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after establishing several genetically engineered mouse models with a disturbed HS(PG) 
expression in the GFB. Mice with podocytes lacking the predominant core protein agrin did 
not develop proteinuria and revealed a normal glomerular architecture, despite the fact that 
they lacked the majority of anionic sites in the GBM [26]. Mice lacking both perlecan and 
agrin did not develop glomerular abnormalities or proteinuria [27]. Mice deficient for the cell 
surface HSPG syndecan-1 and mice deficient in endothelial NDST-1 also display no 
albuminuria [28, 29]. Mice with podocytes lacking the essential HS polymerizing enzyme 
EXT1, developed glomerular ultrastructural abnormalities such as foot process effacement, 
but only a mild, not significant, albuminuria [30]. Finally, mice overexpressing heparanase 
displayed a ~5-fold decrease of GAG-associated anionic sites in the GFB. However, also in 
these mice no ultrastructural abnormalities or severe albuminuria could be observed [31]. 
Thus, several mouse models targeting HS expression in the GFB did not develop proteinuria, 
whereas in proteinuric patients a reduced HS expression is associated with proteinuria 
(Table 1).Taken the experimental animal data together, the primary role of HS in determining 
charge-selective properties of the capillary filter can be rejected. However, a role of HS and 
the HS-degrading enzyme heparanase in the development of proteinuria in situations with 
glomerular pathology cannot be excluded [5].  
 
Table 1: Involvement of HS in the development of proteinuria.  
Disease/ animal model Species Glomerular 
HS expression 
Proteinuria Reference 
Diabetic nephropathy Human Reduced + [25] 
Systemic lupus erythematosus Human Reduced + [25] 
Minimal change disease Human Reduced + [25] 
Membranous glomerulonephritis Human Reduced + [25] 
Dense Deposit disease Human Reduced + [32] 
Podocyte-specific agrin 
knockout 
Mouse Reduced - [26] 
Perlecan/agrin double knockout Mouse Reduced - [27] 
Endothelial-specific NDST1 
knockout 
Mouse Reduced - [29] 
Podocyte-specific EXT1 
knockout 
Mouse Reduced +/- [30] 
Heparanase overexpression  Mouse Reduced  +/- [31] 
+, proteinuria; +/-, mild proteinuria; -, no proteinuria. 
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Heparanase 
Heparanase cleaves the glycosidic bond within the HS chain at a few selective sites, yielding 
HS fragments of 5-7 kDa in size. This cleavage requires N- and 6-O-sulfated moieties in a 
specific context as exemplified in the trisaccharide sequence GlcNS6OS-α(1-4)-GlcA-β(1-4)-
GlcNS6OS [5]. Heparanase is synthesized as a pre-proheparanase of 68 kDa. It is targeted 
to the endoplasmic reticulum via its signal peptide, and processed into a 65 kDa 
proheparanase by cleaving off this signal peptide. The proheparanase is then transported to 
the Golgi apparatus and subsequently packaged into vesicles and secreted. Once secreted, 
heparanase interacts with cell membrane HSPGs (in particular syndecan), low density 
lipoprotein receptor-related proteins and mannose 6-phosphate receptors, followed by 
endocytosis of the heparanase-receptor complex. Proheparanase is then transferred to the 
late endosomes/lysosomes, where it is processed and activated by cathepsin L through the 
cleavage of a linker segment [33]. This results in an active heparanase heterodimer 
consisting of an 8 kDa N-terminal subunit and a 50 kDa C-terminal subunit. Heparanase 
plays a physiological role in HS turnover, embryo development, hair growth and wound 
healing. Furthermore, it plays a pathological role in tumor growth, angiogenesis, metastasis, 
inflammation and glomerular diseases [34].  
 
Heparanase expression in proteinuric diseases 
The first study revealing that heparanase plays a role in the development of proteinuria was 
in rats with puromycin aminonucleoside (PAN)-induced nephrosis. Glomerular heparanase 
expression was upregulated in these rats and therefore may be involved in the loss of 
glomerular HS observed in proteinuria [35]. Similar results were found in rats with passive 
Heymann nephritis (PHN), a model of membranous glomerulopathy. In these rats, glomerular 
heparanase expression was increased in the proteinuric phase. Administration of a 
polyclonal antibody against heparanase reduced the level of proteinuria [36]. Furthermore, 
administration of the heparanase inhibitor PI-88 to rats with PHN reduced proteinuria and 
was associated with the preservation of glomerular HS expression, suggesting that active 
heparanase is important in the development of proteinuria [37].  
In other experimental glomerular diseases such as streptozotocin (STZ)-induced diabetic 
nephropathy and adriamycin nephropathy, and human glomerular diseases, such as diabetic 
nephropathy, IgA nephropathy, minimal change disease, dense deposit diseases and 
membranous glomerulopathy, glomerular heparanase expression is also increased [5, 32, 
38, 39]. In proteinuric diseases, both podocytes and glomerular endothelial cells can show an 
increased heparanase expression, while tubular cells always express high levels of 
heparanase, also under healthy conditions. The increased glomerular heparanase 
expression in patients with glomerular diseases is associated with a decreased expression of 
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HS in the GBM. Furthermore, as mentioned the reduced HS expression inversely correlates 
with the degree of proteinuria, suggesting that heparanase is responsible for the glomerular 
degradation of HS and, most likely, for the development of proteinuria [38]. 
 
Heparanase is involved in the pathogenesis of diabetic nephropathy  
Recently, we demonstrated that heparanase-knockout mice, unlike their wild type littermates, 
failed to develop proteinuria and renal damage in response to STZ-induced type1 diabetes 
[40]. Heparanase mRNA expression was increased in the renal cortex of the diabetic wild 
type mice. No heparanase was detected in diabetic and non-diabetic heparanase-knockout 
mice, which failed to develop diabetic nephropathy and proteinuria. Importantly, in this study 
the expression of 3-O-sulfated HS domains, as recognized by the antibody HS4C3 [41] was 
reduced in glomeruli of diabetic wild type mice, whereas no change was detected in 
glomeruli of diabetic heparanase-knockout mice [40]. The crucial role of heparanase in the 
development of proteinuria was further demonstrated by the treatment of type 1 diabetic wild 
type mice with the specific heparanase inhibitor SST0001, which resulted in a lower degree 
of albuminuria and a better renal function compared to vehicle-treated diabetic mice. These 
results demonstrate that heparanase is causally involved in the pathogenesis of proteinuria 
and diabetic nephropathy. In addition, inhibition of heparanase expression and activity could 
be a relevant therapeutic approach in diabetic nephropathy.  
As outlined, previous studies demonstrated that loss of anionic sites in the GFB in genetically 
engineered mice, including transgenic mice overexpressing heparanase, did not result in the 
development of proteinuria [26, 27, 30, 31]. However, in those previous studies no additional 
pathogenic signals were applied, in contrast to the study using heparanase-deficient mice 
where in addition to a manipulated heparanase expression diabetic nephropathy was 
induced with STZ. However, it is difficult to predict what will happen when diabetic 
nephropathy will be induced in the transgenic heparanase overexpression mouse. It may be 
hypothesized that induction of diabetic nephropathy in the heparanase overexpressing 
mouse will be similar as in wild-type mice, although the disease may be accelerated as well 
since there is already overexpression of heparanase at the start. Alternatively, it can be 
hypothesized that induction of diabetic nephropathy in the heparanase overexpressing 
mouse may not be possible at all, at least when loss of HS is an important event in the chain 
of events that leads to diabetic nephropathy and proteinuria, since these mice lack already 
the majority of HS in their GFB at the start. Notably, the heparanase-deficient mice normally 
have no clear phenotype. We previously suggested several mechanisms due to the action of 
heparanase and loss of HS that could be involved in the pathogenesis of proteinuria, such as 
1) changes in glomerular cell-GBM or cell-cell interactions due to the loss of HS, 2) release 
of HS-bound growth factors, cytokines, chemokines and bioactive HS fragments and/or 3) 
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the induction of signaling cascades resulting in changed cell properties [5]. Additional 
research is needed to proof whether one or more of these mechanisms are required for the 
development of proteinuria and to which extent heparanase is involved. Nevertheless, it can 
be concluded that heparanase activity and most likely loss of HS play a crucial role in the 
pathogenesis of proteinuria in experimental diabetic nephropathy.  
 
The endothelial glycocalyx in proteinuric diseases  
As outlined, the endothelial glycocalyx plays an important role in many physiological 
processes [8]. Damage to the glycocalyx may therefore lead to several vascular pathologies. 
Mice with adriamycin-induced nephropathy displayed a substantial reduction in glomerular 
glycocalyx thickness, caused by the impaired synthesis of certain proteoglycans and HS [12, 
19]. This resulted in a reduction of charge selectivity and in the development of proteinuria. 
Similar results were found in diabetic Zucker fatty rats, who displayed a significant reduction 
in endothelial cell glycocalyx thickness compared to control rats and these rats developed 
albuminuria at 18 weeks of age [42, 43]. Heparanase expression was increased in these 
rats, which could be attributed to an increased production of reactive oxygen species (ROS) 
[42]. Using Munich-Wistar-Fromter (MWF) rats that spontaneously develop albuminuria by 
aging, Salmon et al [44] observed that these rats had a reduction in glycocalyx volume, 
similar to that of healthy animals with an enzymatically removed glycocalyx. The MWF rats 
with a reduced glycocalyx developed albuminuria. Modification of the glycocalyx of these 
MWF rats by adsorption of intravenously injected wheat germ agglutinin (WGA) lectin 
significantly reduced the glomerular albumin permeability, indicating that loss of glycocalyx 
increases microvascular permeability. Another study showed that rats exposed to a 
hypertonic sodium chloride solution to remove non-covalently bound components of the 
glycocalyx, displayed a 12-fold increase in albumin excretion, without any detectable damage 
to the GBM or the podocytes [9]. The permeability of Ficoll was unaltered, indicating that 
damage to the glycocalyx leads to a defect in charge selectivity.  
In a recent study we showed that infusion of mice with the hyaluronan-degrading enzyme 
hyaluronidase leads to degradation of the glycocalyx and leakage of albumin across the 
endothelium, as demonstrated with correlative light-electron microscopy that allows for 
complete and integral assessment of glomerular albumin passage. However, no albumin was 
detected in the urine, and the leaked albumin was found to be associated with podocytes and 
parietal epithelial cells [45]. Importantly, no albumin passage over the GFB could be 
observed with an intact glycocalyx. Since hyaluronan is an important structural component of 
the glycocalyx this recent finding suggests that an intact endothelial glycocalyx is required for 
a proper GFB function. In future experiments we aim to induce experimental proteinuria in 
genetically engineered mice targeted for endothelial hyaluronan and HS.  
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Patients with type 1 and type 2 diabetes show a reduction in systemic glycocalyx volume [16, 
19, 46], which correlates with the presence of microalbuminuria [16]. Importantly, urinary 
heparanase levels in patients with type 1 and type 2 diabetes are associated with 
albuminuria [47]. Systemic glycocalyx reduction may be an effect of hyperglycemia, as high 
glucose alters the biosynthesis of sulfated GAG chains, in particular that of HS, as 
demonstrated in conditionally immortalized human glomerular endothelial cells [43, 48]. 
Hyperglycemia also increases the production of ROS, aldosterone and angiotensin II, 
resulting in an increased heparanase expression by both podocytes and glomerular 
endothelial [39, 42, 49, 50]. Degradation of HS leads to an increased flux of albumin across a 
monolayer of glomerular endothelial cells in vitro [13], also suggesting that the glycocalyx 
plays an important role in the development of proteinuria.  
 
Conclusion 
A causal role for heparanase in the pathogenesis of proteinuria in diabetic nephropathy has 
now been clearly demonstrated. Previous studies that addressed proteinuria mainly focused 
on podocytes and the GBM, whereas glomerular endothelial cells were more or less 
neglected. However, proteinuria can also develop without morphological changes to 
podocytes and the GBM. A reduction of the glycocalyx on glomerular endothelial cells results 
in an increased albumin permeability. All layers of the GFB contribute to a normal glomerular 
filtration, and every layer needs to be intact to maintain a normal filtration barrier. Since there 
may be several mechanisms involved in the pathogenesis of proteinuria due to the action of 
heparanase and loss of HS, the exact role of HS in the development of proteinuria has to be 
determined under pathological conditions. Despite the growing body of evidence, further 
studies are required to unravel the structure and function of the glomerular endothelial 
glycocalyx, and its contribution to the development of proteinuria. Ultimately, this will lead to 
the identification of molecular targets for therapeutic intervention with well-defined GAG-
based drugs. 
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Abstract 
 
Diabetic nephropathy (DN) is the leading cause of chronic kidney disease in the Western 
world. Recently, endothelin receptor antagonists have emerged as a novel treatment for DN, 
but the mechanisms underlying their protective effect remain unknown. We previously 
showed that both heparanase and endothelin-1 are essential for the development of DN. 
Here, we demonstrate that endothelin-1 activates podocytes to release heparanase. 
Conditioned podocyte culture medium increases glomerular transendothelial albumin 
passage in a heparanase-dependent manner. In podocyte-specific endothelin receptor 
knockout (podETRKO) mice, the increased glomerular heparanase expression and 
consequently reduced heparan sulfate expression and endothelial glycocalyx thickness 
during diabetes was prevented, whereas these diabetic podETRKO mice failed to develop 
proteinuria. Taken together, our data suggest that in diabetes endothelin-1 signaling, as 
occurs in endothelial activation, induces heparanase expression in the podocyte, damage to 
the glycocalyx, proteinuria and renal failure. This constitutes a novel mechanism of action of 
endothelin receptor blockers in DN.  
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Introduction 
 
Diabetic nephropathy (DN), a major complication of both type I and type II diabetes mellitus, 
is the leading cause of chronic kidney disease in the Western world. DN is characterized by a 
progressive increase in proteinuria, glomerular capillary widening, secondary podocyte loss, 
mesangial matrix expansion, glomerular basement membrane thickening and finally 
tubulointerstitial fibrosis. Current treatment does not reduce proteinuria sufficiently. 
Therefore, there is a need to identify new therapeutic targets.      
One potent new therapeutic target is the endothelin-1 receptor. Endothelin-1 is a 
vasoconstrictor that is released upon endothelial activation and activates two G-protein-
coupled receptors, endothelin receptor type A (ETRA) and endothelin receptor type B 
(ETRB). Together, these receptors induce a variety of intracellular signaling cascades, 
resulting in vasoconstriction, proliferation, inflammation, extracellular matrix production and 
fibrosis [1-4]. The expression of endothelin-1 is increased in DN [5]. Several studies report a 
renoprotective effect of endothelin receptor antagonists (ERAs) in both experimental as well 
as clinical DN [6-8]. Moreover, ERAs reduce residual proteinuria and improve endothelial 
function in patients with DN, in addition to the standard treatment [6, 9]. In addition to DN, 
ERAs reduce proteinuria in other forms of nephropathy, such as hypertensive nephropathy 
and focal segmental glomerulosclerosis [10]. It was shown that podocyte-specific deletion of 
both ETAR and ETBR protects mice from diabetes-induced glomerulosclerosis and podocyte 
loss, indicating that endothelin-1 signaling in the podocyte may play a role in the 
development of DN and the protective effects of endothelin blockers [11]. The mechanism 
underlying the protective effect of ERAs, however, remains unknown.  
We previously showed that heparanase is essential for the development of DN [12]. 
Heparanase-deficient mice were protected from diabetes-induced proteinuria and renal 
damage. Heparanase is the only known mammalian enzyme that can cleave the negatively 
charged heparan sulfate (HS) side chains of HS proteoglycans (HSPGs). Loss of HS 
expression in the glomerular filtration barrier has been associated with the development of 
proteinuria [13]. In addition, HS is the major functional glycosaminoglycan in the endothelial 
glycocalyx, and remodeling of the glycocalyx is associated with the development of 
proteinuria [14-19]. 
Based on our previous data, we hypothesize that endothelin-1 signaling modulates the 
endothelial glycocalyx in DN through heparanase release by the podocyte. In this study we 
evaluate the effects of endothelin-1 on heparanase expression and function both in vitro and 
in vivo. 
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Materials and methods 
 
Animals 
Mice with podocyte-specific deletion of both Ednar and Ednbr genes (podocin-Cre+ 
Ednarlox/lox Ednbrlox/lox mice) were generated as described [11]. Mice were on a mixed 
C57BL/6J/ 129/SV/ FVB/N genetic background. Mice homozygous for floxed Ednar and 
Ednbr genes but without Cre were used as control mice.  
To induce diabetes, 12-week old male mice were injected intraperitoneally with 100 mg/kg 
streptozotocin in a citrate buffer (pH 4.5) for 2 consecutive days as described [11]. Control 
mice were injected with citrate buffer alone. Mice with a fasted blood glucose >16 mmol/l 
were considered diabetic. Mice were sacrificed 10 weeks after the induction of diabetes. 
Urinary creatinine concentrations were measured spectrophotometrically using colorimetric 
methods. Urinary albumin excretion was measured by ELISA (BIOTREND Chemikalien 
GmbH, Köln, Germany). Glomeruli were isolated from freshly harvested kidneys as 
described previously [11]. All animal experiments were performed according to French 
veterinary guidelines and those formulated by the European Commission for experimental 
animal use (L358-86/609EEC), and approved by the Institute National de la Santé et de la 
Recherche Médicale (INSERM).    
   
Immunofluorescence staining 
Indirect immunofluorescence staining was performed on 2 µM thick cryosections as 
described [20]. Primary antibodies included heparanase (HPA1, ProsPecTany, Rehovot, 
Israel) and the VSV-tagged anti-HS antibody HS4C3 (N-, 2-O, 3-O and 6-O sulfation) [21]. 
Secondary antibodies included goat anti-rabbit IgG Alexa 488 (Invitrogen Life Technologies, 
Breda, The Netherlands) and rabbit anti-VSV Cy3 (Sigma-Aldrich). At least 50 glomeruli per 
section were scored for heparanase and HS staining intensities on a scale between 0 and 10 
(0= no staining, 5= 50% staining, 10= 100% staining) by two independent investigators on 
blinded sections using a Leica CTR6000 microscope.   
 
Glycocalyx staining 
Small pieces of cortex were fixed in periodate-lysine-paraformaldehyde (PLP; pH 6.2), 
immersed in 2.3 M sucrose and snap frozen in liquid nitrogen. Frozen sections (20 µm) were 
stained and fixed with 1% lanthanum hydroxide and 2% glutaraldehyde dissolved in 0.1M 
sodium cacodylate buffer (pH 7.4). Samples were washed in 0.1 M sodium cacodylate buffer 
(pH 7.4), postfixed in Palade-buffered 1% OSO4 with 1% lanthanum hydroxide, washed in 0.1 
M sodium cacodylate buffer (pH 7.4), dehydrated, and embedded in Epon 812, Luft’s 
procedure (EMS, Hatfield, United Kingdom). Endothelial and podocyte glycocalyx thickness 
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(in nm) was measured in 3 non-diabetic and 4 diabetic mice per group. For each mouse at 
least 10 randomly selected capillary loops of at least 5 randomly selected glomeruli were 
analyzed at randomly selected measuring points. The measurements were performed twice 
by two independent investigators on blinded sections using a Jeol JEM 1400 electron 
microscope (JEOL, Tokyo, Japan) and Gata microscopy suite.  
 
Cell culture 
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) and mouse 
podocytes (MPC-5) were cultured as described previously [22, 23]. Differentiated mGEnC-1 
and podocytes were treated with endothelin-1 (100 nM; Sigma-Aldrich, Zwijndrecht, The 
Netherlands) and/or the combined ERA PD 142893 (0.1 µM; Sigma-Aldrich) or the selective 
ETRA antagonist BQ-123 (1 µM; Sigma-Aldrich) for 18 hours.  
 
RNA isolation and real-time PCR 
Total RNA was extracted from kidney cortex, mGEnC-1 and MPC-5 podocytes. RNA 
isolation, cDNA synthesis and real-time PCR were performed as described [24].  
 
Heparanase activity assay  
Heparanase activity of recombinant heparanase, isolated glomeruli, MPC-5 podocytes, and 
culture supernatant was determined using a commercially available assay (AMS 
Biotechnology, Abingdon, UK) according to manufacturer’s instructions.   
 
Transendothelial albumin passage and TEER measurement 
Differentiated mGEnC-1 seeded on polyester membranes in tissue culture inserts (0.4 µm 
pore size; Corning Incorporated, NY, USA). Transendothelial electrical resistance (TEER) of 
untreated cells was measured using a EMD Millipore Millicell-ERS2 Volt-Ohm meter. 
mGEnC-1 were treated with bacterial heparinase and recombinant heparanase for 1 hour, or 
with endothelin-1 and/or the combined ERA PD 142893 or the selective ETRA antagonist 
BQ-123 as outlined. In addition, mGEnC-1 were exposed to culture supernatant of vehicle- or 
endothelin-1-treated podocytes, and where indicated substituted with the anti-heparanase 
antibody HPA1 (ProsPecTany) or the isotype control rabbit IgG (Jackson ImmunoResearch, 
West Grove, PA, USA). Transendothelial albumin passage was determined as described 
[24].   
 
Statistics 
Values are expressed as mean ± SEM. Significance was evaluated by a one-way ANOVA 
and post hoc analysis with Tukey’s multiple comparison test. Significant differences in 
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transendothelial albumin passage were evaluated using a two-way repeated measures 
ANOVA with Bonferroni post-test. Statistical analysis was performed using GraphPad Prism 
5.03 (GraphPad Software, Inc., San Diego, CA, USA). A P-value of ≤ 0.05 was considered 
statistically significant.   
 
 
Results 
 
First, we evaluated the effects of endothelin-1 on cultured podocytes and glomerular 
endothelial cells. Endothelin-1 treatment increased heparanase mRNA expression (Figure 
1A) and heparanase activity (Figure 1B) in mouse podocytes and culture supernatant of 
mouse podocytes (Figure 1C), whereas heparanase expression in cultured mGEnC-1 was 
not affected (Figure 2A). Notably, the endothelin-1-induced increase in heparanase activity 
was larger in the culture supernatant versus the cell extract, respectively ~100% versus 
~20%, suggesting that the majority of endothelin-1 induced heparanase is secreted by the 
podocytes. Treatment of mGEnC-1 with culture supernatant of endothelin-1-stimulated 
podocytes increased transendothelial albumin passage (Figure 1D-E). Heparanase 
expression (Figure 1A), heparanase activity (Figure 1B-C) and transendothelial albumin 
passage (Figure 1D-E) were reduced by treatment with the combined ERA PD142893 and 
the ETRA antagonist BQ-123. Addition of the anti-heparanase antibody HPA1 to the 
conditioned podocyte culture medium also reduced transendothelial albumin passage (Figure 
1F), whereas the isotype control had no effect (Figure 1G). As a control we showed that 
addition of the anti-heparanase antibody to recombinant heparanase reduced heparanase 
activity (Figure 1H), which suggests that the increased transendothelial albumin passage is 
mediated by heparanase. Moreover, stimulation of mGEnC-1 with bacterial heparinase or 
recombinant heparanase to remove HS resulted in an increased transendothelial albumin 
passage (Figure 3), suggesting that HS in the glycocalyx contributes to barrier function in our 
in vitro transendothelial albumin passage system. Stimulation of mGEnC-1 with endothelin-1 
without conditioned podocyte culture medium did not affect transendothelial albumin passage 
(Figure 2B). The observed differences between mGEnC-1 and podocytes in response to 
endothelin-1 can be explained by differences in endothelin receptor expression. Podocytes 
express both ETRA and ETRB, while glomerular endothelial cells only express ETRB [11, 
25]. 
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Figure 1: Endothelin-1-induced heparanase expression in the podocyte increases 
transendothelial albumin passage. (A) Heparanase mRNA expression and (B,C) heparanase 
activity in (A,B) mouse podocytes and (C) culture supernatant of mouse podocytes were increased by 
treatment with endothelin-1 for 18 hours, and reduced by treatment with the ETRA antagonist BQ-123 
and the combined ERA PD 142893. (D,E) Cultured mGEnC-1 were treated with culture supernatant of 
podocytes treated with endothelin-1 in the absence or presence of (D) BQ-123 or (E) PD 142893. 
Cumulative passage of FITC-labeled albumin across the mGEnC-1 monolayer (TEER: 28 Ω cm2) was 
determined over time. Transendothelial albumin passage was increased by endothelin-1, and reduced 
by BQ-123 and PD 142893. To evaluate the role of heparanase on endothelin-1-induced 
transendothelial albumin passage, (F) the anti-heparanase antibody HPA1 (1:100 and 1:250) and (G) 
the isotype control rabbit IgG (1:100 and 1:250) were added to the culture supernatant of endothelin-1-
treated podocytes. Transendothelial albumin passage was reduced by addition of the anti-heparanase 
antibody, but not affected by addition of the isotype control. (H) To show that the anti-heparanase 
antibody HPA1 was able to reduce heparanase activity specifically, recombinant heparanase was co-
incubated with the antibody (1:100 and 1:250). Heparanase activity was reduced by the anti-
heparanase antibody at both tested concentrations. The isotype control had no effect on heparanase 
activity (not shown). *P<0.05, **P<0.01 and ***P<0.001 versus control, #P<0.05, ##P<0.01 and 
###P<0.001 versus ET-1. ETRA; endothelin receptor type A, ERA; endothelin receptor antagonist, ET-
1; endothelin-1, HPSE; heparanase, TEER; transendothelial electrical resistance. 
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Figure 2: Endothelin-1 did not affect heparanase mRNA expression and transendothelial 
albumin passage in mouse glomerular endothelial cells. Cultured mGEnC-1 were treated with 
endothelin-1 in the absence or presence of the combined ERA PD 142893 for 18 hours. Endothelin-1 
did not affect (A) heparanase mRNA expression and (B) transendothelial albumin passage. (A) Each 
bar represents n=4; mean ± SEM; analyzed by a one-way ANOVA. (B) Each dot represents n=3; 
mean ± SEM; analyzed by a two-way repeated measures ANOVA. ERA; endothelin receptor 
antagonist, ET-1; endothelin-1, HPSE; heparanase, mGEnC-1; mouse glomerular endothelial cells.      
 
 
Figure 3: Bacterial heparinase and recombinant heparanase induce transendothelial albumin 
passage in mouse glomerular endothelial cells. Cultured mGEnC-1 were treated with (A) bacterial 
heparinase or (B) recombinant heparanase for 1 hour, which resulted in an increased transendothelial 
albumin passage. Each dot represents n=3; mean ± SEM; analyzed by a two-way repeated measures 
ANOVA. ***P<0.001 versus control. mGEnC-1; mouse glomerular endothelial cells.      
 
To translate our in vitro data, we used podocyte-specific ETRA/ETRB-deficient (podETRKO) 
mice, in which we induced diabetes. As we reported previously, diabetic podETRKO mice 
are, in contrast to diabetic wild type (WT) mice, protected from proteinuria, GBM thickening, 
mesangial matrix expansion, podocyte loss and glomerulosclerosis during streptozotocin-
induced diabetes [11]. Ten weeks after induction of diabetes, WT mice developed a 
significant albuminuria (Figure 4A), which was significantly reduced in the diabetic 
podETRKO mice. Diabetic WT mice showed increased cortical heparanase mRNA (Figure 
4B), glomerular heparanase protein expression (Figure 4C), and glomerular heparanase 
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activity (Figure 4D), whereas glomerular HS expression was reduced (Figure 4E). In 
contrast, heparanase and HS expression were normal in the diabetic podETRKO mice 
(Figure 4B-E). Next, we analyzed glycocalyx thickness, since increased heparanase 
expression may reduce glycocalyx thickness in diabetic mice. The glycocalyx was visualized 
by lanthanum hydroxide staining, which stains the glycocalyx on top of the endothelium and 
podocytes in black. Indeed, glycocalyx thickness on both the endothelium and podocytes 
was reduced ~50-60% in diabetic WT mice (Figure 5A-C). Importantly, endothelial glycocalyx 
thickness was preserved in the diabetic podETRKO mice (Figure 5A-B). Podocyte glycocalyx 
in diabetic podETRKO mice was ~25% reduced (Figure 5A,C), which possibly could be 
explained by a reduction in HS synthesis, as glomerular heparanase activity is not increased 
in the diabetic podETRKO mice. Apparently, the remaining reduction of podocyte glycocalyx 
thickness in podETRKO mice is not sufficient to induce proteinuria and DN. However, we 
cannot exclude the possibility that a combined reduction of endothelial and podocyte 
glycocalyx is required for development of proteinuria and DN in WT mice.  
 
 
Discussion 
 
The present study is the first to show that endothelin-1 regulates heparanase expression in 
podocytes. We previously showed that heparanase is essential for the development of 
proteinuria and renal damage in experimental DN [12]. By induction of diabetes, heparanase-
deficient mice showed no mesangial matrix expansion, macrophage infiltration and 
tubulointerstitial fibrosis, effects that are known to be mediated by signaling through the 
endothelin receptor [1]. In addition, we previously showed that endothelin receptor deficiency 
in podocytes protects mice against experimental DN. In the current study we showed that 
endothelin-1 induced heparanase expression in mouse podocytes both in vitro and in vivo. 
Moreover, we showed that podocyte-specific loss of both ETAR and ETBR prevented 
damage to the endothelial glycocalyx after induction of type 1 diabetes. 
Our data suggest that crosstalk between podocytes and the glomerular endothelium may be 
involved in the development of albuminuria and DN. Most extensively studied is the crosstalk 
of vascular endothelial growth factor (VEGF) and angiopoietin 1 and 2 between podocytes 
and glomerular endothelial cells, where the glomerular endothelial cell integrity depends 
upon signaling from the podocyte [26]. A recent study also reported the crosstalk of 
endothelin-1 between podocytes and glomerular endothelial cells [26, 27]. We recently 
showed that loss of podocyte heparanase prevents the increased passage of albumin across 
the endothelial monolayer induced by adriamycin [24]. In our current study we show that 
heparanase in culture supernatant of endothelin-1 stimulated podocytes is responsible for 
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increased transendothelial albumin passage in vitro, while endothelin-1 had no direct effect 
on endothelial cells, suggesting podocyte endothelial crosstalk. Notably, our transendothelial 
albumin flux model does not intend to mimic albumin flux in vivo, but rather is an assay of 
documenting the effects of endothelin-1 and heparanase on glomerular endothelial cells.  
 
 
Figure 4: Glomerular heparanase and HS expression are normal in diabetic podETRKO mice. 
Ten weeks after induction of diabetes by streptozotocin, (A) WT mice developed a significant 
albuminuria, as indicated by an increased albumin/creatinine ratio. Albuminuria was significantly 
reduced in the diabetic podETRKO mice. (B) cortical heparanase mRNA expression, (C) glomerular 
heparanase protein expression, and (D) glomerular heparanase activity were increased by induction of 
diabetes in WT mice, whereas (E) glomerular HS expression was reduced. Heparanase mRNA 
expression was significantly lower in the diabetic podETRKO mice (B), whereas heparanase protein 
expression (C), heparanase activity (D) and HS expression (E) were normal in the diabetic podETRKO 
mice. 6-7 mice per group were analyzed using a one-way ANOVA. (C,E) Magnification x 400. *P<0.05, 
**P<0.01 and ***P<0.001 versus non-diabetic control, #P<0.05 and  ##P<0.01 versus diabetic WT. HS; 
heparan sulfate, podETRKO; podocyte-specific endothelin receptor knockout, WT; wild type, AU; 
arbitrary units. 
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Figure 5: Glomerular endothelial glycocalyx is preserved in diabetic podETRKO mice. (A) 
Representative transmission electron microscopy images of lanthanum hydroxide visualizing the 
glycocalyx on top of the endothelium and podocytes (in black). Scale bar: 500 nm. (B) Quantification 
of endothelial glycocalyx thickness and (C) quantification of podocyte glycocalyx thickness. Glycocalyx 
thickness on both the endothelium and podocytes was ~50-60% reduced by induction of diabetes in 
WT mice. Endothelial glycocalyx thickness was preserved in diabetic podETRKO mice, but podocyte 
glycocalyx was ~25% reduced in diabetic podETRKO mice. Results were analyzed by a one-way 
ANOVA. ***P<0.001 versus non-diabetic control, ###P<0.001 versus diabetic WT. podETRKO; 
podocyte-specific endothelin receptor knockout, WT; wild type.    
 
In addition to a potential podocyte-endothelial cell crosstalk, there may be various other 
mechanisms involved in the reduced endothelial glycocalyx thickness in WT mice. We have 
previously shown that high glucose, angiotensin II, aldosterone, reactive oxygen species, 
vitamin D and inflammatory cytokines such as TNF-α and IL-1β regulate heparanase 
expression [24, 28-30]. It could be that in WT mice one or more of these mediators induces 
endothelial heparanase expression, whereas these mediators are not operative in 
podETRKO mice or are counteracting each other’s activities. Another possibility could be that 
macrophage influx is altered in podETRKO. Macrophages provide cathepsin L, a protease, 
that is required to activate endothelial-derived inactive proheparanase. Finally, podocyte-
derived cathepsin L may be reduced in podETRKO mice, thereby limiting activation of 
endothelial-derived proheparanase. The exact molecular mechanisms underlying the 
observed differences in endothelial glycocalyx thickness in diabetic WT mice and podETRKO 
remain to be elucidated.   
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The glomerular endothelial glycocalyx plays an important role in vascular permeability, 
attenuation of blood cell-vessel wall interactions, mechanotransduction, signaling and 
vascular protection [31]. The podocyte glycocalyx is essential for maintaining foot process 
and slit diaphragm structure, and is also suggested to play a role keeping a certain distance 
between podocytes and parietal epithelial cells, thereby helping to maintain glomerular 
structure and function [32]. Previous studies have reported variations in endothelial 
glycocalyx thickness, which may be explained by differences in perfusion-fixed staining 
versus immersion-fixed staining. Very few studies showed podocyte glycocalyx staining and, 
to our knowledge, we are the first to report the simultaneous quantitation of podocyte 
glycocalyx thickness and glomerular endothelial glycocalyx thickness.     
Previous studies showed that a reduced endothelial glycocalyx thickness is associated with 
the development of proteinuria [14-19]. Munich-Wistar-Fromter (MFW) rats showed a 
reduced endothelial glycocalyx thickness and spontaneously developed albuminuria [14]. 
Moreover, diabetic Zucker fatty rats showed a reduced endothelial glycocalyx thickness and 
a significant proteinuria, which was at least in part mediated by an increased glomerular 
heparanase expression [16]. Here, we showed that endothelin-1 signaling in the podocyte 
increased heparanase expression, thereby most likely reducing endothelial glycocalyx 
thickness and inducing proteinuria. 
In conclusion, endothelin-1 induces heparanase in the podocyte, which may lead to 
disruption of the glycocalyx and proteinuria in experimental DN, thereby providing a possible 
mechanistic basis for the renoprotective effects of ERAs. In addition, targeting of heparanase 
in DN may serve as an alternative therapeutic option for treatment of DN.  
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Abstract 
 
Endothelial nitric oxide synthase (eNOS) deficiency exacerbates proteinuria and renal injury 
in several glomerular diseases, but the underlying mechanism is not fully understood. We 
recently showed that heparanase is essential for the development of experimental diabetic 
nephropathy and glomerulonephritis, and hypothesize that heparanase expression is 
regulated by eNOS. Here, we demonstrate that induction of adriamycin nephropathy (AN) in 
C57BL/6 eNOS-deficient mice leads to an increased glomerular heparanase expression 
accompanied with overt proteinuria, which was not observed in the AN-resistant wild type 
counterpart. In vitro, the eNOS inhibitor asymmetric dimethylarginine (ADMA) induced 
heparanase expression in cultured mouse glomerular endothelial cells. Moreover, ADMA 
enhanced transendothelial albumin passage in a heparanase-dependent manner. We 
conclude that eNOS prevents heparanase induction and the development of proteinuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Heparanase regulation by eNOS 
 
 
 
  127 
 
 
Introduction 
 
Proteinuria is a key feature of many glomerular diseases and an independent risk factor for 
the progression to renal failure. Proteinuria is caused by damage to the glomerular filtration 
barrier, which is composed of glomerular endothelial cells covered by a glycocalyx, the 
glomerular basement membrane and podocytes. Several studies showed that a reduced 
glomerular endothelial glycocalyx thickness is associated with the development of proteinuria 
[1-3]. We recently showed that endothelial dysfunction and damage precedes podocyte 
damage in adriamycin-induced nephropathy (AN) [4], indicating that a healthy glomerular 
endothelium is important to prevent the development of proteinuria and renal damage.        
Previous studies showed that a decreased nitric oxide (NO) production and availability 
contributes to endothelial dysfunction [5]. NO is produced by endothelial cells through 
endothelial NO synthase (eNOS). Multiple factors have been suggested to be involved in the 
regulation of eNOS, including reactive oxygen species (ROS), angiotensin II, asymmetric 
dimethylarginine (ADMA), protein kinase C (PKC), advanced glycation end products (AGEs), 
vitamin D and tumor necrosis factor (TNF)-α [6, 7]. eNOS deficiency exacerbates renal injury 
in accelerated anti-glomerular basement membrane (GBM) glomerulonephritis [8], 
experimental focal segmental glomerulosclerosis (FSGS) [9], and diabetic nephropathy (DN) 
[10]. In addition, eNOS gene delivery prevented the development of proteinuria in a rat model 
of FSGS [11]. Recently, we showed that induction of AN in C57BL/6 mice, an AN resistant 
strain, with eNOS deficiency induced overt proteinuria, glomerulosclerosis, tubulointerstitial 
fibrosis and inflammation [4]. The mechanism how eNOS deficiency exacerbates proteinuria 
and renal damage remains unknown.   
We previously showed that heparanase, a heparan sulfate (HS) specific endoglycosidase, is 
essential for the development of proteinuria and renal damage in experimental DN and 
glomerulonephritis [12, 13]. In both aforementioned models heparanase-deficient mice 
displayed a preserved glomerular HS expression compared to WT mice. Notably, loss of 
glomerular HS expression is associated with the development of proteinuria in most human 
and experimental glomerular disease [14]. Heparanase is positively regulated by ROS, 
angiotensin II, aldosterone, AGEs, PKC, high glucose and TNF-α [13, 15-18], and negatively 
regulated by vitamin D [19]. Interestingly, the aforementioned factors that regulate 
heparanase are also involved in regulation of eNOS and endothelial function. Importantly, 
glomerular endothelial glycocalyx thickness is reduced in diabetic eNOS-deficient mice 
compared with diabetic wild type (WT) mice [20]. In addition, heparanase has been shown to 
impair glycocalyx thickness [1, 3]. Therefore, we hypothesize that heparanase expression is 
controlled by eNOS.  
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Materials and methods 
 
Animals 
WT C57BL/6J mice (Monash Animal Services, Monash University, Australia) and eNOS-
deficient mice in a C57BL/6J background (Jackson Laboratories, Ben Harbor, ME, USA) 
were housed and bred at Monash Animal Services. Animal handling and experiments were  
approved by the Monash University Animal Ethics Committee and according to the 
“Australian Code of Practice for the Care and Use of Animals for Scientific Purposes”. Balb/c 
mice (Harlan, Horst, The Netherlands) were housed at the “Vrije Universiteit Brussel” and 
animal experiments were approved by the Animal Care and Use Committee of the “Vrije 
Universiteit Brussel”. 
 
Adriamycin-induced nephropathy 
AN was induced in 8-week-old C57BL/6J WT and eNOS-deficient mice by an intravenous 
injection of 10.5 mg/kg body weight of adriamycin (Sigma-Aldrich, St. Louis, MO, USA), as 
described previously [4]. Control mice received an equivalent volume of normal saline (NS). 
Mice were sacrificed 14 days after induction of AN. Five mice were used per group.  
In Balb/c mice (8 weeks old), AN was induced by an intravenous injection with 10 mg/kg 
adriamycin (Pharmacia, Brussels, Belgium) as described  [21]. Control mice were injected 
with NS. Mice, five-six per time point, were sacrificed 10 and 23 days after induction of AN.  
 
Immunofluorescence staining 
Glomerular heparanase and HS expression was determined by indirect immunofluorescence 
staining on cryosections (2 µm) as described [22]. Primary antibodies included heparanase 
(HPA1, ProsPecTany, Rehovot, Israel) and a mouse monoclonal anti-HS antibody, JM403 
[23]. Secondary antibodies included goat anti-rabbit IgG Alexa 488 and goat anti-mouse IgM 
Alexa 488 (Invitrogen Life Technologies, Breda, The Netherlands). Glomerular heparanase 
and HS staining intensities were scored in 50 glomeruli per section on a scale between 0 and 
10 (0= no staining, 5= 50% staining, 10= 100% staining). Scoring was performed by two 
independent investigators on blinded sections using a Leica CTR6000 microscope.   
 
Cell culture and transendothelial albumin passage 
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) were cultured as 
described previously [24]. Heparanase was stably silenced in mGEnC-1 by transfection of a 
heparanase shRNA construct (Qiagen, Venlo, The Netherlands) with Lipofectamine 2000 
into undifferentiated mGEnC-1 and subsequent selection with G418 (Sigma-Aldrich). 
Differentiated mGEnC-1 were treated with the eNOS inhibitor ADMA (10 µg/ml; Millipore, 
Amsterdam, The Netherlands) for 18 hours. For transendothelial albumin passage, 
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differentiated mGEnC-1 seeded on polyester membranes in tissue culture inserts (0.4 m pore 
size; Corning Incorporated, NY, USA) were treated with the eNOS inhibitor ADMA as 
outlined. Transendothelial albumin passage was determined as described previously [19].  
 
RNA isolation, cDNA generation and real-time PCR 
Total RNA was extracted from mouse renal cortex and mGEnC-1 using the RNeasy mini kit 
(Qiagen, Venlo, The Netherlands). 1 µg RNA was reverse-transcribed into cDNA using the 
RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). 
Heparanase mRNA expression levels were measured by real-time PCR using gene-specific 
primers (Isogen Life Science, de Meern, The Netherlands) and the Fast-start SYBR Green 
SuperMix (Roche Diagnostics, Mannheim, Germany), and analyzed with the CFX real-time 
PCR system (Bio-Rad Laboratories, Hercules, CA, USA). Used primers:  Heparanase, 
forward 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’, reverse 5’-
GATCCAGAATTTGACCGTTCAGTT -3’, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), forward 5’-AGAAACCTGCCAAGTATGATGAC-3’, reverse 5’-
TCATTGTCATACCAGGAAATGAG-3’. Heparanase gene expression levels were quantified 
with the delta-delta CT method using GAPDH as the housekeeping gene. 
 
Statistical analysis 
Values are expressed as mean ± SEM. Significance was evaluated by a one-way ANOVA 
and post hoc analysis with Tukey’s multiple comparison test. A Student’s t-test was used for 
comparison of expression between two different groups. A two-way repeated measures 
ANOVA with Bonferroni post-test was used to determine significant differences in 
transendothelial albumin passage. Statistical analysis was performed using GraphPad Prism 
5.03 (GraphPad Software, Inc., San Diego, CA, USA). A P-value of ≤ 0.05 was considered 
statistically significant.   
 
 
Results  
 
eNOS prevents adriamycin-induced heparanase expression and proteinuria 
To study the in vivo effects of eNOS deficiency on heparanase and HS expression, AN was 
induced in C57BL/6 WT, normally an AN resistant strain, and C57BL/6 eNOS-deficient mice. 
Fourteen days after the induction of AN, as expected, WT mice failed to develop proteinuria 
and had a normal renal function [4]. In contrast, eNOS-deficient mice developed overt 
proteinuria and had an impaired renal function [4]. Cortical heparanase mRNA expression 
(Figure 1A) and glomerular heparanase protein expression (Figure 1B,D) were normal in WT 
AN mice, whereas both heparanase mRNA expression and heparanase protein expression 
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were significantly increased in the eNOS-deficient AN mice. In addition, glomerular HS 
expression was normal in the WT mice, but significantly reduced in the eNOS-deficient mice 
after induction of AN (Figure 1C,E). To evaluate whether AN caused similar effects on 
heparanase and HS expression in AN-sensitive mice as observed in the eNOS-deficient 
mice, AN was induced in the AN-sensitive Balb/c mice. We previously showed that eNOS 
expression was significantly reduced 24 hours after induction of AN in Balb/c mice [4]. By 
induction of AN, Balb/c mice develop proteinuria and renal damage after 10 and 23 days, as 
described before [21]. Cortical heparanase mRNA expression (Figure 2A) and glomerular 
heparanase protein expression (Figure 2B,D) were significantly increased 10 and 23 days 
after induction of AN, whereas glomerular HS expression was significantly reduced (Figure 
2C,E). Together, these data indicate that eNOS prevents adriamycin-induced heparanase 
expression.   
 
 
Figure 1: eNOS prevents adriamycin-induced heparanase expression and proteinuria. 
Adriamycin-nephropathy (AN) was induced in C57BL/6 WT mice, an AN resistant strain, and C57BL/6 
eNOS-deficient mice. Mice were sacrificed 14 days after the induction of AN. By induction of AN in WT 
mice, (A) cortical heparanase mRNA expression, (B,D) glomerular heparanase protein expression and 
(C,E) glomerular HS expression were comparable to control. Cortical heparanase mRNA expression 
and glomerular heparanase protein expression were significantly increased in eNOS-deficient mice 
after induction of AN, whereas glomerular HS expression was reduced. (D) Representative pictures 
showing glomerular heparanase protein expression and (E) glomerular HS expression as determined 
by immunofluorescence staining (magnification x400). 5 mice per group were used for analysis. 
*P<0.05 and ***P<0.001 versus CTRL. WT, wild type; eNOS KO, endothelial nitric oxide synthase-
deficient; HS, heparan sulfate; CTRL, control; AU, arbitrary units.   
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The eNOS inhibitor ADMA increases transendothelial albumin passage in a 
heparanase-dependent manner 
To extend the in vivo findings of eNOS deficiency on glomerular heparanase expression in 
AN, we evaluated whether eNOS regulates heparanase expression in glomerular endothelial 
cells in vitro. Treatment of mouse glomerular endothelial cells (mGEnC-1) with the eNOS 
inhibitor ADMA resulted in a 1.5-fold increased heparanase mRNA expression (Figure 3A). 
At the functional level, treatment of a monolayer of mGEnC-1 with AMDA increased 
transendothelial albumin passage 1.4-fold (Figure 3B). To show that the ADMA-induced 
increase in transendothelial albumin passage could be possibly mediated by heparanase, 
heparanase expression in mGEnC-1 was silenced with shRNA leading to ~60% reduced 
heparanase mRNA expression. Upon treatment with ADMA, transendothelial albumin 
passage was significantly lower in heparanase-silenced endothelial cells compared with 
endothelial cells transfected with a scrambled shRNA (Figure 3C). Taken together, these 
data indicate that eNOS inhibition increased heparanase expression and thereby 
transendothelial albumin passage.     
 
 
Figure 2: Heparanase expression was increased and HS expression reduced by induction of 
adriamycin nephropathy (AN) in AN-sensitive Balb/c mice. AN was induced in Balb/c, which are 
sensitive for AN-induced renal damage. Mice were sacrificed 10 and 23 days after the induction of AN. 
By induction of AN, (A) cortical heparanase mRNA expression and (B,D) glomerular heparanase 
protein expression  were significantly increased after 10 and 23 days. (C,E) glomerular HS expression 
was significantly reduced 10 and 23 days after induction of AN. (D) Representative pictures showing 
glomerular heparanase protein expression and (E) glomerular HS expression, as determined by 
immunofluorescence staining (magnification x400). 5-6 mice were used for analysis. *P<0.05, 
**P<0.01 and ***P<0.001 versus CTRL. CTRL, control; AU, arbitrary units.   
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Figure 3: Inhibition of eNOS induces heparanase expression and increases transendothelial 
albumin passage in a heparanase-dependent manner in cultured mouse glomerular endothelial 
cells. (A) Treatment of mouse glomerular endothelial cells (mGEnC-1) with the eNOS inhibitor ADMA 
for 18 hours resulted in an increased heparanase mRNA expression. (B) Cumulative passage of 
FITC-labeled albumin across the mGEnC-1 monolayer (TEER: 28 Ω cm2) was increased 1.4-fold 
compared to control after treatment with ADMA for 18 hours. (C) Treatment of heparanase-silenced 
mGEnC-1 with ADMA for 18 hours led to lower transendothelial albumin passage compared with 
scrambled mGEnC-1 treated with ADMA. *P<0.05, **P<0.01 and ***P<0.001 versus control. ##P<0.01 
versus ADMA scrambled. eNOS; endothelial nitric oxide synthase, ADMA;  asymmetric 
dimethylarginine.     
 
 
Discussion 
 
Our data suggest that eNOS prevents the induction of glomerular heparanase expression 
and the development of proteinuria in AN. In addition, inhibition of eNOS activity in cultured 
mouse glomerular endothelial cells induces heparanase expression and increases 
transendothelial albumin passage in a heparanase-dependent manner.   
Our study is the first to show that heparanase expression is regulated by eNOS. As outlined, 
eNOS and heparanase share regulating factors such as ROS, angiotensin II, PKC, AGEs, 
vitamin D and TNF-α [6, 7, 13, 15-17, 19]. However, not all of these aforementioned  
regulating factors are activators of eNOS and heparanase, nor solely operative in the 
endothelium, whereas none of these factors is specific for the glomerular endothelium. 
Interestingly, vitamin D is a positive regulator of eNOS, but a negative regulator of 
heparanase [7, 19]. It has also been described that HS present in the endothelial glycocalyx 
is important for mechanosensing and eNOS-mediated NO production [25], which may 
suggest that a reduced glycocalyx thickness further hampers NO production, thereby further 
increasing heparanase expression. This self amplifying loop will ultimately lead to loss of 
endothelial glycocalyx and loss of NO production, and therefore endothelial dysfunction. We 
provided clear evidence for the interplay between eNOS and heparanase in AN, which may 
be operative in other glomerular diseases as well, since in the majority of glomerular 
diseases heparanase expression is increased, whereas glomerular HS expression is 
  Heparanase regulation by eNOS 
 
 
 
  133 
 
 
decreased [14]. Nevertheless, additional research is required to elucidate the complex 
regulation of both eNOS and heparanase, and their interplay, in glomerular diseases. 
The regulation of heparanase expression by eNOS seems important for glomerular diseases, 
but may have important implications for other vascular beds outside the kidney as well. The 
vascular involvement in clinical manifestations associated with diabetes, sepsis, ischemia, 
artherosclerosis, and angiogenesis in cancer [26] may be dictated in part by the interplay 
between eNOS and heparanase. Future research should address the beneficial effects of a 
combined targeting of both eNOS and heparanase in experimental models of the  
aforementioned clinical manifestations and glomerular diseases.   
Taken together, we postulate that a reduced glomerular expression/activity of eNOS 
increases heparanase expression, most likely due to a low NO level. This increased 
heparanase expression may explain a reduced thickness of the glomerular endothelial 
glycocalyx in (experimental) glomerular diseases, like diabetic nephropathy and adriamycin 
nephropathy [2, 3].  
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Abstract 
 
The glomerular filtration barrier consists of podocytes, the glomerular basement membrane, 
and endothelial cells covered with a glycocalyx. Heparan sulfate (HS) expression in the 
glomerular filtration barrier is reduced in patients with proteinuria, which is associated with an 
increased expression of the HS-degrading enzyme heparanase. Previously, we showed that 
heparanase is essential for the development of proteinuria in experimental diabetic 
nephropathy. Vitamin D supplementation reduces podocyte loss and proteinuria in vitro and 
in vivo. Therefore, we hypothesize that vitamin D reduces proteinuria by reduction of 
glomerular heparanase expression. Adriamycin-exposed rats developed proteinuria and 
showed increased heparanase expression, which was reduced by 1,25-dihydroxyvitamin D3 
(1,25-D3) treatment. In vitro, adriamycin treatment increased heparanase mRNA expression 
in the podocyte, which could be corrected by 1,25-D3 treatment. In addition, 1,25-D3 
treatment reduced transendothelial albumin passage after adriamycin stimulation. In line with 
these results, we showed direct binding of the vitamin D receptor to the heparanase 
promoter, which dose-dependently reduced heparanase promoter activity. Finally, 1,25-D3-
deficient 25-hydroxy-1α-hydroxylase knockout mice developed proteinuria, and showed 
increased heparanase expression, which was normalized by 1,25-D3 treatment. Our data 
suggest that the protective effect of vitamin D on the development of proteinuria is mediated 
by inhibiting heparanase expression in the podocyte.  
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Introduction 
 
The glomerular filtration barrier (GFB), composed of glomerular endothelial cells covered 
with a glycocalyx, the glomerular basement membrane (GBM) and podocytes, is responsible 
for the charge- and size-selective filtration of the blood. The charge-selective filtration of the 
GFB has been attributed to the presence of negatively charged molecules in the GFB, of 
which heparan sulfate (HS) is the most abundant. Heparan sulfate proteoglycans (HSPGs) 
consist of a core protein to which one or more HS side chains are covalently attached. Loss 
of HS expression in the GFB is associated with the development of proteinuria [1, 2]. During 
the last decade, the primary role of HS in the glomerular basement membrane in charge-
selective filtration was refuted [2, 3]. However, in patients proteinuria is associated with a 
reduction in glomerular HS expression, which suggest that the presence of HS in the 
endothelial glycocalyx is key in dictating the charge-selective properties of the GFB [2].      
The decreased glomerular HS expression in patients with proteinuria could be attributed to 
an increased glomerular expression of the HS-degrading enzyme heparanase, the only 
known mammalian enzyme that can cleave HS [4]. The expression of heparanase is 
increased in many experimental and human glomerular diseases [2-6]. Inhibition of 
heparanase in experimental passive Heymann nephritis by a polyclonal anti-heparanase 
antibody or the heparanase inhibitor PI-88 reduced proteinuria, suggesting that heparanase 
is important for the development of proteinuria [7, 8]. Recently, we showed that heparanase 
is essential for the development of proteinuria in experimental diabetic nephropathy [9]. In 
response to streptozotocin-induced type 1 diabetes, heparanase knockout mice, unlike their 
wildtype littermates, failed to develop proteinuria and diabetic nephropathy, and diabetic 
heparanase knockout mice had had a normal renal function. In addition, treatment with the 
heparanase inhibitor SST0001 reduced proteinuria and renal function loss [9].  
Proteinuria is an independent risk factor for the progression of renal failure. Current 
treatment of patients with proteinuria is blockade of the renin-angiotensin-aldosterone system 
(RAAS) by angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers 
(ARBs). This treatment only partly reduces proteinuria, and therefore there is a need for 
additional anti-proteinuric agents. Recent findings suggest anti-proteinuric effects of vitamin 
D analogues in experimental and human glomerular diseases. Vitamin D is a steroid 
hormone that is involved in the regulation of calcium and phosphate homeostasis. Vitamin D3 
(cholecalciferol) is taken up from the diet and produced in the skin from 7-dehydrocholesterol 
by exposure to ultraviolet radiation. Subsequently, vitamin D3 is converted to 25-
hydroxyvitamin D3 in the liver and to 1,25-dihydroxyvitamin D3 (1,25-D3), the active form of 
vitamin D3, in the kidney. Vitamin D binds to the vitamin D receptor (VDR). The VDR then 
interacts with the retinoid X receptor to form a heterodimer that binds to vitamin D responsive 
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elements in the promoter regions of vitamin D-responsive genes [10]. As a result of renal 
damage, many patients with chronic kidney disease (CKD) develop a progressive 1,25-D3 
deficiency [11]. Several clinical studies showed that proteinuria in CKD patients, in addition to 
ACE inhibitors or ARBs, could be further reduced by treatment with 1,25-D3 [12-18]. In 
experimental animal models for focal segmental glomerulosclerosis (FSGS) such as 
adriamycin nephropathy and 5/6 nephrectomy, proteinuria and podocyte loss were 
decreased by treatment with 1,25-D3 [19-21].  
Since heparanase is a key mediator in the development of proteinuria and vitamin D seems 
beneficial in reducing proteinuria and kidney injury, we hypothesize that vitamin D regulates 
glomerular heparanase expression. In the current study, we evaluated the effects of vitamin 
D on the glomerular heparanase and HS expression in animal models of FSGS or 1,25-D3 
deficiency. In addition, we evaluated whether vitamin D was able to directly regulate 
heparanase expression in cultured mouse glomerular endothelial cells and mouse 
podocytes.  
 
 
Materials and methods 
 
Animals  
Animals were housed in a temperature-controlled room with a 12-hour light/dark cycle with 
ad libitum access to food and water. All animal experiments were approved by the Animal 
Ethical Committee of the Radboud University Nijmegen. 
Rats. Adriamycin nephropathy (AN) was induced in 8-week-old Wistar rats (Charles River 
Laboratories, Wilmington, MA) by an intravenous injection of 5 mg/kg body weight of 
adriamycin (Sigma-Aldrich, St. Louis, MO), as described previously [21]. Rats were treated 
with daily i.p. injections of 2.5 µg/kg bodyweight of 1,25-D3 (Sigma-Aldrich Chemie, 
Zwijndrecht, The Netherlands) or vehicle. After 6 weeks, rats were placed in metabolic cages 
for 24 hours to collect urine, and sacrificed to collect kidneys and blood.   
Mice. 1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout (KO) mice were generated and 
genotyped as described [22]. 5-week-old KO mice and their wildtype (WT) littermates 
received daily i.p. injections with 500 pg/g bodyweight of 1,25-D3 (Sigma-Aldrich) or vehicle. 
After 6 weeks, mice were housed in metabolic cages for 24 hours to collect urine. 
Subsequently, mice were sacrificed and kidneys and blood were collected.     
 
Immunofluorescence staining 
Glomerular heparanase and HS expression was determined by immunofluorescence staining 
as described [23]. Primary antibodies included anti-heparanase (HPA1, ProsPecTany, 
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Rehovot, Israel) and the VSV-tagged single chain variable fragment (scFv) antibody HS4C3 
(N-, 2-O, 3-O and 6-O sulfation) [24]. Bound antibodies were detected with goat anti-rabbit 
IgG Alexa 488 (Invitrogen Life Technologies, Breda, The Netherlands) for heparanase and 
anti-VSV-Cy3 (Sigma-Aldrich) for HS4C3. Twenty five glomeruli per section were scored for 
staining intensities of heparanase and HS on a scale between 0 and 10 (0= no staining, 5= 
50% staining, 10= 100% staining), which was performed by two independent investigators on 
blinded sections.  
 
Heparanase activity assay 
Heparanase activity in kidney cortex was determined using a commercially available assay 
(AMS Biotechnology, Abingdon, UK) according to the manufacturer’s instruction. 
 
Cell culture  
Conditionally immortalized mouse glomerular endothelial cells (mGEnC-1) and mouse 
podocytes (MPC-5) were cultured as described previously [25, 26]. Silencing of heparanase 
in MPC-5 was achieved after transfecting a heparanase shRNA construct (Qiagen, Venlo, 
The Netherlands) and subsequent selection with G418 (Sigma-Aldrich). Where indicated, 
differentiated mGEnC-1 and MPC5 were stimulated with vehicle or 0.25 µg/ml adriamycin 
(Sigma-Aldrich) and treated with different concentrations of 1,25-D3 (10 nmol/L, 100 nmol/L, 
and 1 µmol/L; Sigma-Aldrich).   
 
Transendothelial albumin passage 
Differentiated mGEnC-1 seeded on polyester membranes (0.4 µm pore size) in tissue culture 
inserts (Corning Incorporated, NY, USA) were treated with adriamycin and/or 100 nmol/L 
1,25-D3 as outlined. In addition, mGEnC-1 were treated with a 1:1 mix of medium 
supplemented with adriamycin and/or 100 nmol/L 1,25-D3 and conditioned culture 
supernatant of podocytes also treated with adriamycin and/or 100 nmol/L 1,25-D3. After 16 
hours, medium in the insert was replaced by serum free medium (SFM) containing 0.5 mg/ml 
FITC-labeled BSA (Sigma) and medium in the well was replaced by SFM. After 1, 2 and 3 
hours, aliquots were removed from the well and replaced with SFM. Fluorescence of the 
aliquots was measured on a fluorometer with excitation at 495 nm and emission at 520 and 
the amount of albumin passing the endothelial cell monolayer was determined by a set of 
standard dilutions.       
 
RNA isolation and real-time PCR 
Total RNA was extracted from kidney cortex, podocytes and mGEnC-1 using the RNeasy 
mini kit (Qiagen, Venlo, The Netherlands). RNA (1 µg) was reverse transcribed into cDNA 
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using the RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific, Waltham, MA, USA). 
The mRNA levels of heparanase were quantified on the CFX real-time PCR system (Bio-Rad 
Laboratories, Hercules, CA, USA) using SYBR Green SuperMix (Roche Diagnostics, 
Mannheim, Germany) with gene-specific primers (Isogen Life Science, De Meern, The 
Netherlands). Heparanase (HPSE): forward 5’-GAGCGGAGCAAACTCCGAGTGTATC-3’, 
reverse 5’-GATCCAGAATTTGACCGTTCAGTT-3’, and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH): forward 5’-AGAAACCTGCCAAGTATGATGAC-3’, reverse 5’-
TCATTGTCATACCAGGAAATGAG-3’. Gene expression levels of heparanase were 
quantified by the delta-delta CT method using GAPDH as the housekeeping gene.  
 
Determination of HS expression on mGEnC-1 by ELISA 
mGEnC-1 were differentiated for 7 days in 96-wells plates and stimulated with vehicle or 
adriamycin in the absence or presence of 1,25-D3 for 16 hours. Cells were washed and 
incubated with the VSV-tagged scFv antibody HS4C3 [24]. Cells were washed and incubated 
with anti-VSV-G-peroxidase (Sigma-Aldrich). Finally, cells were washed and incubated with 
tetramethylbenzidine (TMB) substrate (Biolegend, London, UK). Reaction was stopped with 2 
M H2SO4 and absorption was measured at 450 nm.   
 
Transfection and luciferase activity assay 
A pGL3 luciferase reporter vector containing the 3.5 kb promoter region of the human HPR1 
(heparanase) gene was generated previously [27]. Opossum Kidney (OK) cells were cultured 
in 12-well plates as described previously [28]. Cells were treated with different concentrations 
of 1,25-D3 (100 nmol/L and 1 µmol/L; Sigma-Aldrich) and transfected using the following 
mixture: either pGL3-HPR1 promoter construct or pGL3-basic empty vector with 50 ng of 
pRL-CMV (Promoga Corp., Fitchburg, WI) as control for transfection efficiency, and 1,25 µL 
lipofectamin in 120 µL Opti-MEM medium (Invitrogen, Carlsbad, CA). Twenty-four hours after 
transfection cells were harvested and luciferase activity was determined using the Dual-
Luciferase reporter assay (Promega) following manufacturer’s instructions.  
 
Chromatin Immunoprecipitation (ChIP) 
OK cells were transfected with the HPR1 promoter construct or the empty vector as outlined 
above and treated with 1 µmol/L 1,25-D3. Four hours after transfection, the ChIP assay was 
performed according to manufacturer’s protocol (Merck Millipore, Billerica, MA). Briefly, cells 
were treated with formaldehyde to crosslink proteins to DNA, lysed and sonicated twice on 
melting ice. Samples were incubated with protein A magnetic beads and 5.0 µg of the rabbit 
polyclonal anti-VDR antibody (ab3508; Abcam Inc., Cambridge, MA) or the normal rabbit IgG 
antibody as a negative control. Subsequently, protein-DNA cross-links were reversed and 
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DNA was isolated. Real-time PCR analysis was performed using specific primers for the 
HPR1 promoter region (forward 5’-TGTTCCTCCTTCCTATGTATCC-3’, reverse 5’-
TTGGCTGAGATCTTGCTCCT-3’). Amplified DNA samples were resolved by 2% agarose 
gel electrophoresis and visualized by ethidium bromide. 
 
Statistical analysis 
Values are expressed as mean ± SEM. Significance was evaluated by an one-way ANOVA 
and post hoc analysis with Tukey’s multiple comparison test. Comparison of expression 
between two different groups was evaluated using the Student’s t-test. A 2-way repeated 
measures ANOVA with Bonferroni post-test was used to evaluate significance for the 
transendothelial albumin passage experiments. Statistical analysis was performed using 
GraphPad Prism 5.03 (GraphPad Software, Inc., San Diego, CA, USA). A P-value of ≤ 0.05 
was considered statistically significant.   
 
 
Results 
 
Adriamycin-induced heparanase expression is attenuated by 1,25-D3 in podocytes 
To study the in vivo effects of 1,25-D3 treatment on heparanase and HS expression, AN (an 
animal model for FSGS) was induced in rats, which were subsequently treated with either 
1,25-D3 or vehicle for 6 weeks. As shown previously, these AN rats develop proteinuria, 
which could be ameliorated by treatment with 1,25-D3 [21]. Induction of AN resulted in an 
increased cortical heparanase mRNA expression (Figure 1A), glomerular heparanase protein 
expression (Figure 1B,E) and cortical heparanase activity (Figure 1C). Heparanase 
expression and activity were reduced by treatment with 1,25-D3, although this was not 
significant for heparanase protein expression (Figure 1A-C,E). Heparanase mRNA 
expression was also significantly reduced by 1,25-D3 treatment in control rats (Figure 1A), 
suggesting that endogenous heparanase expression is regulated by 1,25-D3. In addition, 
glomerular HS expression was reduced in AN rats, but significantly increased by treatment 
with 1,25-D3 (Figure 1D,F).   
To extend the in vivo findings of 1,25-D3 on glomerular heparanase expression in AN, we 
evaluated the effects of adriamycin and 1,25-D3 on heparanase expression in cultured 
mouse podocytes and mGEnC-1. Stimulation of mouse podocytes with adriamycin resulted 
in an increased heparanase mRNA expression (Figure 2). Treatment with increasing 
concentrations of 1,25-D3 dose-dependently reduced heparanase expression in both 
adriamycin-injured and uninjured podocytes (Figure 2). Stimulation of mGEnC-1 with 
adriamycin initially increased heparanase mRNA expression, but reduced heparanase 
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Figure 1: 1,25-D3 treatment reduces heparanase expression and increases HS expression in 
rats with AN. By induction of AN in Wistar rats, (A) cortical heparanase mRNA expression, (B,E) 
glomerular heparanase protein expression, and (C) cortical heparanase activity were significantly 
increased, whereas (D,F) glomerular HS expression was significantly reduced. Daily treatment with 
2.5 µg/kg bodyweight of 1,25-D3 for 6 weeks reduced heparanase mRNA expression and activity and 
increased glomerular HS expression. In addition, treatment with 1,25-D3 alone also reduced 
heparanase mRNA expression. (E) Representative images showing glomerular heparanase protein 
expression and (F) glomerular HS expression as determined by immunofluorescence staining 
(magnification x 400). 8 rats per group were used for analysis. *P<0.05 and **P<0.01 versus VEH 
CTRL, #P<0.05 versus VEH AN. VEH, vehicle; CTRL, control; AN, adriamycin nephropathy.      
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mRNA expression after 16 hours (Figure 3A-B). Importantly, adriamycin decreased HS 
expression on mGEnC-1 (Figure 3C). 1,25-D3 treatment did not affect heparanase mRNA 
expression and HS expression on mGEnC-1 (Figure 3B-C). 
 
 
Figure 2: Adriamycin-induced heparanase mRNA expression is attenuated by 1,25-D3 in 
podocytes. Cultured mouse podocytes were stimulated with vehicle (VEH) or adriamycin (ADRIA) in 
the absence or presence of different concentrations of 1,25-D3 for 24 hours. By stimulation with 
adriamycin, heparanase mRNA expression was increased. Heparanase mRNA expression was dose-
dependently reduced by treatment with 1,25-D3 in both injured and uninjured podocytes. *P<0.05, 
**P<0.01 and ***P<0.001 versus VEH CTRL, #P<0.05 versus VEH ADRIA. CTRL; control.  
 
1,25-D3 directly regulates heparanase promoter activity 
Our in vivo and in vitro data show that heparanase mRNA expression is reduced by 
treatment with 1,25-D3. To determine whether 1,25-D3 directly regulates heparanase 
transcription, a luciferase reporter assay was performed using the luciferase HPR1-3.5 
promoter construct [27]. OK cells were transfected with the HPR1-3.5 construct or the empty 
vector, i.e. without heparanase promoter, and treated with vehicle, 100 nM 1,25-D3 or 1 µM 
1,25-D3 for 24 hours. Treatment with 1,25-D3 resulted in a decrease in heparanase promoter 
activity, whereas the luciferase activity in cells with empty vector was very low and not 
affected by treatment (Figure 4A).  
To evaluate whether this effect of 1,25-D3 on heparanase promoter activity is mediated by 
direct binding of the VDR to the heparanase promoter, a ChIP assay was performed. By real-
time PCR analysis we showed an 8-fold enrichment of the heparanase promoter when 
precipitated with the anti-VDR antibody compared to the rabbit IgG isotype control (Figure 
4B).  
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Figure 3: 1,25-D3 treatment did not affect heparanase mRNA expression and HS expression on 
mouse glomerular endothelial cells. (A) Cultured mouse glomerular endothelial cells (mGEnC-1) 
were stimulated with vehicle (VEH) or adriamycin (ADRIA) for several time points. Stimulation of 
mGEnC-1 with adriamycin increased heparanase mRNA expression after 4-6 hours, but reduced 
heparanase mRNA expression after 16 hours. (B) mGEnC-1 were stimulated with VEH or ADRIA in 
the absence or presence of different concentrations of 1,25-D3 for 16 hours. By stimulation with 
adriamycin, heparanase mRNA expression was reduced. Heparanase mRNA expression was not 
affected by treatment with 1,25-D3. (C) mGEnC-1 were stimulated with VEH or ADRIA in the absence 
or presence of 1 µM 1,25-D3 for 16 hours. By stimulation with adriamycin, HS expression was 
reduced. HS expression was not affected by treatment with 1,25-D3. *P<0.05 and ***P<0.001 versus 
VEH CTRL. CTRL; control.  
 
1,25-D3 treatment reduces transendothelial albumin passage in the presence of 
podocyte-conditioned culture medium 
To study the effects of 1,25-D3 treatment on transendothelial albumin passage, mGEnC-1 
were stimulated with vehicle or adriamycin in the presence or absence of 100 nM 1,25-D3. 
Transendothelial albumin passage was increased by stimulation with adriamycin, but 1,25-D3 
treatment did not have an effect on transendothelial albumin passage (Figure 5A). Since 
1,25-D3 treatment also did not have an effect on heparanase and HS expression in mGEnC-
1, but reduced heparanase mRNA expression in mouse podocytes, we added culture 
supernatant of mouse podocytes treated with either vehicle or adriamycin, in the presence or 
absence of 1,25-D3, to the mGEnC-1 monolayer. In the presence of podocyte culture 
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Figure 4: 1,25-D3 directly regulates heparanase promoter activity. (A) Heparanase promoter 
activity determined by a luciferase reporter assay revealed a 40% and 55% decrease in heparanase 
promoter activity when OK cells transiently transfected with the luciferase HPR1-3.5 promoter 
construct were treated with 100 nM or 1 µM 1,25-D3, respectively. The luciferase activity of cells with 
the empty vector, without promoter, was unaltered. (B) A ChIP assay was performed to determine 
whether the VDR binds directly to the heparanase promoter. Real-time PCR analysis showed an 8-fold 
enrichment of the heparanase promoter using the anti-VDR antibody (anti-VDR lane) compared with 
the isotype control (IgG lane). As a control, 2% of the chromatin used for the immunoprecipitation is 
shown (input lane). *P<0.05 and **P<0.01 versus VEH (vehicle). VDR: Vitamin D receptor. 
 
supernatant, transendothelial albumin passage was increased after adriamycin stimulation, 
and normalized by 1,25-D3 treatment of cultured podocytes (Figure 5B). To show that this 
effect was really mediated by heparanase, heparanase expression in MPC5 podocytes was 
completely silenced with shRNA, since no heparanase mRNA expression could be measured 
(HPSE KD). Stimulation of mGEnC-1 with culture supernatant of adriamycin-stimulated 
podocytes containing a scrambled shRNA increased transendothelial albumin passage, 
whereas stimulation of mGEnC-1 with culture supernatant of adriamycin-stimulated HPSE 
KD podocytes did not have an effect on transendothelial albumin passage (Figure 5C), 
indicating that the effect of adriamycin on transendothelial albumin passage is completely 
heparanase-dependent.  
 
1,25-D3 deficiency leads to increased glomerular expression of heparanase that can be 
corrected by treatment with 1,25-D3 
To evaluate the effects of 1,25-D3 deficiency on heparanase expression in vivo, 1,25-D3-
deficient 25-hydroxy-1α-hydroxylase knockout (KO) mice were used. These mice lack the 
enzyme 1α-hydroxylase in the kidney, and therefore are not able to produce the active form 
of vitamin D3. 5-week-old KO mice were daily treated with 1,25-D3 for 6 weeks. Heparanase 
mRNA expression (Figure 6A), protein expression (Figure 6B-C) and activity (Figure 6D)  
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Figure 5: 1,25-D3 treatment reduces transendothelial albumin passage in the presence of 
podocyte-conditioned culture medium. Cultured mGEnC-1 were stimulated with vehicle (VEH) or 
adriamycin (ADRIA) in the absence or presence of 100 nM 1,25-D3 for 16 hours. Cumulative passage 
of FITC-labeled albumin across the mGEnC-1 monolayer was determined over time. (A) Stimulation of 
mGEnC-1 with adriamycin increased the passage of albumin compared to vehicle treated cells. 
Combined treatment of adriamycin with 1,25-D3 did not reduce transendothelial albumin passage. (B) 
mGEnC-1 were treated with a 1:1 mix of medium supplemented with vehicle or adriamycin in the 
absence or presence of 100 nM 1,25-D3, and culture supernatant of podocytes also treated with 
vehicle or adriamycin in the absence or presence of 100 nM 1,25-D3. Stimulation of mGEnC-1 with 
culture supernatant of adriamycin-stimulated podocytes increased transendothelial albumin passage. 
Passage of albumin across the mGEnC-1 monolayer was reduced after combined treatment of 
adriamycin with 1,25-D3 only in the presence of podocyte cell culture supernatant. (C) mGEnC-1 were 
treated with a 1:1 of medium supplemented with vehicle or adriamycin and culture supernatant of 
scrambled or HPSE KD podocytes treated with vehicle or adriamycin. Stimulation of mGEnC-1 with 
culture supernatant of adriamycin-stimulated scrambled podocytes increased transendothelial albumin 
passage, whereas stimulation of mGEnC-1 with culture supernatant of adriamycin-stimulated HPSE 
KD podocytes did not have an effect on transendothelial albumin passage. ***P<0.001 versus VEH, 
###P<0.001 versus ADRIA. mGEnC-1; mouse glomerular endothelial cells, CTRL; control. 
 
were increased in the untreated KO mice, which showed a significant proteinuria (Figure 6E). 
Proteinuria was corrected by daily 1,25-D3 treatment, which was accompanied by a 
normalized heparanase expression and activity (Figure 6A-E). 
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Figure 6: Vitamin D deficiency leads to increased glomerular expression of heparanase that 
can be corrected by treatment with 1,25-D3. (A) Cortical heparanase mRNA expression, (B,C) 
glomerular heparanase protein expression, (D) cortical heparanase activity and (E) proteinuria were 
significantly increased in 11-week-old 1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout (KO) 
mice. Daily treatment with 500 pg/g bodyweight of 1,25-D3 for 6 weeks normalized proteinuria and 
heparanase expression and activity. (C) Representative images showing glomerular heparanase 
protein expression as determined by immunofluorescence staining (magnification x 400). 10 WT, 8 KO 
and 5 KO+1,25-D3 mice were used for analysis. *P<0.05 and **P<0.01 versus WT, #P<0.05 versus 
KO. WT; wildtype. 
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Discussion 
 
Our in vivo and in vitro data show that 1,25-D3 regulates heparanase expression in cultured 
podocytes and in animal models for FSGS and 1,25-D3 deficiency. Consistent with our 
previous studies [6, 29], glomerular heparanase expression was increased and glomerular 
HS expression reduced in AN in vivo. These effects were attenuated by treatment with 1,25-
D3, suggesting that these effects are, at least in part, mediated by 1,25-D3. This is supported 
by the in vitro data, where we showed that adriamycin induced heparanase expression in 
podocytes, which could be normalized by treatment with 1,25-D3. 1,25-D3 treatment also 
reduced transendothelial albumin passage, which was dependent on conditioned medium of 
podocytes. Moreover, we demonstrated that the VDR directly binds to the heparanase 
promoter region and that 1,25-D3 treatment inhibits heparanase promoter activity. Finally, 
1,25-D3-deficient mice developed proteinuria and showed increased heparanase expression 
and activity, which both could be normalized by treatment with 1,25-D3. Taken together, we 
showed that vitamin D reduced heparanase expression in in vitro and in vivo podocyte injury, 
possibly through a direct effect on heparanase promoter activity.  
The present study is the first study that shows that heparanase promoter activity and 
expression are regulated by the steroid hormone vitamin D. By binding of vitamin D to the 
VDR, the VDR interacts with the retinoid X receptor to form a heterodimer that binds to 
vitamin D responsive elements in the promoter regions of vitamin D-responsive genes [10]. 
In this study we showed that the VDR indeed binds to the heparanase promoter. Most genes 
regulated by vitamin D are positively regulated. Heparanase is one of the few genes that are 
negatively regulated by vitamin D, which also include the genes encoding parathyroid 
hormone, renin, and, as we recently reported, the transient receptor potential cation channel 
C6 (TRPC6) [21, 30-32].      
The importance of heparanase in the development of proteinuria was recently demonstrated 
in heparanase-deficient mice, which failed to develop proteinuria and had a normal renal 
function after induction of type 1 diabetes [2, 9]. Moreover, proteinuria and renal function loss 
were limited when diabetic WT mice were treated with the heparanase inhibitor SST0001. In 
addition to its essential role in the development of proteinuria in diabetic nephropathy, 
heparanase has also been suggested to play a role in the development of proteinuria in other 
glomerular diseases. Treatment with the heparanase inhibitor PI-88 reduced proteinuria in 
rats with Passive Heymann Nephritis [7] and treatment with an anti-heparanase antibody 
reduced proteinuria in anti-glomerular basement membrane disease in rats [8]. Moreover, the 
expression of heparanase is increased in many experimental and human glomerular 
diseases [2-6], suggesting that heparanase may play an important role in the development of 
proteinuria in many glomerular diseases.  
  Heparanase as vitamin D target 
 
 
 
  151 
 
 
A recent paper suggests that heparanase may play a nephroprotective role in the 
development of AN [33]. Transgenic heparanase overexpressing mice developed only mild 
albuminuria and failed to develop renal damage after induction of AN. We previously showed 
that transgenic overexpression of heparanase did not result in proteinuria, which we 
explained by the lack of induced pathology [34]. Results in the paper by Assady et al. seem 
in contrast to previous studies that showed a pathological role of heparanase in models for 
diabetic nephropathy, minimal change disease, accelerated anti-GBM disease and 
membranous glomerulopathy [2, 3, 7-9]. Unfortunately, the study by Assady et al. does not 
provide a mechanism for the observed nephroprotective effect of transgenic heparanase 
overexpression. However, it may be possible that transgenic heparanase overexpression 
since birth makes the mice more resistant to develop AN. It is known that enzymatically 
inactive heparanase promotes vascular endothelial growth factor (VEGF) expression, which 
promotes endothelial health and survival [35, 36]. A recent study showed that endothelial 
dysfunction precedes podocyte injury in AN [37]. Therefore, heparanase overexpression 
since birth may increase endothelial health, thereby making these mice more resistant to 
develop AN. Nevertheless, additional research is needed to evaluate the protective role of 
heparanase on endothelial cells in AN.  
In the present study, we showed that 1,25-D3 treatment significantly reduced proteinuria and 
heparanase expression and activity in AN in vivo. In addition, we used 1,25-D3-deficient 25-
hydroxy-1α-hydroxylase KO mice to further evaluate the importance of 1,25-D3. These 1,25-
D3-deficient mice developed proteinuria and showed increased heparanase expression and 
activity, which both could be normalized by treatment with 1,25-D3. Although current data 
demonstrate that heparanase expression and proteinuria are regulated by 1,25-D3 treatment, 
and previous studies indicate that heparanase is associated with the development of 
proteinuria, it does not rule out that simultaneous regulation of other genes by vitamin D also 
plays a role in the development of proteinuria. We recently reported that the expression of 
TRPC6, a slit diaphragm protein expressed by podocytes, is regulated by vitamin D [21]. The 
expression of TRCP6 is increased in several acquired proteinuric diseases, suggesting that 
TRPC6 also plays a role in the pathogenesis of podocyte injury in proteinuric diseases [38]. 
In addition to TRPC6, renin is negatively regulated by vitamin D. Renin plays an important 
role in the biosynthesis of angiotensin II, and the latter can even be produced locally by the 
podocyte itself. Finally, 1,25-D3 also negatively regulates the expression of the 
proinflammatory cytokine tumor necrosis factor-α (TNF-α) [39, 40]. We and others previously 
showed that both angiotensin II and TNF-α can induce heparanase expression [29, 41, 42], 
suggesting that the reduction of renin or TNF-α expression may also be involved in the 
reduced heparanase expression after 1,25-D3 treatment.  
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AN in rats has mainly been regarded as a podocyte-injury model for FSGS. However, 
glomerular endothelial cells also play a role in the pathogenesis of AN, as adriamycin 
reduces the thickness of the endothelial glycocalyx by 80% in mice [43]. We observed similar 
effects in vitro, where HS expression on mouse glomerular endothelial cells was decreased 
after stimulation with adriamycin. Our data, however, suggest that 1,25-D3 treatment only has 
a direct protective effect on the podocyte. No direct effect of 1,25-D3 treatment was observed 
on mouse glomerular endothelial cells. This could be expected, since the VDR is expressed 
only at very low concentrations by the glomerular endothelium, whereas it is expressed at 
much higher levels by podocytes [44]. In line with this, 1,25-D3 treatment did not have an 
effect on transendothelial albumin passage for adriamycin injured glomerular endothelial 
cells. Interestingly, when conditioned culture supernatant of mouse podocytes treated with 
vehicle or adriamycin, in the presence or absence of 1,25-D3, was added to the mouse 
glomerular endothelial cells, we observed a reduction in transendothelial albumin passage by 
1,25-D3 treatment after adriamycin stimulation. This further demonstrates that 1,25-D3 
treatment mainly affects podocytes and suggests that crosstalk between cells in the 
glomerulus is involved in the pathogenesis of proteinuria.  
We previously showed that heparanase is mainly expressed in the podocyte in AN in vivo, as 
heparanase was expressed on the outside of the GBM and colocalized with synaptopodin 
[6]. Only minimal heparanase staining was observed inside the capillary loops. This is in line 
with our current in vitro data, where we observed a marked increase in heparanase 
expression by adriamycin in mouse podocytes, whereas a slight increase followed by a 
reduced heparanase expression was observed in mouse glomerular endothelial cells. Loss 
of heparanase expression in the podocyte prevents the increased passage of albumin across 
the endothelial monolayer induced by adriamycin, suggesting that heparanase is the 
permeability factor in the conditioned medium of podocytes that is regulated by1,25-D3. 
Future research should reveal how podocyte-derived heparanase crosses the GBM in vivo. 
VEGF and endothelin are other examples of podocyte-derived proteins that need to cross the 
GBM to reach the endothelium. 
In conclusion, in this report we provide further mechanistic evidence for the potential benefits 
of vitamin D treatment in patients with glomerular disease. We add heparanase as a target 
regulated in experimental glomerular disease. Our current in vivo and in vitro results show 
that the protective effect of vitamin D on the development of proteinuria in AN could be 
mediated by reduction of the increased heparanase expression in the podocyte.  
 
 
 
 
  Heparanase as vitamin D target 
 
 
 
  153 
 
 
Acknowledgments 
 
This study was financially supported by the Dutch Kidney Foundation, by grants C09.2296, 
KJPB 09.010, KJPB 07.0001, 13OKS023, by the consortium grant CP09.03 (GLYCOREN), 
and by a Diabetes Research grant 2009.80.118. We thank Rene St. Arnaud (McGill 
University, Montreal, Quebec, Canada) for kindly providing the 25-hydroxy-1α-hydroxylase 
KO mouse model.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 8   
 
 
154 
 
 
References 
 
1. van den Born, J., et al., Distribution of GBM heparan sulfate proteoglycan core 
protein and side chains in human glomerular diseases. Kidney international, 1993. 
43(2): p. 454-63. 
2. Garsen, M., et al., The role of heparanase and the endothelial glycocalyx in the 
development of proteinuria. Nephrology, dialysis, transplantation : official publication 
of the European Dialysis and Transplant Association - European Renal Association, 
2014. 29(1): p. 49-55. 
3. van den Hoven, M.J., et al., Heparanase in glomerular diseases. Kidney international, 
2007. 72(5): p. 543-8. 
4. van den Hoven, M.J., et al., Increased expression of heparanase in overt diabetic 
nephropathy. Kidney international, 2006. 70(12): p. 2100-8. 
5. Smith, R.J., et al., New approaches to the treatment of dense deposit disease. 
Journal of the American Society of Nephrology : JASN, 2007. 18(9): p. 2447-56. 
6. Kramer, A., et al., Induction of glomerular heparanase expression in rats with 
adriamycin nephropathy is regulated by reactive oxygen species and the renin-
angiotensin system. Journal of the American Society of Nephrology : JASN, 2006. 
17(9): p. 2513-20. 
7. Levidiotis, V., et al., A synthetic heparanase inhibitor reduces proteinuria in passive 
Heymann nephritis. Journal of the American Society of Nephrology : JASN, 2004. 
15(11): p. 2882-92. 
8. Levidiotis, V., et al., Heparanase inhibition reduces proteinuria in a model of 
accelerated anti-glomerular basement membrane antibody disease. Nephrology 
(Carlton, Vic.), 2005. 10(2): p. 167-73. 
9. Gil, N., et al., Heparanase is essential for the development of diabetic nephropathy in 
mice. Diabetes, 2012. 61(1): p. 208-16. 
10. Haussler, M.R., et al., Vitamin D receptor (VDR)-mediated actions of 
1alpha,25(OH)(2)vitamin D(3): genomic and non-genomic mechanisms. Best practice 
& research. Clinical endocrinology & metabolism, 2011. 25(4): p. 543-59. 
11. Levin, A., et al., Prevalence of abnormal serum vitamin D, PTH, calcium, and 
phosphorus in patients with chronic kidney disease: results of the study to evaluate 
early kidney disease. Kidney international, 2007. 71(1): p. 31-8. 
12. de Borst, M.H., et al., Active vitamin D treatment for reduction of residual proteinuria: 
a systematic review. Journal of the American Society of Nephrology : JASN, 2013. 
24(11): p. 1863-71. 
13. Agarwal, R., et al., Antiproteinuric effect of oral paricalcitol in chronic kidney disease. 
Kidney international, 2005. 68(6): p. 2823-8. 
14. Krairittichai, U., R. Mahannopkul, and S. Bunnag, An open label, randomized 
controlled study of oral calcitriol for the treatment of proteinuria in patients with 
diabetic kidney disease. Journal of the Medical Association of Thailand = Chotmaihet 
thangphaet, 2012. 95 Suppl 3: p. S41-7. 
15. de Zeeuw, D., et al., Selective vitamin D receptor activation with paricalcitol for 
reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised 
controlled trial. Lancet, 2010. 376(9752): p. 1543-51. 
16. Fishbane, S., et al., Oral paricalcitol in the treatment of patients with CKD and 
proteinuria: a randomized trial. American journal of kidney diseases : the official 
journal of the National Kidney Foundation, 2009. 54(4): p. 647-52. 
17. Liu, L.J., et al., Oral calcitriol for reduction of proteinuria in patients with IgA 
nephropathy: a randomized controlled trial. American journal of kidney diseases : the 
official journal of the National Kidney Foundation, 2012. 59(1): p. 67-74. 
18. Thadhani, R., et al., Vitamin D therapy and cardiac structure and function in patients 
with chronic kidney disease: the PRIMO randomized controlled trial. JAMA : the 
journal of the American Medical Association, 2012. 307(7): p. 674-84. 
  Heparanase as vitamin D target 
 
 
 
  155 
 
 
19. Kuhlmann, A., et al., 1,25-Dihydroxyvitamin D3 decreases podocyte loss and 
podocyte hypertrophy in the subtotally nephrectomized rat. American journal of 
physiology. Renal physiology, 2004. 286(3): p. F526-33. 
20. Zou, M.S., et al., 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte 
apoptosis and loss. International journal of medical sciences, 2010. 7(5): p. 290-9. 
21. Sonneveld, R., et al., Vitamin D down-regulates TRPC6 expression in podocyte injury 
and proteinuric glomerular disease. The American journal of pathology, 2013. 182(4): 
p. 1196-204. 
22. Hoenderop, J.G., et al., Modulation of renal Ca2+ transport protein genes by dietary 
Ca2+ and 1,25-dihydroxyvitamin D3 in 25-hydroxyvitamin D3-1alpha-hydroxylase 
knockout mice. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology, 2002. 16(11): p. 1398-406. 
23. Rops, A.L., et al., Syndecan-1 deficiency aggravates anti-glomerular basement 
membrane nephritis. Kidney international, 2007. 72(10): p. 1204-15. 
24. van Kuppevelt, T.H., et al., Generation and application of type-specific anti-heparan 
sulfate antibodies using phage display technology. Further evidence for heparan 
sulfate heterogeneity in the kidney. The Journal of biological chemistry, 1998. 
273(21): p. 12960-6. 
25. Rops, A.L., et al., Isolation and characterization of conditionally immortalized mouse 
glomerular endothelial cell lines. Kidney international, 2004. 66(6): p. 2193-201. 
26. Mundel, P., et al., Rearrangements of the cytoskeleton and cell contacts induce 
process formation during differentiation of conditionally immortalized mouse podocyte 
cell lines. Experimental cell research, 1997. 236(1): p. 248-58. 
27. Jiang, P., et al., Cloning and characterization of the human heparanase-1 (HPR1) 
gene promoter: role of GA-binding protein and Sp1 in regulating HPR1 basal 
promoter activity. The Journal of biological chemistry, 2002. 277(11): p. 8989-98. 
28. Malstrom, K., G. Stange, and H. Murer, Identification of proximal tubular transport 
functions in the established kidney cell line, OK. Biochimica et biophysica acta, 1987. 
902(2): p. 269-77. 
29. van den Hoven, M.J., et al., Regulation of glomerular heparanase expression by 
aldosterone, angiotensin II and reactive oxygen species. Nephrology, dialysis, 
transplantation : official publication of the European Dialysis and Transplant 
Association - European Renal Association, 2009. 24(9): p. 2637-45. 
30. Silver, J., et al., Regulation by vitamin D metabolites of parathyroid hormone gene 
transcription in vivo in the rat. The Journal of clinical investigation, 1986. 78(5): p. 
1296-301. 
31. Silver, J., J. Russell, and L.M. Sherwood, Regulation by vitamin D metabolites of 
messenger ribonucleic acid for preproparathyroid hormone in isolated bovine 
parathyroid cells. Proceedings of the National Academy of Sciences of the United 
States of America, 1985. 82(12): p. 4270-3. 
32. Zhou, C., et al., Calcium-independent and 1,25(OH)2D3-dependent regulation of the 
renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney international, 
2008. 74(2): p. 170-9. 
33. Assady, S., et al., Nephroprotective effect of heparanase in experimental nephrotic 
syndrome. PLoS One, 2015. 10(3): p. e0119610. 
34. van den Hoven, M.J., et al., Reduction of anionic sites in the glomerular basement 
membrane by heparanase does not lead to proteinuria. Kidney international, 2008. 
73(3): p. 278-87. 
35. Zetser, A., et al., Heparanase induces vascular endothelial growth factor expression: 
correlation with p38 phosphorylation levels and Src activation. Cancer Res, 2006. 
66(3): p. 1455-63. 
36. Doi, K., E. Noiri, and T. Fujita, Role of vascular endothelial growth factor in kidney 
disease. Curr Vasc Pharmacol, 2010. 8(1): p. 122-8. 
37. Sun, Y.B., et al., Glomerular endothelial cell injury and damage precedes that of 
podocytes in adriamycin-induced nephropathy. PLoS One, 2013. 8(1): p. e55027. 
Chapter 8   
 
 
156 
 
 
38. Moller, C.C., et al., Induction of TRPC6 channel in acquired forms of proteinuric 
kidney disease. Journal of the American Society of Nephrology : JASN, 2007. 18(1): 
p. 29-36. 
39. Kuo, Y.T., et al., Effects of vitamin D3 on expression of tumor necrosis factor-alpha 
and chemokines by monocytes. J Food Sci, 2010. 75(6): p. H200-4. 
40. Tan, X., X. Wen, and Y. Liu, Paricalcitol inhibits renal inflammation by promoting 
vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc 
Nephrol, 2008. 19(9): p. 1741-52. 
41. Rops, A.L., et al., Heparan sulfate domains on cultured activated glomerular 
endothelial cells mediate leukocyte trafficking. Kidney Int, 2008. 73(1): p. 52-62. 
42. Lerner, I., et al., Heparanase powers a chronic inflammatory circuit that promotes 
colitis-associated tumorigenesis in mice. J Clin Invest, 2011. 121(5): p. 1709-21. 
43. Jeansson, M., et al., Adriamycin alters glomerular endothelium to induce proteinuria. 
Journal of the American Society of Nephrology : JASN, 2009. 20(1): p. 114-22. 
44. Wang, Y., M.L. Borchert, and H.F. Deluca, Identification of the vitamin D receptor in 
various cells of the mouse kidney. Kidney international, 2012. 81(10): p. 993-1001. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
Chapter 9 
 
 
 
Summary, future perspectives and translational aspects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 9   
160 
 
Summary 
  
Proteinuria is a key feature of many glomerular diseases and an independent risk factor for 
the progression to renal failure, cardiovascular mortality and all-cause mortality. Proteinuria 
is caused by damage to the glomerular filtration barrier (GFB), consisting of glomerular 
endothelial cells covered with a glycocalyx, the glomerular basement membrane (GBM) and 
podocytes. All layers of the GFB contain negatively charged heparan sulfate proteoglycans 
(HSPGs). The glomerular expression of heparan sulfate (HS) is reduced in the majority of 
patients with proteinuria, which is associated with an increased glomerular expression of the 
HS-degrading enzyme heparanase. Previous studies suggested that heparanase may play 
an important role in the development of proteinuria, but the exact role remained unknown. In 
this thesis, the exact role of heparanase in the development of proteinuria in experimental 
diabetic nephropathy (DN) and experimental glomerulonephritis was evaluated. Moreover, 
possible mechanisms involved in the regulation of glomerular heparanase expression were 
evaluated.      
 
In the first part of this thesis the exact role of heparanase in the development of proteinuria in 
experimental DN and experimental glomerulonephritis was evaluated. To evaluate the role of 
heparanase in DN, experimental DN was induced by streptozotocin in wild type (WT) and 
heparanase-deficient mice (chapter 2). Heparanase-deficient mice failed to develop 
proteinuria after induction of diabetes. In contrast, WT mice developed a significant 
proteinuria accompanied with an increased glomerular heparanase expression and reduced 
HS expression. The occurrence of proteinuria in diabetic WT mice was paralleled by the 
development of mesangial matrix expansion, tubulointerstitial fibrosis and macrophage 
accumulation, characteristics of DN, which was not observed in the diabetic heparanase-
deficient mice. To investigate whether inhibition of excessive heparanase activity may 
prevent the progression of DN, diabetic WT mice were treated with the heparanase inhibitor 
SST0001. Treatment with SST0001 markedly reduced proteinuria and improved renal 
function in experimental DN. Finally, by investigating the molecular mechanism underlying 
the induction of heparanase in DN, it appeared that the transcription factor early growth 
response 1 (Egr1) is responsible for the activation of the heparanase promoter. In 
conclusion, heparanase appears essential for the development of proteinuria and renal 
damage in experimental DN.  
Cathepsin L, a lysosomal cysteine protease, can be involved in the development of 
proteinuria by the activation of heparanase or the degradation of proteins that are essential 
to maintain a normal podocyte architecture, such as the CD2-assiciated protein, 
synaptopodin and dynamin. In chapter 3 the role of cathepsin L in DN was evaluated in 
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streptozotocin-induced diabetes in WT and cathepsin L-deficient mice. Diabetic cathepsin L-
deficient mice, in contrast to their diabetic WT littermates, failed to develop proteinuria, 
mesangial matrix expansion, tubulointerstitial fibrosis and macrophage accumulation. In 
addition, diabetic cathepsin L-deficient mice showed a normal renal function. In diabetic WT 
mice the development of proteinuria correlated with the induction of heparanase activity, loss 
of glomerular HS expression and macrophage accumulation, whereas a reduced 
synaptopodin expression accompanied with podocyte damage was observed at a later stage. 
In conclusion, cathepsin L is causally involved in the pathogenesis of experimental DN. 
Cathepsin L deficiency prevents the induction of heparanase activity and the subsequent 
development of proteinuria and renal damage. 
The glomerular expression of heparanase is increased in the majority of proteinuric diseases.  
To find out whether the essential role of heparanase in the development of proteinuria was 
not restricted to DN, in chapter 4 the role of heparanase in experimental glomerulonephritis 
was evaluated. Two models of experimental glomerulonephritis, being anti-GBM and 
lipopolysaccharide (LPS) glomerulonephritis, were induced in WT and heparanase-deficient 
mice. Heparanase expression was increased by induction of experimental glomerulonephritis 
in WT mice, which was associated with a reduced glomerular HS expression and proteinuria. 
Proteinuria was reduced in the heparanase-deficient mice, which was accompanied by a 
preserved glomerular HS expression, a better renal function and less renal damage. In 
addition, glomerular leukocyte influx, macrophage influx and the expression of Th1 and Th2 
cytokines were reduced in the heparanase-deficient mice. In vitro, tumor necrosis factor 
(TNF)-α and LPS directly induced heparanase expression in mouse glomerular endothelial 
cells and mouse podocytes, thereby increasing transendothelial albumin passage. In 
conclusion, heparanase mediates the development of proteinuria and renal damage in 
experimental glomerulonephritis. Heparanase deficiency preserves glomerular HS 
expression, reduces leukocyte and macrophage influx, and affects the local cytokine milieu 
compared to WT conditions.    
In chapter 5 the current knowledge on the role of heparanase and HS in the development of 
proteinuria is summarized. In addition, the importance of the glomerular endothelial 
glycocalyx in the development of proteinuria is discussed.    
 
The second part of this thesis focused on the mechanisms that could play a role in the 
regulation of glomerular heparanase expression. Previous studies showed that endothelin 
receptor antagonists (ERAs) reduce proteinuria in several glomerular diseases, but the 
mechanism underlying the renoprotective effect of ERAs remained unknown. In chapter 6 
the effect of endothelin-1 on heparanase and HS expression was evaluated in vitro and in 
vivo. Endothelin-1 failed to induce heparanase expression in cultured mouse glomerular 
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endothelial cells. In contrast, endothelin-1 induced heparanase expression in cultured mouse 
podocytes. Transendothelial albumin passage in vitro was increased by culture supernatant 
of endothelin-1-stimulated podocytes in a heparanase-dependent manner. To extend the in 
vitro data, the effect of endothelin-1 signaling in the podocyte on proteinuria and glomerular 
heparanase expression was studied in podocyte-specific endothelin receptor knockout 
(podETRKO) mice. By induction of diabetes, WT mice developed proteinuria and renal 
damage, which was accompanied by an increased glomerular heparanase expression and a 
reduced glomerular HS expression. Proteinuria and renal damage were reduced in diabetic 
podETRKO mice, which displayed a normal heparanase and HS expression. Moreover, 
glycocalyx thickness was reduced by induction of diabetes in WT mice, but preserved in 
diabetic podETRKO mice. In conclusion, endothelin-1 induces heparanase expression in the 
podocyte, which cleaves HS in the endothelial glycocalyx, resulting in a reduced glycocalyx 
thickness and the development of proteinuria.  
Loss of endothelial nitric oxide synthase (eNOS) activity exacerbates proteinuria and renal 
injury in several glomerular diseases, but the underlying mechanism is not completely 
understood. Previous studies showed that glomerular endothelial glycocalyx thickness is 
reduced in diabetic eNOS-deficient mice, and indicated that heparanase plays an important 
role in the impairment of the glomerular endothelial glycocalyx. Therefore, in chapter 7 the 
effect of eNOS deficiency on glomerular heparanase expression was studied in adriamycin 
nephropathy (AN). C57BL/6 WT mice, normally an AN resistant strain, failed to develop 
proteinuria and had a normal heparanase expression after induction of AN, whereas eNOS-
deficient C57BL/6 mice developed overt proteinuria and displayed an increased glomerular  
heparanase expression. In vitro, the eNOS inhibitor asymmetric dimethylarginine (ADMA) 
induced heparanase expression in mouse glomerular endothelial cells and enhanced 
transendothelial albumin passage in a heparanase-dependent manner. In conclusion, eNOS 
controls heparanase expression in the glomerular endothelium, thereby preventing the 
development of proteinuria.    
Vitamin D received recent attention for the treatment of proteinuria. In chapter 8 the effect of 
vitamin D on heparanase expression and heparanase promoter activity was studied. By 
induction of AN, rats developed proteinuria and showed an increased heparanase 
expression, which was reduced by 1,25-dihydroxyvitamin D3 (1,25-D3) treatment. In addition, 
1,25-D3-deficient 25-hydroxy-1α-hydroxylase knockout mice developed proteinuria and 
showed increased heparanase expression, which was normalized by 1,25-D3 treatment. In 
vitro, adriamycin increased heparanase expression in cultured mouse podocytes. In addition, 
medium of combined adriamycin and 1,25-D3 treated podocytes reduced transendothelial 
albumin passage compared with medium of adriamycin-treated podocytes. Finally, 1,25-D3 
dose-dependently reduced heparanase promoter activity, and direct binding of the vitamin D 
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receptor to the heparanase promoter could be demonstrated. In conclusion, the protective 
effect of vitamin D on the development of proteinuria is mediated by inhibition of heparanase 
expression in the podocyte.      
 
Taken all data together, it appears that heparanase is essential for the development of 
proteinuria and renal damage in experimental DN and experimental glomerulonephritis. 
Induction of heparanase activity resulted in a loss of glomerular HS expression and a 
reduced endothelial glycocalyx thickness, which causes a loss of negative charge in the 
GFB. As a result, proteins like albumin can pass the GFB more easily, resulting in the 
development of proteinuria and renal damage. In addition, it appears that heparanase plays 
an important role in the renal influx of inflammatory cells such as macrophages, which also 
play a role in the destruction of the GFB and the development of proteinuria and renal 
damage. Additional studies are required to evaluate the exact mechanism of heparanase-
induced proteinuria. In conclusion, inhibition of heparanase expression/activity represents an 
potential therapeutic target to reduce proteinuria and renal damage.  
In this thesis several factors that are involved in the regulation of heparanase were identified. 
Heparanase is upregulated by LPS, TNF-α and endothelin-1, whereas heparanase is 
downregulated by eNOS and vitamin D. Previous studies showed that heparanase is 
positively regulated by high glucose, angiotensin II, aldosterone and reactive oxygen species 
(ROS) [1-4]. Interestingly, whereas some of these regulating factors induce heparanase 
expression in both endothelial cells and podocytes (LPS, high glucose, TNF-α and ROS), 
other regulating factors are solely operative in the endothelium (eNOS) or the podocyte 
(angiotensin II, aldosterone, endothelin-1 and vitamin D). Even more interesting, whereas 
endothelin-1 and vitamin D solely regulate heparanase in the podocyte and fail to regulate 
heparanase in the endothelium, they are involved in the regulation of endothelial glycocalyx 
thickness in vivo and transendothelial albumin passage in vitro, suggesting that there is 
cross-talk between the podocyte and the endothelium. The effects of endothelin-1 and 
adriamycin on transendothelial albumin passage were heparanase-dependent, which 
suggests that heparanase is a key player in the pathogenic cross-talk between podocyte and 
glomerular endothelium.     
 As outlined, several factors involved in the direct regulation of heparanase have been 
described in literature and this thesis. Interestingly, several of these factors seem to regulate 
each other as well. In figure 1 a schematic representation of interacting factors in the 
regulation of heparanase expression is depicted. To become biologically active, heparanase 
needs to be processed by cathepsin L. Previous studies showed that active heparanase may 
in turn activate macrophages, resulting in an increased production of TNF-α and an 
enhanced sensitivity to TNF-α, which leads to a further increase of heparanase expression 
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[5, 6]. Targeting any of the factors involved in the regulation or activation of heparanase may 
therefore represent an attractive therapy for the reduction of proteinuria and renal damage.  
 
 
Figure 1: Factors involved in the regulation of heparanase expression. In the presence of LPS or 
high glucose, TNF-α expression is induced. TNF-α subsequently induces angiotensin II expression 
and reduces eNOS expression. Angiotensin II induces the expression of endothelin-1, which induces 
the expression of aldosterone, and thereby further increases angiotensin II expression. Endothelin-1 
induces heparanase expression by stimulation of the production of ROS, and reduction of eNOS 
expression. eNOS controls heparanase expression by a reduced ROS production and an increased 
production of NO. Vitamin D may reduce heparanase expression either directly, or indirectly by the 
reduction of TNF-α expression. Abbreviations: LPS, lipopolysaccharide; vit D, vitamin D; TNF-α, tumor 
necrosis factor-α; Ang II, angiotensin II; ET-1, endothelin-1; ROS, reactive oxygen species; eNOS, 
endothelial nitric oxide synthase; NO, nitric oxide; HPSE, heparanase.  
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Future perspectives and translational aspects 
 
In this thesis it is shown that heparanase is essential for the development of proteinuria and 
renal damage in experimental DN and experimental glomerulonephritis. Previous studies 
showed that the expression of HS in the GBM is reduced by induction of heparanase 
expression, which was associated with the development of proteinuria [7]. The primary role 
of HS in the development of proteinuria was questioned, as genetically engineered mice with 
a reduced HS expression failed to develop proteinuria [3, 8-10]. However, in these animal 
models HS expression was only reduced in the GBM, but not in the endothelial glycocalyx. 
Therefore, an important role for HS in the endothelial glycocalyx in the development of 
proteinuria seems obvious. Recent studies showed that a reduction in glycocalyx thickness is 
associated with the development of proteinuria [11-16]. To study the exact role of HS in the 
endothelial glycocalyx in the development of proteinuria, endothelium-specific EXT1-deficient 
mice, which most likely lack all HS-associated anionic sites in the glomerular endothelium, 
should be used. Unfortunately, these mice are not viable (personal communication Jeffrey 
Esko), which argues to evaluate inducible endothelial-specific EXT1-deficient mice.  As the 
development of proteinuria most likely is not a single-hit mechanism, glomerular pathology 
should be induced in addition to a manipulated glomerular HS expression. By evaluating the 
development of proteinuria and renal damage in the aforementioned approach, it can be 
determined whether loss of HS in the endothelial glycocalyx is important for the development 
of proteinuria and renal pathology. In addition to the degradation of HS, recent studies, in 
particular aimed at DN, indicate that heparanase is involved in the development of 
proteinuria by the activation of macrophages, which also play a role in the destruction of the 
glomerular capillary wall [5]. Therefore, additional studies are required to evaluate whether 
proteinuria mediated by heparanase is caused by loss of glomerular HS expression, the 
activation of macrophages, or both. To this end, bone marrow transplantation experiments, 
where bone marrow is derived from wild type and heparanase-deficient mice, should be 
performed in experimental models for DN and glomerulonephritis. 
Currently, blockade of the renin-angiotensin-aldosterone system (RAAS) by angiotensin 
converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) is the therapy of 
choice for the treatment of patients with proteinuria. Our group previously showed that the 
RAAS system is involved in the induction of glomerular heparanase expression [3, 4]. 
However, RAAS blockade only partially reduces proteinuria, and it is therefore crucial to 
develop additional anti-proteinuric strategies. In this thesis vitamin D, endothelin-1, and 
eNOS were identified as regulators of heparanase expression. Vitamin D, endothelin 
receptor antagonists (ERAs), and tetrahydrobiopeterin (BH4), an eNOS co-factor, have been 
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approved for clinical use in other diseases, and therefore they are readily available to 
evaluate their antiproteinuric and renoprotective effect in clinical studies.  
Vitamin D has been approved for the prevention and treatment of secondary 
hyperparathyroidism, which develops in later stages of chronic kidney disease. During the 
progression of renal diseases, serum levels of active vitamin D decrease progressively, 
making patients vitamin D-deficient [17]. Vitamin D deficiency may be caused by a reduced 
vitamin D intake, or a reduction of 1α-hydroxylase activity as a result of loss of renal mass. A 
recent study showed that vitamin D deficiency itself may also induce proteinuria and renal 
damage [18]. Several clinical trials in patients with chronic kidney disease showed that 
vitamin D can reduce residual proteinuria with 16% [19]. Whether this reduction of proteinuria 
can reduce disease progression should be addressed in future studies.  
This thesis also described that endothelin-1 regulates heparanase. ERAs have been 
approved for the treatment of pulmonary arterial hypertension and for the treatment of digital 
ulcers in scleroderma [20]. In addition, several phase II and phase III clinical trials have been 
conducted to test the effect of ERAs in cardiac failure and chronic kidney disease. However, 
some of these studies were terminated due to increased morbidity and mortality, which was 
associated with the development of fluid retention [21-23]. The development of fluid retention 
is dose-dependent, as another study showed that the ERA avosentan caused only modest 
fluid retention, but was able to reduce proteinuria, at lower doses [24]. Moreover, a recent 
phase II clinical trial showed that the ERA atrasentan was still able to reduce proteinuria at a 
dosage where it did not cause significant fluid retention [25]. Therefore, optimal dose finding 
studies are required to study the antiproteinuric effects of ERAs.  
Finally, this thesis described that heparanase is controlled by eNOS. Previous studies 
identified BH4 as a critical cofactor to maintain a stable eNOS. When the availability of BH4 
is reduced, eNOS becomes uncoupled, and produces superoxide instead of NO. BH4 
availability is therefore essential to prevent the occurrence of endothelial dysfunction. BH4 is 
currently approved for the treatment of phenylketonuria (PKU), which is a metabolic disorder. 
A previous study showed that BH4 supplementation reduced proteinuria and renal damage in 
a rat model for focal segmental glomerulosclerosis [26]. However, treatment of patients with 
oral BH4 is limited by oxidation of BH4 to the inactive form BH2, and therefore has no effect 
on endothelial function [27]. 
In this thesis we showed that vitamin D supplementation seems to be a promising therapy for 
reduction of proteinuria in chronic kidney disease, most likely caused by the regulation of 
heparanase and the regulation of the transient receptor potential cation channel 6 (TRPC6) 
by vitamin D, as was previously described [28]. The therapeutic effect of ERAs and BH4, on 
the other hand, seem to be limited due to severe side effects in the case of ERAs, or 
inactivation of the compound by oxidation in the case of BH4. This thesis describes that both 
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endothelin-1 and eNOS may affect proteinuria by regulation of heparanase. As heparanase 
was shown to be essential for the development of proteinuria in several glomerular diseases, 
heparanase inhibitors represent an attractive alternative treatment to reduce proteinuria.    
Currently, there are a few heparin-based heparanase inhibitors described, which have 
originally been developed as anti-cancer therapy. So far, the heparanase inhibitor PI-88 has 
been approved for the treatment of post resection liver cancer. In addition, several phase II 
and phase III clinical trials have been conducted for the heparanase inhibitors PG545 and 
SST0001 for the treatment of cancer. These heparin-based heparanase inhibitors are very 
well tolerated and cause only minimal side effects, including mild anticoagulation. Preclinical 
studies showed that the heparin-based heparanase inhibitors PI-88 and SST0001 reduced 
proteinuria in experimental diabetic nephropathy and passive Heymann nephritis [29, 30]. 
However, sulodexide, which is a mixture of glycosaminoglycans composed of low molecular 
weight heparin and dermatan sulfate, is an effective heparanase inhibitor, but failed to 
demonstrate renoprotection in a clinical trial aimed at type 2 DN, although preclinical studies 
with sulodexide were promising [31, 32]. Most likely, the outcome of the clinical trial was 
affected by the use of sulodexide derived from different sources, i.e. Chinese pigs compared 
to American pigs for the preclinical studies. A recent study showed that heparin-based 
heparanase inhibitors mimic soluble HS, and may stimulate macrophage activation 
independently of its heparanase inhibiting capacity [5]. As macrophages play an important 
role in the development of proteinuria and renal damage in several glomerular diseases, this 
may serve as an additional explanation for the failure of sulodexide in the type 2 DN clinical 
trial. To overcome this problem, there is an unmet need for a better structural 
characterization of GAG-based therapeutics aimed to inhibit heparanase activity. Preferably, 
novel heparanase-inhibiting compounds that do not mimic soluble HS and which are not able 
to activate macrophages should be developed.   
Cathepsin L inhibitors may represent such a group of novel, but indirect, heparanase 
inhibitors. This thesis showed that cathepsin L is causally involved in the development of 
proteinuria, which is most likely mediated by the activation of heparanase. Previous studies 
showed that proteinuria can be reduced in accelerated anti-GBM glomerulonephritis by 
several unspecific cathepsin inhibitors [33, 34]. More specific cathepsin L inhibitors are 
currently available, but none of these inhibitors have been tested for their ability to reduce 
proteinuria, nor have they been tested in clinical trials for the treatment of other cathepsin L-
mediated diseases such as cancer, inflammatory bowel disease, atherosclerosis, and skin 
diseases like atopic dermatitis and psoriasis. Preclinical and clinical studies should be 
performed to test the therapeutic potential of specific cathepsin L inhibitors for the treatment 
of proteinuria.  
Chapter 9   
168 
 
Heparanase 2, the structural homolog of heparanase, may represent another novel 
heparanase-inhibiting compound. Heparanase 2 shares 44% identity and 59% similarity with 
heparanase, but has no enzymatic activity like heparanase. Interestingly, a recent study 
showed that heparanase 2 inhibited the activity of heparanase [35]. To become activated, 
heparanase needs to be re-internalized through binding to cell-associated HS proteoglycans. 
Heparanase 2 binds with higher affinity to HS than heparanase and stays on the cell surface 
for a relatively long time. Thereby, heparanase fails to get internalized and remains inactive. 
In addition, heparanase 2 can physically interact with active heparanase, which interferes 
with the enzymatic functions of heparanase, such as cleaving the HS chain. A very recent 
study showed that heparanase 2-deficient mice develop significant albuminuria and die 
within one month after birth [36]. Heparanase 2 most likely is not able to activate 
macrophages, and may represent an attractive alternative heparanase inhibitor. Therefore, 
the potential of heparanase 2 as an inhibitor of heparanase activity in glomerular diseases 
should be investigated.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                           Summary, future perspectives and translational aspects 
  169 
 
References 
1. Han, J., et al., Heparanase upregulation in high glucose-treated endothelial cells is 
prevented by insulin and heparin. Exp Biol Med (Maywood), 2007. 232(7): p. 927-34. 
2. Maxhimer, J.B., et al., Heparanase-1 gene expression and regulation by high glucose 
in renal epithelial cells: a potential role in the pathogenesis of proteinuria in diabetic 
patients. Diabetes, 2005. 54(7): p. 2172-8. 
3. van den Hoven, M.J., et al., Regulation of glomerular heparanase expression by 
aldosterone, angiotensin II and reactive oxygen species. Nephrol Dial Transplant, 
2009. 24(9): p. 2637-45. 
4. Kramer, A., et al., Induction of glomerular heparanase expression in rats with 
adriamycin nephropathy is regulated by reactive oxygen species and the renin-
angiotensin system. J Am Soc Nephrol, 2006. 17(9): p. 2513-20. 
5. Goldberg, R., et al., Role of heparanase-driven inflammatory cascade in 
pathogenesis of diabetic nephropathy. Diabetes, 2014. 63(12): p. 4302-13. 
6. Lerner, I., et al., Heparanase powers a chronic inflammatory circuit that promotes 
colitis-associated tumorigenesis in mice. J Clin Invest, 2011. 121(5): p. 1709-21. 
7. van den Hoven, M.J., et al., Heparanase in glomerular diseases. Kidney Int, 2007. 
72(5): p. 543-8. 
8. Harvey, S.J., et al., Disruption of glomerular basement membrane charge through 
podocyte-specific mutation of agrin does not alter glomerular permselectivity. Am J 
Pathol, 2007. 171(1): p. 139-52. 
9. Goldberg, S., et al., Glomerular filtration is normal in the absence of both agrin and 
perlecan-heparan sulfate from the glomerular basement membrane. Nephrol Dial 
Transplant, 2009. 24(7): p. 2044-51. 
10. Chen, S., et al., Loss of heparan sulfate glycosaminoglycan assembly in podocytes 
does not lead to proteinuria. Kidney Int, 2008. 74(3): p. 289-99. 
11. Jeansson, M., et al., Adriamycin alters glomerular endothelium to induce proteinuria. 
J Am Soc Nephrol, 2009. 20(1): p. 114-22. 
12. Dane, M.J., et al., Association of kidney function with changes in the endothelial 
surface layer. Clin J Am Soc Nephrol, 2014. 9(4): p. 698-704. 
13. Nieuwdorp, M., et al., Endothelial glycocalyx damage coincides with microalbuminuria 
in type 1 diabetes. Diabetes, 2006. 55(4): p. 1127-32. 
14. Kuwabara, A., et al., Deterioration of glomerular endothelial surface layer induced by 
oxidative stress is implicated in altered permeability of macromolecules in Zucker fatty 
rats. Diabetologia, 2010. 53(9): p. 2056-65. 
15. Salmon, A.H., et al., Loss of the endothelial glycocalyx links albuminuria and vascular 
dysfunction. J Am Soc Nephrol, 2012. 23(8): p. 1339-50. 
16. Dane, M.J., et al., Glomerular endothelial surface layer acts as a barrier against 
albumin filtration. Am J Pathol, 2013. 182(5): p. 1532-40. 
17. Levin, A., et al., Prevalence of abnormal serum vitamin D, PTH, calcium, and 
phosphorus in patients with chronic kidney disease: results of the study to evaluate 
early kidney disease. Kidney Int, 2007. 71(1): p. 31-8. 
18. Sonneveld, R., et al., 1,25-Vitamin D Deficiency Induces Albuminuria. Am J Pathol, 
2016. 
19. de Borst, M.H., et al., Active vitamin D treatment for reduction of residual proteinuria: 
a systematic review. J Am Soc Nephrol, 2013. 24(11): p. 1863-71. 
20. Kohan, D.E., et al., Clinical trials with endothelin receptor antagonists: what went 
wrong and where can we improve? Life Sci, 2012. 91(13-14): p. 528-39. 
21. Kohan, D.E. and D.M. Pollock, Endothelin antagonists for diabetic and non-diabetic 
chronic kidney disease. Br J Clin Pharmacol, 2013. 76(4): p. 573-9. 
22. Rich, S. and V.V. McLaughlin, Endothelin receptor blockers in cardiovascular 
disease. Circulation, 2003. 108(18): p. 2184-90. 
Chapter 9   
170 
 
23. Packer, M., et al., Clinical effects of endothelin receptor antagonism with bosentan in 
patients with severe chronic heart failure: results of a pilot study. J Card Fail, 2005. 
11(1): p. 12-20. 
24. Wenzel, R.R., et al., Avosentan reduces albumin excretion in diabetics with 
macroalbuminuria. J Am Soc Nephrol, 2009. 20(3): p. 655-64. 
25. Kohan, D.E., et al., Addition of atrasentan to renin-angiotensin system blockade 
reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol, 2011. 22(4): p. 763-
72. 
26. Podjarny, E., et al., Effect of chronic tetrahydrobiopterin supplementation on blood 
pressure and proteinuria in 5/6 nephrectomized rats. Nephrol Dial Transplant, 2004. 
19(9): p. 2223-7. 
27. Cunnington, C., et al., Systemic and vascular oxidation limits the efficacy of oral 
tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation, 
2012. 125(11): p. 1356-66. 
28. Sonneveld, R., et al., Vitamin D down-regulates TRPC6 expression in podocyte injury 
and proteinuric glomerular disease. Am J Pathol, 2013. 182(4): p. 1196-204. 
29. Gil, N., et al., Heparanase is essential for the development of diabetic nephropathy in 
mice. Diabetes, 2012. 61(1): p. 208-16. 
30. Levidiotis, V., et al., A synthetic heparanase inhibitor reduces proteinuria in passive 
Heymann nephritis. J Am Soc Nephrol, 2004. 15(11): p. 2882-92. 
31. Masola, V., et al., A new mechanism of action of sulodexide in diabetic nephropathy: 
inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal 
transition. J Transl Med, 2012. 10: p. 213. 
32. Packham, D.K., et al., Sulodexide fails to demonstrate renoprotection in overt type 2 
diabetic nephropathy. J Am Soc Nephrol, 2012. 23(1): p. 123-30. 
33. Baricos, W.H., et al., Evidence suggesting a role for cathepsin L in an experimental 
model of glomerulonephritis. Arch Biochem Biophys, 1991. 288(2): p. 468-72. 
34. Baricos, W.H., et al., The cysteine proteinase inhibitor, E-64, reduces proteinuria in 
an experimental model of glomerulonephritis. Biochem Biophys Res Commun, 1988. 
155(3): p. 1318-23. 
35. Levy-Adam, F., et al., Heparanase 2 interacts with heparan sulfate with high affinity 
and inhibits heparanase activity. J Biol Chem, 2010. 285(36): p. 28010-9. 
36. Guo, C., et al., A mouse model of urofacial syndrome with dysfunctional urination. 
Hum Mol Genet, 2015. 24(7): p. 1991-9. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
Chapter 10 
 
 
 
Nederlandse samenvatting 
List of publications 
Curriculum Vitae 
Dankwoord 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 10   
174 
 
Nederlandse samenvatting 
  
Proteïnurie is een belangrijk symptoom van veel glomerulaire ziekten en een onafhankelijke 
risicofactor voor de progressie tot nierfalen en hart- en vaatziekten. Proteïnurie wordt 
veroorzaakt door schade aan de glomerulaire filtratiebarrière (GFB), die bestaat uit 
glomerulaire endotheelcellen bedekt met een glycocalyx, de glomerulaire basaalmembraan 
(GBM) en podocyten. Alle lagen van de GFB bevatten negatief geladen heparansulfaat 
proteoglycanen (HSPG). De expressie van heparansulfaat (HS) in de glomerulus is 
gereduceerd in de meeste patiënten met proteïnurie. Deze afname is geassocieerd met een 
verhoogde expressie van het HS-afbrekend enzym heparanase in de glomerulus. 
Voorgaande studies hebben gesuggereerd dat heparanase een belangrijke rol speelt in de 
ontwikkeling van proteïnurie, maar de exacte rol van heparanase in de ontwikkeling van 
proteïnurie is nog niet bekend. In dit proefschrift wordt de precieze rol van heparanase in de 
ontwikkeling van proteïnurie in experimentele diabetische nefropatie (DN) en experimentele 
glomerulonefritis onderzocht. Daarnaast worden mogelijke mechanismen die betrokken zijn 
bij de regulatie van glomerulaire heparanase-expressie bekeken.       
 
In het eerste deel van dit proefschrift is de exacte rol van heparanase in de ontwikkeling van 
proteïnurie in experimentele DN en experimentele glomerulonephritis bekeken. Om de rol 
van heparanase in DN te bepalen, werd experimentele DN geïnduceerd in wildtype (WT) en 
heparanase-deficiënte muizen door middel van streptozotocine (hoofdstuk 2). Heparanase-
deficiënte muizen ontwikkelden geen proteïnurie na inductie van diabetes. Daarentegen 
ontwikkelden WT muizen een significante proteïnurie, welke gepaard ging met een 
verhoogde glomerulaire heparanase expressie en een gereduceerde glomerulaire HS 
expressie. Het ontwikkelen van proteïnurie in diabetische WT muizen ging gepaard met de 
ontwikkeling van mesangiale matrixexpansie, tubuloïnterstitiële fibrose en accumulatie van 
macrofagen. Heparanase-deficiënte muizen ontwikkelden deze kenmerken van diabetische 
nefropathie niet. Om te onderzoeken of remming van verhoogde heparanase activiteit de 
ontwikkeling van DN kan voorkomen, werden diabetische WT muizen behandeld met de 
heparanase remmer SST0001. Behandeling met SST0001 zorgt voor een verminderde 
proteïnurie en een verbeterde nierfunctie in experimentele DN. Tenslotte is ook het 
moleculaire mechanisme achter de inductie van heparanase in DN onderzocht. Het bleek dat 
de transcriptiefactor early growth response 1 (Egr1) verantwoordelijk is voor de activatie van 
de heparanase promoter. Concluderend, heparanase is essentieel voor de ontwikkeling van 
proteïnurie en nierschade in experimentele DN.  
Cathepsine L, een lysosomaal cysteïne protease, kan een rol spelen in de ontwikkeling van 
proteïnurie door de activatie van heparanase of door de afbraak van eiwitten die essentieel 
                         Nederlandse samenvatting 
  175 
 
zijn voor een normale podocytarchitectuur, zoals het CD2-geassocieerde eiwit (CD2AP), 
synaptopodine, en dynamine. In hoofdstuk 3 is de rol van cathepsine L in streptozotocine-
geïnduceerde diabetes bepaald in WT en cathepsine L-deficiënte muizen. Diabetische 
cathepsine L-deficiënte muizen ontwikkelden, in tegenstelling tot diabetische WT muizen, 
geen proteïnurie, mesangiale matrixexpansie, tubuloïnterstitiële fibrose en accumulatie van 
macrofagen. Daarnaast hebben de diabetische cathepsine L-deficiënte muizen een normale 
nierfunctie. De ontwikkeling van proteïnurie in WT muizen correleerde met de inductie van 
heparanase-activiteit, een verlaagde glomerulaire HS expressie en de accumulatie van 
macrofagen, terwijl een verlaagde synaptopodine expressie vergezeld met podocytschade 
pas werd waargenomen in een later stadium. Concluderend, cathepsine L speelt een 
causale rol in de pathogenese van experimentele DN. Cathepsine L deficiëntie voorkomt de 
inductie van heparanase activiteit en de daaropvolgende ontwikkeling van proteïnurie en 
nierschade. 
De glomerulaire expressie van heparanase is verhoogd in de meeste proteïnurische ziekten. 
Om te bepalen of de essentiële rol van heparanase in de ontwikkeling van proteïnurie niet 
beperkt was tot DN, werd in hoofdstuk 4 de rol van heparanase op de ontwikkeling van 
proteïnurie in experimentele glomerulonefritis bekeken. Anti-GBM en lipopolysaccharide 
(LPS) glomerulonefritis, twee modellen voor experimentele glomerulonefritis, werden 
geïnduceerd in WT en heparanase-deficiënte muizen. De glomerulaire expressie van 
heparanase was verhoogd door inductie van experimentele glomerulonefritis in WT muizen, 
wat gepaard ging met een verlaagde glomerulaire HS expressie en proteïnurie. De 
heparanase-deficiënte muizen hadden een lagere proteïnurie, die gepaard ging met een 
normale HS expressie, een betere nierfunctie en minder nierschade. Daarnaast hadden de 
heparanase-deficiënte muizen een verlaagde glomerulaire leukocytinflux, macrofaaginflux en 
een lagere expressie van Th1 en Th2 cytokines in vergelijking met de WT muizen. In vitro 
experimenten toonden aan dat tumor necrose factor (TNF)-α en LPS de expressie van 
heparanase induceren in gekweekte muis glomerulaire endotheelcellen en muispodocyten, 
waardoor de transendotheliale albuminepassage toenam. Samenvattend, heparanase 
medieert de ontwikkeling van proteïnurie en nierschade in experimentele glomerulonefritis. In 
heparanase-deficiënte muizen is er sprake van een normale glomerulaire HS-expressie, een 
verminderde influx van leukocyten en macrofagen, en een gunstige beïnvloeding van het 
lokale cytokinemilieu in vergelijking met WT muizen  
In hoofdstuk 5 werd de huidige kennis over de rol van heparanase en HS in de ontwikkeling 
van proteïnurie samengevat. Daarnaast werd de rol van de glomerulaire endotheliale 
glycocalyx op de ontwikkeling van proteïnurie besproken.  
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Het tweede deel van dit proefschrift richt zich op mechanismen die een rol kunnen spelen in 
de regulatie van glomerulaire heparanase-expressie. Eerdere studies hebben aangetoond 
dat endotheline receptor antagonisten (ERA’s) proteïnurie kunnen verminderen in 
verschillende glomerulaire ziekten, maar het onderliggende mechanisme van de 
nierbeschermende effecten van ERA’s was nog niet bekend. In hoofdstuk 6 werd het effect 
van endotheline-1 op heparanase en HS expressie zowel in vitro als in vivo bekeken. 
Endotheline-1 was niet in staat om heparanase-expressie te induceren in gekweekte muis 
glomerulaire endotheelcellen. Daarentegen werd heparanase expressie geïnduceerd door 
endotheline-1 in gekweekte muispodocyten. Transendotheliale albuminepassage in vitro 
werd verhoogd door kweeksupernatant van podocyten die met endotheline-1 waren 
gestimuleerd, welk effect afhankelijk was van heparanase. Om de in vitro resultaten verder 
uit te breiden, werd het effect van endotheline-1 signalering in de podocyt op proteïnurie en 
glomerulaire heparanase-expressie onderzocht in podocyt-specifieke endothelinereceptor 
knockout (podETRKO) muizen. Door het induceren van diabetes ontwikkelden WT muizen 
proteïnurie en nierschade, welke gepaard ging met een verhoogde glomerulaire heparanase-
expressie en een verminderde glomerulaire HS expressie. Proteïnurie en nierschade waren 
verminderd in diabetische podETRKO muizen, die een normale heparanase en HS expressie 
hadden. Verder hadden de WT muizen een dunnere glycocalyx dikte, terwijl deze behouden 
was in de diabetische podETRKO muizen. Concluderend, endotheline-1 induceert de 
expressie van heparanase in de podocyt. Heparanase knipt vervolgens HS in de 
endotheliale glycocalyx, hetgeen resulteert in een dunnere glycocalyx en de ontwikkeling van 
proteïnurie.        
Het verlies van endotheliale nitric oxide synthase (eNOS) activiteit verergert proteïnurie en 
nierschade in verschillende glomerulaire ziekten, maar het onderliggende mechanisme is 
niet volledig bekend. Eerdere studies hebben aangetoond dat de glomerulaire endotheliale 
glycocalyx dunner is in diabetische eNOS-deficiënte muizen, en dat heparanase een 
belangrijke rol speelt in de afbraak van de glomerulaire endotheliale glycocalyx. Daarom 
werd in hoofdstuk 7 het effect van eNOS deficiëntie op glomerulaire heparanase expressie 
onderzocht in adriamycine nefropathie (AN). C57BL/6 WT muizen, die niet gevoelig zijn voor 
het ontwikkelen van AN, ontwikkelden geen proteïnurie en hadden een normale heparanase-
expressie na inductie van AN. eNOS-deficiënte C57BL/6 muizen ontwikkelden proteïnurie en 
hadden een verhoogde glomerulaire heparanase expressie. In in vitro experimenten werd 
aangetoond dat de eNOS remmer asymmetrisch dimethylarginine (ADMA) heparanase-
expressie induceerde in muis glomerulaire endotheelcellen en de transendotheliale 
albuminepassage verhoogde op een heparanase-afhankelijke wijze. Concluderend, eNOS 
remt de expressie van heparanase in het glomerulair endotheel, en voorkomt daarmee de 
ontwikkeling van proteïnurie.       
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Vitamine D heeft recente aandacht gekregen voor de behandeling van proteïnurie. In 
hoofdstuk 8 werd het effect van vitamine D op heparanase-expressie en heparanase 
promoteractiviteit bestudeerd. Na het induceren van AN ontwikkelden ratten proteïnurie en 
een verhoogde heparanase-expressie, die beide werden gereduceerd door behandeling met 
1,25-dihydroxyvitamine D3 (1,25-D3). 1,25-D3-deficiënte 25-hydroxy-1α-hydroxylase knockout 
muizen ontwikkelden ook proteïnurie en hadden een verhoogde heparanase-expressie, die 
beide genormaliseerd werden door behandeling met 1,25-D3. In in vitro experimenten werd 
aangetoond dat adriamycine de heparanase-expressie verhoogde in gekweekte 
muispodocyten. Daarnaast was de transendotheliale albuminepassage lager door 
toevoeging van medium van podocyten behandeld met adriamycine samen met 1,25-D3 in 
vergelijking met medium van podocyten behandeld met alleen adriamycine. Tenslotte werd 
aangetoond dat 1,25-D3 zorgde voor een dosisafhankelijke afname van de heparanase 
promoteractiviteit, en dat vitamine D direct bindt aan de heparanase promoter. 
Concluderend, het beschermende effect van vitamine D op de ontwikkeling van proteïnurie 
wordt gemedieerd door remming van heparanase-expressie in de podocyt.            
 
Samennemend blijkt dat heparanase essentieel is voor de ontwikkeling van proteïnurie en 
nierschade in experimentele DN en experimentele glomerulonefritis. Inductie van 
heparanase-activiteit resulteerde in een verlies van glomerulaire HS expressie en een 
afname van de glycocalyxdikte, wat zorgt voor een verlies van negatieve lading in de GFB. 
Hierdoor kunnen eiwitten als albumine makkelijker de GFB passeren, wat leidt tot de 
ontwikkeling van proteïnurie en nierschade. Daarnaast blijkt dat heparanase een belangrijke 
rol speelt in de influx van ontstekingscellen zoals macrofagen in de nier. Deze 
ontstekingscellen spelen ook een belangrijke rol in de afbraak van de GFB en de 
ontwikkeling van proteïnurie en nierschade. Vervolgstudies zijn nodig om het exacte 
mechanisme van heparanase-geïnduceerde proteïnurie te evalueren. Concluderend, 
remming van heparanase-expressie en/of -activiteit lijkt een uitstekende manier om 
proteïnurie en nierschade te verminderen.        
In dit proefschrift werden verschillende factoren die betrokken zijn bij de regulatie van 
heparanase geïdentificeerd. Heparanase wordt positief gereguleerd door LPS, TNF-α en 
endotheline-1, terwijl heparanase negatief gereguleerd wordt door eNOS en vitamine D. 
Eerdere studies hebben al aangetoond dat heparanase positief gereguleerd wordt door hoog 
glucose, angiontensine II, aldosteron en reactieve zuurstofradicalen (ROS) [1-4]. Interessant 
is dat sommige van deze regulerende factoren heparanase-expressie induceren in zowel 
endotheelcellen als podocyten (LPS, hoog glucose, TNF-α en ROS), terwijl andere 
regulerende factoren uitsluitend werkzaam zijn in het endotheel (eNOS) of de podocyt 
(angiontensin II, aldosterone, endotheline-1 and vitamine D). Nog interessanter is dat terwijl 
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endotheline-1 en vitamine D uitsluitend heparanase reguleren in de podocyt en niet in het 
endotheel, dat ze wel betrokken zijn bij de regulatie van de dikte van de glomerulaire 
endotheliale glycocalyx in vivo en transendotheliale albuminepassage in vitro. Dit suggereert 
dat er sprake is van crosstalk (communicatie) tussen de podocyt en het endotheel. De 
effecten van endotheline-1 en adriamycine op transendotheliale albuminepassage waren 
afhankelijk van heparanase, hetgeen suggereert dat heparanase een belangrijke speler is in 
de pathogene crosstalk (communicatie) tussen de podocyt en het glomerulaire endotheel.         
Verschillende factoren die betrokken zijn bij de directe regulatie van heparanase zijn 
beschreven in de literatuur en dit proefschrift. Het is interessant dat sommige van deze 
factoren ook elkaar lijken te reguleren. Een schematische weergave van factoren betrokken 
bij de regulatie van heparanase wordt weergegeven in figuur 1.  
 
 
Figuur 1: Factoren die betrokken zijn bij de regulatie van heparanase-expressie. De expressie 
van TNF-α wordt geïnduceerd door LPS of hoog glucose. TNF-α induceert vervolgens de expressie 
van angiotensine II en vermindert de expressie van eNOS. Angiotensine II induceert de expressie van 
endotheline-1, die de expressie van aldosteron induceert, wat de expressie van angiotensine II verder 
verhoogd. Endotheline-1 induceert de expressie van heparanase door stimulatie van de productie van 
ROS en door een afname van de eNOS expressie. eNOS reguleert de expressie van heparanase 
door een afgenomen ROS productie en een verhoogde NO productie. Vitamine D verlaagt de 
expressie van heparanase ofwel direct, of indirect door het verlagen van de TNF-α expressie. 
Afkortingen: LPS, lipopolysaccharide; vit D, vitamine D; TNF-α, tumor necrose factor-α; Ang II, 
angiontensine II; ET-1, endotheline-1; ROS, reactieve zuurstofradicalen; eNOS, endotheel 
stikstofoxide synthase; NO, stikstofoxide; HPSE, heparanase. 
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Om biologisch actief te worden, moet heparanase gesplitst worden door cathepsine L. 
Eerdere studies hebben aangetoond dat actief heparanase macrofagen kan activeren, wat 
resulteert in een verhoogde TNF-α productie en een verhoogde gevoeligheid voor TNF-α, 
leidend tot een verdere toename van de heparanase expressie [5, 6]. Het reguleren van de 
expressie van elk van de factoren betrokken bij de regulatie van heparanase is dan ook een 
aantrekkelijke alternatieve therapie voor de vermindering van proteïnurie en nierschade.   
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Toekomstperspectieven en translationele aspecten  
 
In dit proefschrift werd aangetoond dat heparanase essentieel is voor de ontwikkeling van 
proteïnurie en nierschade in experimentele DN en experimentele glomerulonefritis. Eerdere 
studies hebben aangetoond dat de expressie van HS in de GBM is afgenomen na inductie 
van heparanase-expressie, dat geassocieerd was met de ontwikkeling van proteïnurie [7]. 
De primaire rol van HS in de ontwikkeling van proteïnurie werd in twijfel getrokken toen 
genetisch gemanipuleerde muizen met een verminderde HS expressie geen proteïnurie 
ontwikkelden [3, 8-10]. Echter, in deze diermodellen was de HS expressie alleen verminderd 
in de GBM en niet in de endotheliale glycocalyx. Het lijkt dan ook voor de hand liggend dat 
HS in de endotheliale glycocalyx een belangrijke rol speelt in de ontwikkeling van proteïnurie. 
Recente studies hebben aangetoond dat een afname van de dikte van de endotheliale 
glycocalyx geassocieerd is met de ontwikkeling van proteïnurie [11-16]. Om de exacte rol 
van HS in de endotheliale glycocalyx op de ontwikkeling van proteïnurie te bestuderen, 
moeten endotheel-specifieke EXT1-deficiënte muizen, die waarschijnlijk geen HS tot 
expressie brengen op het endotheel, gebruikt worden. Deze muizen zijn helaas niet 
levensvatbaar (persoonlijke communicatie Jeffrey Esko), wat pleit voor het gebruik van 
induceerbare endotheel-specifieke EXT1-deficiënte muizen. Aangezien de ontwikkeling van 
proteïnurie hoogstwaarschijnlijk niet het gevolg is van een single-hit mechanisme is, moet er 
sprake zijn van glomerulaire schade naast een verminderde glomerulaire HS expressie. Door 
de ontwikkeling van proteïnurie en nierschade in de bovengenoemde aanpak te evalueren, 
kan bepaald worden of verlies van HS in de endotheliale glycocalyx belangrijk is voor de 
ontwikkeling van proteïnurie en nierschade. Naast afbraak van HS, hebben recente studies, 
die zich met name hebben gericht op DN, aangetoond dat heparanase ook betrokken is bij 
de ontwikkeling van proteïnurie door het activeren van macrofagen, die ook een rol spelen bij 
de afbraak van de glomerulaire capillaire wand [5]. Er zijn dan ook extra studies nodig om te 
bepalen of proteïnurie gemedieerd door heparanase wordt veroorzaakt door een afname van 
glomerulaire HS expressie, de activatie van macrofagen, of beide. Hiervoor moeten 
beenmergtransplantaties, waarbij beenmerg wordt verkregen uit WT en heparanase-
deficiënte muizen, worden uitgevoerd in experimentele DN en experimentele 
glomerulonefritis.  
Momenteel is remming van het renine-angiotensine-aldosteron systeem (RAAS) door 
angiotensine converterend enzym (ACE) remmers en angiotensine receptor blokkers 
(ARB’s) de behandeling van keuze voor patiënten met proteïnurie. Onze groep heeft eerder 
aangetoond dat het RAAS systeem betrokken is bij de inductie van glomerulaire heparanase 
expressie [3, 4]. Remming van het RAAS systeem zorgt echter slechts voor een gedeeltelijke 
vermindering van proteïnurie, en het is dan ook belangrijk om additionele antiproteïnurische 
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middelen te ontwikkelen. In dit proefschrift werden vitamine D, endotheline-1 en eNOS 
geïdentificeerd als regulatoren van heparanase-expressie. Vitamine D, endotheline receptor 
antagonisten (ERA’s), en tetrahydrobiopterine (BH4), een eNOS cofactor, zijn momenteel 
goedgekeurd voor klinisch gebruik bij andere ziekten, en zijn daarom beschikbaar voor 
evaluatie van hun antiproteïnurisch effect.                 
Vitamine D is goedgekeurd voor de preventie en behandeling van secundaire 
hyperparathyroïdie, die zich ontwikkelt tijdens de latere stadia van chronische nierziekten. De 
serumspiegels van actief vitamine D nemen geleidelijk af tijdens de vermindering van de 
nierfunctie als gevolg van de progressie van nierziekten, met als consequentie dat patiënten 
vitamine D deficiënt worden [17]. Vitamine D deficiëntie kan veroorzaakt worden door een 
verminderde inname van vitamine D, of een verlies van 1α-hydroxylase ten gevolge van het 
verlies van niermassa. Een recente studie heeft aangetoond dat vitamine D deficiëntie zelf 
ook proteïnurie en nierschade kan veroorzaken [18]. Verschillende klinische studies met 
patiënten met chronische nierziekten hebben aangetoond dat toevoeging van vitamine D aan 
de standaard antiproteïnurische therapie de resterende proteïnurie met 16% kan 
verminderen [19]. Of deze vermindering van proteïnurie ook daadwerkelijk de 
ziekteprogressie kan verminderen, moet nog aangetoond worden in toekomstige studies.  
In dit proefschrift is ook aangetoond dat endotheline-1 heparanase reguleert. ERA’s zijn 
goedgekeurd voor de behandeling van pulmonale arteriële hypertensie en voor de 
behandeling digitale ulcera by sclerodermie [20]. Daarnaast zijn verschillende fase II en fase 
III klinische studies uitgevoerd om het effect van ERA’s te testen bij hartfalen en chronische 
nierziekten. Sommige van deze studies werden voortijdig beëindigd door een verhoogde 
morbiditeit en mortaliteit, die geassocieerd waren met de ontwikkeling van vochtretentie [21-
23]. Een andere studie toonde echter aan dat de ontwikkeling van vochtretentie 
dosisafhankelijk is, aangezien de ERA avosentan slechts milde vochtretentie veroorzaakte, 
maar nog wel in staat was proteïnurie te verminderen bij lagere doses [24]. Daarnaast heeft 
een recente fase II klinische studie aangetoond dat de ERA atrasentan nog in staat was 
proteïnurie te verminderen bij concentraties die geen significante vochtretentie meer 
veroorzaakte [25]. Daarom zijn er studies nodig om de optimale dosis van ERA’s te bepalen, 
zodat de antiproteïnurische effecten van ERA’s beter bepaald kunnen worden.     
Tot slot hebben is in dit proefschrift ook aangetoond dat heparanase wordt gereguleerd door 
eNOS. Eerdere studies hebben BH4 geïdentificeerd als een essentiële cofactor voor een 
stabiele eNOS expressie. Wanneer de beschikbaarheid van BH4 is verminderd, wordt eNOS 
ontkoppeld, en produceert het superoxide in plaats van NO. De aanwezigheid van BH4 is 
daarom essentieel om het ontstaan van endotheeldysfunctie te voorkomen. BH4 is 
momenteel goedgekeurd voor de behandeling van fenylketonurie (PKU), een 
stofwisselingsziekte. Een eerdere studie heeft aangetoond dat BH4 suppletie proteïnurie en 
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nierschade kan verminderen in een ratmodel voor focale segmentale glomerulosclerose [26]. 
Behandeling van patiënten met orale BH4 is echter beperkt door oxidatie van BH4 naar de 
inactieve vorm BH2, en heeft dus ook geen invloed op de endotheelfunctie [27].      
In dit proefschrift hebben we laten zien dat vitamine D suppletie een veelbelovende therapie 
lijkt voor de vermindering van proteïnurie bij chronische nierziekten, hetgeen waarschijnlijk 
wordt veroorzaakt door de regulatie van heparanase en de regulatie van het transient 
receptor potentiaal kation kanaal 6 (TRPC6) door vitamine D [28]. Het therapeutische effect 
van ERA’s en BH4 lijkt beperkt door ernstige bijwerkingen bij ERA’s en inactivatie van het 
middel door oxidatie bij BH4. Dit proefschrift beschrijft dat zowel endotheline-1 als eNOS 
invloed hebben op proteïnurie door de regulatie van heparanase. Aangezien heparanase 
essentieel is voor de ontwikkeling van proteïnurie in verschillende glomerulaire ziekten, 
vormen heparanase remmers een aantrekkelijke alternatieve behandeling om proteïnurie te 
verminderen.   
Momenteel zijn er enkele heparanaseremmers beschreven die gebaseerd zijn op heparine. 
Deze heparanase remmers zijn oorspronkelijk ontwikkeld voor de behandeling van kanker. 
Op dit moment is de heparanaseremmer PI-88 goedgekeurd voor de behandeling van 
leverkanker nadat een deel van de lever is verwijderd. Daarnaast zijn er verschillende fase II 
en fase III klinische studies uitgevoerd om de effectiviteit van de heparanaseremmers PG545 
en SST0001 voor de behandeling van kanker te testen. Deze heparanaseremmers, 
gebaseerd op heparine, worden zeer goed verdragen en veroorzaken slechts milde 
bijwerkingen, waaronder milde antistolling. Preklinische studies hebben aangetoond dat de 
heparanaseremmers PI-88 en SST0001 proteïnurie verminderen in experimentele DN en 
passieve Heymann nefritis [29, 30]. Een recente klinische studie heeft echter aangetoond dat 
sulodexide, een mengsel van glycosaminoglycanen bestaande uit laag moleculair gewicht 
heparine en dermatan sulfaat, een effectieve heparanaseremmer is, maar geen 
nierbeschermende effecten had in patiënten met type 2 diabetes, terwijl preklinische studies 
met sulodexide veelbelovend waren [31, 32]. Waarschijnlijk zijn de resultaten van de 
klinische studie beïnvloed door het gebruik van sulodexide afkomstig van verschillende 
bronnen, namelijk Chinese varkens in de klinische studie versus Amerikaanse varkens in de 
preklinische studies. Een recente studie heeft aangetoond dat heparanase remmers 
gebaseerd op heparine op oplosbaar HS lijken, en in staat zijn macrofagen te activeren, een 
effect dat onafhankelijk is van het heparanase remmend vermogen [5]. Aangezien 
macrofagen een belangrijke rol spelen in de ontwikkeling van proteïnurie en nierschade in 
verschillende glomerulaire ziekten, kan dit een aanvullende verklaring zijn voor het falen van 
sulodexide in de type 2 DN klinische studie. Om dit probleem te ondervangen is er behoefte 
aan een betere structurele karakterisering van GAG-gebaseerde therapieën gericht op de 
remming van heparanase-activiteit. Bij voorkeur moeten nieuwe heparanase remmende 
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middelen ontwikkeld worden die niet lijken op oplosbaar HS en die niet in staat zijn 
macrofagen te activeren.    
Cathepsine L-remmers vertegenwoordigen zo’n groep van nieuwe, maar indirecte, 
heparanaseremmers. Dit proefschrift heeft aangetoond dat cathepsine L een belangrijke 
causale rol speelt in de ontwikkeling van proteïnurie, wat waarschijnlijk werd gemedieerd 
door het activeren van heparanase. Eerdere studies hebben aangetoond dat proteïnurie in 
versnelde anti-GBM glomerulonefritis verminderd kan worden door verschillende aspecifieke 
cathepsine remmers [33, 34]. Meer specifieke cathepsine L-remmers zijn beschikbaar, maar 
geen van deze remmers zijn getest op hun vermogen om proteïnurie te verminderen, en 
evenmin zijn ze getest in klinische studies voor de behandeling van andere cathepsine L-
gemedieerde ziekten als kanker, inflammatoire darmziekten, atherosclerose, en 
huidaandoeningen als atopische dermatitis en psoriasis. Preklinische en klinische studies 
moeten worden uitgevoerd om het therapeutisch effect van deze specifieke cathepsine L 
remmers voor de behandeling van proteïnurie te testen. 
Heparanase 2, de structurele homoloog van heparanase, kan een ander nieuw heparanase 
remmend middel vertegenwoordigen. Heparanase 2 komt op aminozuurniveau voor 44% 
overeen met heparanase en heeft 59% gelijkenis met heparanase, maar heeft geen 
enzymatische activiteit zoals heparanase. Interessant is dat een recente studie heeft 
aangetoond dat heparanase 2 de activiteit van heparanase kan remmen [35]. Om 
geactiveerd te worden, moet heparanase gereïnternaliseerd worden door binding aan 
celgebonden HS proteoglycanen. Heparanase 2 bindt met hogere affiniteit aan HS dan 
heparanase, en blijft voor een relatief lange periode gebonden aan het celoppervlak. 
Hierdoor wordt heparanase niet geïnternaliseerd en blijft het inactief. Daarnaast kan 
heparanase 2 ook een directe interactie aangaan met heparanase, wat interfereert met de 
enzymatische functies van heparanase, zoals het knippen van de HS keten. Een recente 
studie heeft aangetoond dat heparanase-2-deficiënte muizen een significante albuminurie 
ontwikkelen en binnen één maand na de geboorte sterven [36]. Heparanase 2 is 
waarschijnlijk niet in staat om macrofagen te activeren, en is mogelijk een zeer aantrekkelijke 
alternatieve heparanase remmer. Daarom moet de potentie van heparanase 2 als remmer 
van heparanase activiteit in glomerulaire ziekten onderzocht worden.           
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